TITLE	O
:	O
The	O
viral	O
nucleocapsid	O
protein	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
is	O
cleaved	O
by	O
caspase	O
-	O
6	O
and	O
-	O
7	O
during	O
TGEV	O
-	O
induced	O
apoptosis	B-PATH
.	O

ABSTRACT	O
:	O
The	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
),	O
like	O
many	O
other	O
viruses	O
,	O
exerts	O
much	O
of	O
its	O
cytopathic	O
effect	O
through	O
the	O
induction	O
of	O
apoptosis	B-PATH
of	O
its	O
host	O
cell	O
.	O

In	O
young	O
patients	O
with	O
cerebral	O
vascular	O
pathology	O
the	O
possibility	O
of	O
hepatitis	B-PATH
C	I-PATH
and	O
essential	O
mixed	O
cryoglobulinemia	O
should	O
be	O
considered	O
,	O
especially	O
when	O
the	O
transaminases	O
are	O
raised	O
as	O
in	O
our	O
patient	O
.	O

Sixty	O
-	O
nine	O
patients	O
suffered	O
from	O
Plasmodium	O
falciparum	O
malaria	B-PATH
(	O
66	O
%),	O
seven	O
of	O
these	O
were	O
admitted	O
to	O
the	O
ICU	O
.	O

Because	O
of	O
the	O
continuing	O
interest	O
in	O
the	O
potential	O
relationship	O
between	O
viral	B-PATH
myocarditis	I-PATH
and	O
cardiomyopathy	O
,	O
we	O
evaluated	O
hearts	O
from	O
cats	O
with	O
spontaneous	O
,	O
idiopathic	O
cardiomyopathy	O
for	O
viral	O
genomic	O
material	O
within	O
myocytes	O
by	O
polymerase	O
chain	O
reaction	O
,	O
and	O
for	O
the	O
presence	O
of	O
myocarditis	O
by	O
light	O
microscopy	O
.	O

TITLE	O
:	O
Fulminant	O
tracheobronchial	O
and	O
pulmonary	O
aspergillosis	O
complicating	O
imported	O
Plasmodium	O
falciparum	O
malaria	B-PATH
in	O
an	O
apparently	O
immunocompetent	O
woman	O
.	O

This	O
report	O
shows	O
that	O
patients	O
with	O
P	O
falciparum	O
malaria	B-PATH
should	O
be	O
monitored	O
closely	O
and	O
transferred	O
to	O
an	O
intensive	O
care	O
unit	O
for	O
additional	O
management	O
if	O
respiratory	O
distress	O
develops	O
.	O

ABSTRACT	O
:	O
Evidence	O
of	O
apoptosis	B-PATH
caused	O
by	O
infection	O
with	O
the	O
Purdue	O
strain	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
was	O
sought	O
in	O
vitro	O
(	O
in	O
infected	O
swine	O
testicular	O
[	O
ST	O
]	O
cells	O
)	O
and	O
in	O
vivo	O
(	O
in	O
the	O
intestinal	O
tissues	O
of	O
infected	O
piglets	O
).	O

The	O
development	O
of	O
apoptosis	B-PATH
,	O
regulative	O
gene	O
expression	O
,	O
and	O
viral	O
clearance	O
were	O
similar	O
in	O
both	O
retinal	O
degeneration	O
-	O
susceptible	O
(	O
BALB	O
/	O
c	O
)	O
and	O
-	O
resistant	O
(	O
CD	O
-	O
1	O
)	O
mice	O
.	O

Exogenous	O
catecholamines	O
can	O
increase	O
the	O
rate	O
of	O
alveolar	O
fluid	O
clearance	O
in	O
several	O
species	O
,	O
including	O
the	O
human	O
lung	O
,	O
and	O
it	O
is	O
also	O
apparent	O
that	O
release	B-PATH
of	O
endogenous	O
catecholamines	O
can	O
upregulate	O
alveolar	O
fluid	O
clearance	O
in	O
animals	O
with	O
septic	O
or	O
hypovolemic	O
shock	O
.	O

Premorbid	O
lung	O
conditions	O
,	O
i	O
.	O
e	O
.	O
asthma	B-PATH
and	O
airway	O
hyperresponsiveness	O
,	O
might	O
have	O
been	O
risk	O
factors	O
for	O
illness	O
severity	O
but	O
not	O
for	O
persistent	O
complaints	O
.	O

ABSTRACT	O
:	O
Structure	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
product	O
-	O
based	O
inhibitors	O
of	O
hepatitis	B-PATH
C	I-PATH
virus	O
NS3	O
protease	O
were	O
evaluated	O
using	O
an	O
in	O
vitro	O
assay	O
system	O
comprising	O
the	O
native	O
bifunctional	O
full	O
-	O
length	O
NS3	O
(	O
protease	O
-	O
helicase	O
/	O
NTPase	O
).	O

Crack	O
cocaine	O
use	O
can	O
lead	O
to	O
a	O
variety	O
of	O
acute	O
pulmonary	O
complications	O
,	O
including	O
severe	O
exacerbations	O
of	O
asthma	B-PATH
and	O
an	O
acute	O
lung	O
injury	O
syndrome	O
associated	O
with	O
a	O
broad	O
spectrum	O
of	O
histopathologic	O
changes	O
"("""	O
crack	O
lung	O
""")."	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
infection	O
of	O
piglets	O
results	O
in	O
a	O
very	O
rapid	O
and	O
massive	O
release	B-PATH
of	O
IFN	O
-	O
alpha	O
in	O
serum	O
and	O
secretions	O
.	O

The	O
most	O
common	O
complication	O
is	O
anaemia	O
accounting	O
for	O
76	O
.	O
56	O
%	O
followed	O
by	O
cerebral	O
malaria	B-PATH
(	O
59	O
.	O
38	O
%).	O

TITLE	O
:	O
Cricoarytenoid	O
arthritis	O
with	O
rheumatoid	B-PATH
arthritis	I-PATH
and	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
.	O

Although	O
chemotherapy	O
of	O
malaria	B-PATH
is	O
challenged	O
by	O
the	O
continuing	O
evolution	O
of	O
antimalarial	O
resistance	O
,	O
quinine	O
remains	O
the	O
first	O
-	O
line	O
drug	O
for	O
severe	O
imported	O
disease	O
.	O

When	O
control	O
over	O
safe	O
iron	O
sequestration	O
is	O
lost	O
or	O
compromised	O
,	O
leading	O
to	O
the	O
release	B-PATH
of	O
low	O
molecular	O
mass	O
forms	O
of	O
iron	O
,	O
the	O
heart	O
appears	O
to	O
be	O
particularly	O
sensitive	O
to	O
iron	O
toxicity	O
with	O
cardiomyopathies	O
often	O
developing	O
as	O
a	O
consequence	O
.	O

TITLE	O
:	O
Induction	O
of	O
caspase	O
-	O
dependent	O
apoptosis	B-PATH
in	O
cultured	O
cells	O
by	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

A	O
few	O
cases	O
have	O
been	O
reported	O
of	O
progressive	O
pulmonary	O
cystic	O
disease	O
associated	O
with	O
PCP	O
pneumonia	O
in	O
patients	O
with	O
AIDS	O
,	O
in	O
which	O
the	O
cause	O
of	O
bulla	O
formation	O
was	O
thought	O
to	O
be	O
lung	O
parenchyma	O
destruction	O
induced	O
by	O
HIV	O
itself	O
,	O
or	O
increased	O
elastase	O
release	B-PATH
from	O
HIV	O
-	O
infected	O
macrophages	O
.	O

Patients	O
with	O
ARF	O
and	O
smear	O
positive	O
malaria	B-PATH
were	O
evaluated	O
.	O

CONCLUSIONS	O
:	O
ARF	O
necessitating	O
dialysis	O
was	O
seen	O
in	O
92	O
%	O
of	O
patients	O
with	O
ARF	O
in	O
malaria	B-PATH
.	O

These	O
result	O
either	O
from	O
bronchial	O
reactions	O
,	O
asthma	B-PATH
exacerbation	O
or	O
eosinophil	O
bronchopneumonia	O
,	O
or	O
alveolar	O
involvement	O
:	O
intra	O
-	O
alveolar	O
bleeding	O
,	O
pulmonary	O
edema	O
or	O
organized	O
pneumonia	O
.	O

TITLE	O
:	O
Lack	O
of	O
nitric	O
oxide	O
synthase	O
type	O
2	O
(	O
NOS2	O
)	O
results	O
in	O
reduced	O
neuronal	O
apoptosis	B-PATH
and	O
mortality	O
following	O
mouse	O
hepatitis	O
virus	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Confocal	O
microscopy	O
revealed	O
that	O
the	O
majority	O
of	O
cells	O
(>	O
70	O
%)	O
undergoing	O
apoptosis	B-PATH
were	O
neurons	O
.	O

These	O
studies	O
indicate	O
that	O
NOS2	O
-	O
generated	O
NO	O
contributes	O
to	O
apoptosis	B-PATH
of	O
neurons	O
but	O
not	O
demyelination	O
following	O
MHV	O
infection	O
.	O

However	O
,	O
as	O
more	O
effective	O
antiviral	O
treatments	O
and	O
vaccines	O
become	O
available	O
,	O
such	O
therapies	O
are	O
likely	O
to	O
be	O
effective	O
in	O
patients	O
with	O
asthma	B-PATH
.	O

It	O
most	O
often	O
concerns	O
patients	O
admitted	O
to	O
intensive	O
care	O
units	O
for	O
acute	O
respiratory	O
failure	O
,	O
mainly	O
asthma	B-PATH
or	O
adult	O
respiratory	O
distress	O
syndrome	O
,	O
that	O
may	O
require	O
mechanical	O
ventilation	O
,	O
use	O
of	O
neuromuscular	O
blocking	O
agents	O
and	O
steroids	O
.	O

During	O
a	O
winter	O
when	O
influenza	B-PATH
A	I-PATH
infection	O
was	O
prevalent	O
,	O
100	O
elderly	O
adults	O
hospitalized	O
because	O
of	O
cardiopulmonary	O
illnesses	O
were	O
evaluated	O
for	O
rhinovirus	O
and	O
coronavirus	O
infection	O
.	O

We	O
diagnosed	O
miliary	O
tuberculosis	B-PATH
because	O
the	O
transbronchial	O
lung	O
biopsy	O
specimen	O
showed	O
caseous	O
granuloma	O
and	O
the	O
PCR	O
test	O
for	O
Mycobacterium	O
tuberculosis	B-PATH
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
was	O
positive	O
.	O

TITLE	O
:	O
Acute	O
asphyxia	O
caused	O
by	O
Gerhardt	O
'	O
s	O
syndrome	O
associated	O
with	O
asthma	B-PATH
.	O

However	O
,	O
there	O
is	O
also	O
strong	O
evidence	O
that	O
asthma	B-PATH
may	O
be	O
associated	O
with	O
VCD	O
,	O
sometimes	O
masquerading	O
as	O
exercise	O
-	O
induced	O
asthma	B-PATH
.	O

Recently	O
it	O
was	O
shown	O
that	O
low	O
tidal	O
volume	O
ventilation	O
reduces	O
mortality	O
and	O
pro	O
-	O
inflammatory	O
mediator	O
release	B-PATH
in	O
these	O
patients	O
,	O
suggesting	O
biotrauma	O
as	O
a	O
side	O
effect	O
of	O
mechanical	O
ventilation	O
.	O

We	O
hypothesize	O
that	O
ventilation	O
-	O
induced	O
mediator	O
release	B-PATH
is	O
explained	O
by	O
stretching	O
of	O
lung	O
cells	O
,	O
which	O
is	O
reinforced	O
by	O
surfactant	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
-	O
induced	O
apoptosis	B-PATH
in	O
17Cl	O
-	O
1	O
cells	O
involves	O
a	O
mitochondria	O
-	O
mediated	O
pathway	O
and	O
its	O
downstream	O
caspase	O
-	O
8	O
activation	O
and	O
bid	O
cleavage	O
.	O

In	O
conclusion	O
,	O
we	O
confirmed	O
the	O
high	O
incidence	O
of	O
viral	O
infection	O
in	O
acute	O
exacerbations	O
of	O
asthma	B-PATH
,	O
especially	O
enteroviruses	O
or	O
rhinoviruses	O
.	O

ABSTRACT	O
:	O
Although	O
known	O
as	O
common	O
causes	O
of	O
upper	O
respiratory	O
infections	O
,	O
rhinoviruses	O
,	O
enteroviruses	O
,	O
and	O
corona	O
-	O
viruses	O
are	O
poorly	O
studied	O
as	O
inducers	O
of	O
wheezing	O
in	O
infants	O
,	O
and	O
their	O
possible	O
role	O
in	O
the	O
development	O
of	O
childhood	O
asthma	B-PATH
has	O
not	O
been	O
investigated	O
.	O

As	O
single	O
viral	O
findings	O
,	O
rhinoviruses	O
were	O
associated	O
with	O
the	O
development	O
of	O
asthma	B-PATH
(	O
P	O
=.	O
047	O
;	O
odds	O
ratio	O
,	O
4	O
.	O
14	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
02	O
-	O
16	O
.	O
77	O
versus	O
rhinovirus	O
-	O
negative	O
cases	O
[	O
by	O
logistic	O
regression	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
and	O
atopic	O
dermatitis	O
on	O
entry	O
)].	O

This	O
area	O
of	O
central	O
Italy	O
was	O
formerly	O
endemic	O
for	O
malaria	B-PATH
and	O
it	O
is	O
now	O
covered	O
by	O
a	O
population	O
-	O
based	O
cancer	O
registry	O
.	O

Though	O
acute	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
(	O
GVHD	O
)	O
of	O
systemic	O
skin	O
(	O
grade	O
II	O
)	O
and	O
pneumonia	O
were	O
observed	O
during	O
neutropenia	O
due	O
to	O
the	O
post	O
-	O
conditioning	O
regimen	O
,	O
he	O
could	O
be	O
discharged	O
from	O
our	O
hospital	O
on	O
the	O
135th	O
day	O
after	O
BMT	O
.	O

TITLE	O
:	O
Cleaning	O
products	O
and	O
work	O
-	O
related	O
asthma	B-PATH
.	O

Nested	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
amplify	O
the	O
RNA	B-PATH
polymerase	I-PATH
gene	O
of	O
the	O
novel	O
coronavirus	O
and	O
the	O
PCR	O
products	O
were	O
sequenced	O
directly	O
or	O
after	O
cloned	O
to	O
pMD18	O
-	O
T	O
vector	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
role	O
and	O
mechanism	O
of	O
apoptosis	B-PATH
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

It	O
may	O
be	O
beneficial	O
to	O
suppress	O
cytokines	O
storm	O
in	O
SARS	O
patients	O
in	O
early	O
stage	O
,	O
which	O
will	O
stop	O
the	O
progression	O
of	O
SIRS	O
and	O
release	B-PATH
hepatic	O
damage	O
and	O
improve	O
the	O
prognosis	O
of	O
SARS	O
patients	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
artificial	O
genetic	O
information	O
systems	O
(	O
AEGIS	O
)	O
that	O
we	O
have	O
developed	O
have	O
been	O
used	O
in	O
FDA	O
-	O
approved	O
commercial	O
tests	O
for	O
managing	O
HIV	O
and	O
hepatitis	B-PATH
C	I-PATH
infections	O
in	O
individual	O
patients	O
,	O
and	O
in	O
a	O
tool	O
that	O
seeks	O
the	O
virus	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

No	O
approved	O
laboratory	O
tests	O
are	O
available	O
to	O
screen	O
the	O
blood	O
for	O
Chagas	O
disease	O
,	O
malaria	B-PATH
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
or	O
variant	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
.	O

Treatment	O
with	O
the	O
pan	O
-	O
caspase	O
inhibitor	O
Z	O
-	O
VAD	O
-	O
fmk	O
blocked	O
MHV	O
-	O
induced	O
apoptosis	B-PATH
,	O
suggesting	O
an	O
involvement	O
of	O
the	O
caspase	O
-	O
dependent	O
pathway	O
.	O

There	O
were	O
similar	O
findings	O
in	O
the	O
ECMO	O
group	O
:	O
survivors	O
had	O
proapoptotic	O
BAL	O
fluid	O
compared	O
with	O
non	O
-	O
survivors	O
(	O
apoptosis	B-PATH
ratio	O
day	O
1	O
,	O
survivors	O
7	O
.	O
9	O
(	O
2	O
.	O
1	O
)	O
v	O
non	O
-	O
survivors	O
2	O
.	O
1	O
(	O
0	O
.	O
7	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)).	O

We	O
report	O
the	O
case	O
of	O
a	O
woman	O
who	O
had	O
undergone	O
a	O
successful	O
allogeneic	O
bone	O
marrow	O
transplant	O
for	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
lactam	O
12	O
,	O
as	O
well	O
as	O
lactam	O
1	O
,	O
potently	O
inhibits	O
colony	O
formation	O
of	O
human	O
prostate	B-PATH
cancer	I-PATH
cells	O
.	O

ABSTRACT	O
:	O
The	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
an	O
important	O
regulator	O
of	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
and	O
was	O
very	O
recently	O
identified	O
as	O
a	O
functional	O
receptor	O
for	O
the	O
SARS	O
virus	O
.	O

ABSTRACT	O
:	O
Highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
viruses	O
of	O
subtypes	O
H5	O
and	O
H7	O
are	O
the	O
causative	O
agents	O
of	O
fowl	O
plague	O
in	O
poultry	O
.	O

A	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
virus	O
of	O
subtype	O
H7N7	O
,	O
closely	O
related	O
to	O
low	O
pathogenic	O
virus	O
isolates	O
obtained	O
from	O
wild	O
ducks	O
,	O
was	O
isolated	O
from	O
chickens	O
.	O

Marked	O
accumulation	O
of	O
cells	O
in	O
mitosis	O
was	O
observed	O
in	O
two	O
patients	O
and	O
apoptosis	B-PATH
was	O
observed	O
in	O
all	O
three	O
patients	O
.	O

TITLE	O
:	O
Hypothesis	O
links	O
emergence	O
of	O
chloroquine	O
-	O
resistant	O
malaria	B-PATH
and	O
other	O
intracellular	O
pathogens	O
and	O
suggests	O
a	O
new	O
strategy	O
for	O
treatment	O
of	O
diseases	O
caused	O
by	O
intracellular	O
parasites	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
clinical	O
and	O
demographic	O
aspects	O
as	O
well	O
as	O
the	O
outcomes	O
of	O
severe	O
cases	O
of	O
malaria	B-PATH
infections	O
managed	O
in	O
the	O
intensive	O
care	O
unit	O
of	O
the	O
Sarawak	O
General	O
Hospital	O
,	O
Kuching	O
from	O
January	O
1996	O
to	O
December	O
2001	O
.	O

A	O
single	O
case	O
of	O
vivax	O
malaria	B-PATH
,	O
which	O
was	O
complicated	O
by	O
septicaemic	O
shock	O
and	O
disseminated	O
intravascular	O
coagulopathy	O
was	O
also	O
documented	O
.	O

The	O
antiviral	O
mechanism	O
of	O
GA	O
appears	O
to	O
be	O
associated	O
with	O
Hsp90	O
inactivation	O
and	O
cell	B-PATH
cycle	I-PATH
restoration	O
,	O
which	O
indicates	O
that	O
GA	O
exhibits	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
.	O

Four	O
patients	O
had	O
underlying	O
pulmonary	O
pathology	O
:	O
past	O
pulmonary	O
tuberculosis	B-PATH
(	O
2	O
),	O
emphysema	O
(	O
1	O
)	O
and	O
recurrent	O
right	O
pleural	O
effusion	O
from	O
autoimmune	O
serositis	O
(	O
1	O
).	O

ABSTRACT	O
:	O
Before	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
outbreak	O
,	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
'	O
s	O
(	O
CDC	O
)	O
legal	O
authority	O
to	O
apprehend	O
,	O
detain	O
,	O
or	O
conditionally	O
release	B-PATH
persons	O
was	O
limited	O
to	O
seven	O
listed	O
diseases	O
,	O
not	O
including	O
SARS	O
,	O
and	O
could	O
only	O
be	O
changed	O
using	O
a	O
two	O
-	O
step	O
process	O
:	O
1	O
)	O
executive	O
order	O
of	O
the	O
President	O
of	O
the	O
United	O
States	O
on	O
recommendation	O
by	O
the	O
Secretary	O
,	O
U	O
.	O
S	O
.	O
Department	O
of	O
Health	O
and	O
Human	O
Services	O
(	O
HHS	O
),	O
and	O
2	O
)	O
amendment	O
to	O
CDC	O
quarantine	O
regulations	O
(	O
42	O
CFR	O
Parts	O
70	O
and	O
71	O
).	O

In	O
addition	O
to	O
the	O
revised	O
recommendations	O
,	O
the	O
guideline	O
contains	O
new	O
sections	O
on	O
pertussis	B-PATH
and	O
lower	O
respiratory	O
tract	O
infections	O
caused	O
by	O
adenovirus	O
and	O
human	O
parainfluenza	O
viruses	O
and	O
refers	O
readers	O
to	O
the	O
source	O
of	O
updated	O
information	O
about	O
prevention	O
and	O
control	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

RESULTS	O
:	O
The	O
airborne	O
spread	O
of	O
measles	B-PATH
,	O
tuberculosis	B-PATH
and	O
SARS	O
is	O
well	O
-	O
documented	O
in	O
the	O
medical	O
literature	O
.	O

This	O
observation	O
has	O
some	O
implications	O
for	O
the	O
SARS	O
-	O
CoV	O
pathogenicity	O
:	O
SARS	O
-	O
CoV	O
does	O
induce	O
apoptosis	B-PATH
in	O
cell	O
cultures	O
and	O
might	O
have	O
the	O
same	O
effect	O
in	O
vivo	O
,	O
responsible	O
for	O
the	O
severe	O
damage	O
of	O
the	O
respiratory	O
system	O
.	O

TITLE	O
:	O
Attenuation	O
of	O
SARS	O
coronavirus	O
by	O
a	O
short	O
hairpin	O
RNA	O
expression	O
plasmid	O
targeting	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

TITLE	O
:	O
A	O
novel	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
protein	O
,	O
U274	O
,	O
is	O
transported	O
to	O
the	O
cell	O
surface	O
and	O
undergoes	O
endocytosis	B-PATH
.	O

ABSTRACT	O
:	O
In	O
Singapore	O
,	O
of	O
236	O
patients	O
with	O
probable	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
2	O
were	O
coinfected	O
with	O
tuberculosis	B-PATH
,	O
a	O
phenomenon	O
not	O
previously	O
reported	O
.	O

The	O
patients	O
'	O
tuberculosis	B-PATH
episodes	O
only	O
came	O
to	O
light	O
after	O
full	O
recovery	O
from	O
SARS	O
,	O
when	O
they	O
presented	O
with	O
persistent	O
respiratory	O
symptoms	O
and	O
/	O
or	O
worsening	O
chest	O
radiography	O
findings	O
.	O

We	O
conclusively	O
show	O
that	O
SCoV	O
E	O
protein	O
contains	O
an	O
unusually	O
short	O
,	O
palindromic	O
transmembrane	O
helical	O
hairpin	O
around	O
a	O
previously	O
unidentified	O
pseudo	O
-	O
center	O
of	O
symmetry	O
,	O
a	O
structural	O
feature	O
which	O
seems	O
to	O
be	O
unique	O
to	O
SCoV	O
.	O
The	O
hairpin	O
deforms	O
lipid	O
bilayers	O
by	O
way	O
of	O
increasing	O
their	O
curvature	O
,	O
providing	O
for	O
the	O
first	O
time	O
a	O
molecular	O
explanation	O
of	O
E	O
protein	O
'	O
s	O
pivotal	O
role	O
in	O
viral	O
budding	B-PATH
.	O

TITLE	O
:	O
The	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	O
induces	O
actin	O
reorganization	O
and	O
apoptosis	B-PATH
in	O
COS	O
-	O
1	O
cells	O
in	O
the	O
absence	O
of	O
growth	O
factors	O
.	O

This	O
is	O
the	O
first	O
report	O
showing	O
the	O
ability	O
of	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
to	O
induce	O
apoptosis	B-PATH
and	O
actin	O
reorganization	O
in	O
mammalian	O
cells	O
under	O
stressed	O
conditions	O
.	O

TITLE	O
:	O
Emerging	O
infectious	O
disease	O
issues	O
in	O
international	O
adoptions	O
:	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
avian	O
influenza	O
and	O
measles	B-PATH
.	O

Accumulation	O
of	O
hypophosphorylated	O
pRb	O
thus	O
prevents	O
cell	B-PATH
cycle	I-PATH
progression	O
from	O
G	O
(	O
0	O
)/	O
G	O
(	O
1	O
)	O
to	O
S	O
phase	O
.	O

So	O
it	O
is	O
perhaps	O
not	O
surprising	O
that	O
the	O
ACE	O
D	O
/	O
D	O
genotype	O
is	O
associated	O
with	O
several	O
major	O
psychiatric	O
diseases	O
,	O
most	O
cancers	O
except	O
prostate	B-PATH
cancer	I-PATH
(	O
where	O
the	O
D	O
/	O
D	O
genotype	O
is	O
actually	O
protective	O
),	O
most	O
cardiovascular	O
diseases	O
,	O
most	O
autoimmune	O
diseases	O
,	O
and	O
even	O
infectious	O
diseases	O
like	O
tuberculosis	B-PATH
and	O
HIV	O
.	O

This	O
is	O
currently	O
estimated	O
as	O
one	O
case	O
of	O
asthma	B-PATH
of	O
occupational	O
origin	O
in	O
one	O
adult	O
out	O
of	O
ten	O
.	O

On	O
the	O
other	O
hand	O
,	O
simultaneous	O
high	O
level	O
expression	O
of	O
S	O
,	O
E	O
and	O
M	O
by	O
a	O
single	O
recombinant	O
virus	O
allowed	O
the	O
very	O
efficient	O
assembly	O
and	O
release	B-PATH
of	O
VLPs	O
.	O

Measures	O
analogous	O
to	O
those	O
employed	O
against	O
the	O
plague	O
have	O
been	O
adopted	O
to	O
fight	O
against	O
the	O
disease	O
termed	O
the	O
Great	O
White	O
Plague	O
,	O
i	O
.	O
e	O
.	O
tuberculosis	B-PATH
,	O
and	O
in	O
recent	O
times	O
various	O
countries	O
have	O
set	O
up	O
official	O
entities	O
for	O
the	O
identification	O
and	O
control	O
of	O
infections	O
.	O

The	O
role	O
of	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
and	O
airway	O
pressure	O
release	B-PATH
ventilation	O
in	O
ARDS	O
is	O
uncertain	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
examined	O
whether	O
they	O
can	O
induce	O
apoptosis	B-PATH
,	O
which	O
has	O
been	O
observed	O
clinically	O
.	O

The	O
majority	O
of	O
studies	O
have	O
been	O
conducted	O
on	O
DNA	O
and	O
retroviruses	O
whose	O
primary	O
site	O
of	O
replication	O
is	O
the	O
nucleus	O
,	O
but	O
increasingly	O
a	O
number	O
of	O
researchers	O
are	O
demonstrating	O
that	O
RNA	O
viruses	O
,	O
whose	O
primary	O
site	O
of	O
replication	O
is	O
normally	O
the	O
cytoplasm	O
,	O
also	O
interfere	O
with	O
the	O
cell	B-PATH
cycle	I-PATH
.	O

Viral	O
interference	O
with	O
the	O
cell	B-PATH
cycle	I-PATH
can	O
have	O
a	O
myriad	O
of	O
different	O
effects	O
to	O
improve	O
virus	O
infection	O
,	O
for	O
example	O
to	O
promote	O
replication	O
of	O
viral	O
DNA	O
genomes	O
,	O
or	O
to	O
delay	O
the	O
cell	B-PATH
cycle	I-PATH
to	O
allow	O
sufficient	O
time	O
for	O
RNA	O
virus	O
assembly	O
.	O

The	O
nucleolus	O
and	O
associated	O
subnuclear	O
structures	O
can	O
sequester	O
cell	B-PATH
cycle	I-PATH
regulatory	O
complexes	O
,	O
and	O
nucleolar	O
proteins	O
also	O
have	O
a	O
direct	O
and	O
indirect	O
effect	O
on	O
the	O
cycling	O
cell	O
.	O

Diseases	O
such	O
as	O
drug	O
-	O
resistant	O
malaria	B-PATH
continue	O
to	O
be	O
threats	O
.	O

The	O
emergence	O
of	O
these	O
diseases	O
,	O
and	O
resurgence	O
of	O
old	O
ones	O
like	O
tuberculosis	B-PATH
and	O
cholera	O
,	O
reflects	O
various	O
changes	O
in	O
human	O
ecology	O
:	O
rural	O
-	O
to	O
-	O
urban	O
migration	O
resulting	O
in	O
high	O
-	O
density	O
peri	O
-	O
urban	O
slums	O
;	O
increasing	O
long	O
-	O
distance	O
mobility	O
and	O
trade	O
;	O
the	O
social	O
disruption	O
of	O
war	O
and	O
conflict	O
;	O
changes	O
in	O
personal	O
behavior	O
;	O
and	O
,	O
increasingly	O
,	O
human	O
-	O
induced	O
global	O
changes	O
,	O
including	O
widespread	O
forest	O
clearance	O
and	O
climate	O
change	O
.	O

These	O
proteins	O
include	O
rennin	O
,	O
amyloglucosidases	O
(	O
glucamylases	O
),	O
interferons	O
,	O
interleukins	O
,	O
insulin	O
,	O
monoclonal	O
antibodies	O
,	O
tissue	O
plasminogen	O
activators	O
(	O
t	O
-	O
PA	O
),	O
sexually	O
transmitted	O
disease	O
antigens	O
,	O
and	O
measles	B-PATH
,	O
mumps	O
and	O
rubella	O
antigens	O
,	O
growth	O
hormones	O
,	O
somatotropin	O
,	O
blood	O
clotting	O
factors	O
VIII	O
and	O
XIII	O
.	O

Decreased	O
production	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
in	O
ARDS	O
may	O
favour	O
vascular	O
lesions	O
,	O
since	O
VEGF	O
promotes	O
endothelial	O
survival	O
by	O
inhibiting	O
apoptosis	B-PATH
.	O

Extensive	O
cellular	O
apoptosis	B-PATH
(	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
deoxyuridine	O
triphosphate	O
nick	O
-	O
end	O
labelling	O
staining	O
),	O
including	O
endothelial	O
and	O
alveolar	O
type	O
II	O
cells	O
,	O
was	O
demonstrated	O
,	O
and	O
vascular	O
bed	O
density	O
(	O
CD31	O
immunostaining	O
)	O
decreased	O
in	O
ARDS	O
lungs	O
as	O
compared	O
with	O
controls	O
.	O

Women	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
should	O
be	O
advised	O
to	O
become	O
pregnant	O
when	O
the	O
disease	O
is	O
inactive	O
and	O
should	O
be	O
observed	O
at	O
an	O
appropriate	O
centre	O
using	O
a	O
multidisciplinary	O
approach	O
.	O

Patients	O
exhibited	O
cerebral	O
malaria	B-PATH
,	O
renal	O
failure	O
,	O
circulatory	O
collapse	O
,	O
severe	O
anemia	O
,	O
hemoglobinurea	O
,	O
abnormal	O
bleeding	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
jaundice	O
.	O

Several	O
influenza	B-PATH
A	I-PATH
virus	O
subtypes	O
were	O
transmitted	O
from	O
birds	O
to	O
humans	O
,	O
and	O
these	O
viruses	O
continue	O
to	O
constitute	O
a	O
pandemic	O
threat	O
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
shown	O
that	O
heat	O
shock	O
protein	O
60	O
(	O
Hsp60	O
)	O
is	O
a	O
danger	O
signal	O
for	O
the	O
immune	O
system	O
and	O
appears	O
to	O
be	O
a	O
key	O
endogenous	O
inflammatory	O
mediator	O
that	O
activates	O
the	O
toll	O
-	O
like	O
receptors	O
and	O
causes	O
the	O
release	B-PATH
of	O
proinflammatory	O
cytokines	O
and	O
nitric	O
oxide	O
by	O
immune	O
competent	O
cells	O
,	O
but	O
no	O
data	O
are	O
available	O
for	O
trauma	O
patients	O
.	O

At	O
24	O
hrs	O
and	O
,	O
in	O
part	O
,	O
already	O
at	O
2	O
hrs	O
,	O
cytokine	O
release	B-PATH
from	O
peritoneal	O
macrophages	O
,	O
splenic	O
macrophages	O
,	O
and	O
splenocytes	O
was	O
significantly	O
suppressed	O
.	O

Strikingly	O
,	O
live	O
SARS	O
-	O
CoV	O
could	O
further	O
prime	O
cell	O
types	O
to	O
respond	O
to	O
a	O
suboptimal	O
dose	O
of	O
bacterial	O
LPS	O
(	O
100	O
ng	O
/	O
ml	O
),	O
resulting	O
in	O
massive	O
release	B-PATH
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
12	O
.	O

In	O
vitro	O
experiments	O
of	O
chromatin	O
condensation	O
and	O
DNA	O
fragmentation	O
suggested	O
that	O
the	O
3a	O
protein	O
may	O
trigger	O
apoptosis	B-PATH
.	O

Viroporins	O
are	O
a	O
growing	O
family	O
of	O
viral	O
proteins	O
able	O
to	O
enhance	O
membrane	O
permeability	O
,	O
promoting	O
virus	O
budding	B-PATH
.	O

A	O
panel	O
of	O
viruses	O
including	O
swine	O
gastroenteritis	O
virus	O
,	O
bovine	O
coronavirus	O
,	O
avian	O
bronchitis	O
virus	O
(	O
Connecticut	O
strain	O
),	O
avian	O
bronchitis	O
virus	O
(	O
Massachusetts	O
strain	O
),	O
human	O
coronaviruses	O
229E	O
and	O
OC43	O
,	O
parainfluenza	O
virus	O
(	O
type	O
III	O
),	O
human	O
metapneumovirus	O
,	O
adenovirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
influenza	B-PATH
A	I-PATH
were	O
tested	O
by	O
all	O
assays	O
.	O

However	O
,	O
other	O
components	O
of	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
,	O
including	O
ACE	O
,	O
angiotensin	O
II	O
and	O
the	O
angiotensin	O
II	O
type	O
1a	O
receptor	O
(	O
AT1a	O
),	O
promote	O
disease	O
pathogenesis	O
,	O
induce	O
lung	O
oedemas	O
and	O
impair	O
lung	O
function	O
.	O

TITLE	O
:	O
Experience	O
with	O
ARDS	O
caused	O
by	O
tuberculosis	B-PATH
in	O
a	O
respiratory	O
intensive	O
care	O
unit	O
.	O

Nine	O
(	O
4	O
.	O
9	O
%)	O
of	O
187	O
patients	O
had	O
ARDS	O
secondary	O
to	O
tuberculosis	B-PATH
.	O

Tuberculosis	B-PATH
is	O
an	O
uncommon	O
but	O
definite	O
cause	O
of	O
ARDS	O
,	O
and	O
in	O
patients	O
with	O
ARDS	O
of	O
obscure	O
aetiology	O
where	O
the	O
clinical	O
features	O
suggest	O
tuberculosis	B-PATH
as	O
the	O
inciting	O
cause	O
,	O
antitubercular	O
therapy	O
should	O
be	O
started	O
empirically	O
and	O
the	O
diagnosis	O
actively	O
pursued	O
later	O
.	O

These	O
studies	O
demonstrate	O
that	O
retinal	O
degeneration	O
following	O
viral	O
infection	O
is	O
associated	O
with	O
increased	O
release	B-PATH
of	O
TNF	O
-	O
alpha	O
/	O
TNF	O
receptors	O
combined	O
with	O
a	O
down	O
-	O
regulation	O
of	O
NO	O
.	O

TITLE	O
:	O
Bcl	O
-	O
xL	O
inhibits	O
T	O
-	O
cell	O
apoptosis	B-PATH
induced	O
by	O
expression	O
of	O
SARS	O
coronavirus	O
E	O
protein	O
in	O
the	O
absence	O
of	O
growth	O
factors	O
.	O

We	O
hypothesized	O
that	O
SARS	O
-	O
CoV	O
encodes	O
a	O
small	O
envelope	O
E	O
protein	O
that	O
is	O
homologous	O
with	O
MHV	O
E	O
protein	O
,	O
thus	O
inducing	O
T	O
-	O
cell	O
apoptosis	B-PATH
.	O

SARS	O
-	O
CoV	O
virus	O
is	O
able	O
to	O
induce	O
both	O
IFN	O
-	O
alpha	O
and	O
-	O
gamma	O
mRNA	O
accumulation	O
and	O
protein	O
release	B-PATH
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
MOI	O
10	O
being	O
the	O
most	O
effective	O
.	O

These	O
latter	O
two	O
patients	O
died	O
of	O
infections	O
32	O
and	O
36	O
days	O
after	O
HSCT	O
,	O
with	O
grade	O
IV	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
and	O
multiorgan	O
dysfunction	O
.	O

In	O
addition	O
,	O
several	O
subtypes	O
of	O
the	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
previously	O
known	O
to	O
infect	O
only	O
poultry	O
and	O
wild	O
birds	O
,	O
were	O
recently	O
found	O
to	O
have	O
been	O
directly	O
transmitted	O
to	O
humans	O
.	O

TITLE	O
:	O
Role	O
of	O
vascular	O
cell	O
adhesion	O
molecules	O
and	O
leukocyte	O
apoptosis	B-PATH
in	O
the	O
lymphopenia	O
and	O
thrombocytopenia	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

RESULTS	O
:	O
Coexisting	O
maternal	O
disease	O
,	O
including	O
asthma	B-PATH
and	O
anemia	O
,	O
increase	O
the	O
risk	O
of	O
contracting	O
pneumonia	O
in	O
pregnancy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
acute	O
lung	O
injury	O
on	O
the	O
gut	O
epithelium	O
and	O
examine	O
mechanisms	O
underlying	O
changes	O
in	O
crypt	O
proliferation	O
and	O
apoptosis	B-PATH
.	O

Changes	O
in	O
both	O
gut	O
epithelial	O
proliferation	O
and	O
death	O
were	O
apparent	O
within	O
12	O
hrs	O
,	O
but	O
proliferation	O
was	O
decreased	O
36	O
hrs	O
following	O
acute	O
lung	O
injury	O
while	O
apoptosis	B-PATH
returned	O
to	O
normal	O
.	O

The	O
pathogenesis	O
of	O
this	O
kind	O
of	O
diarrhea	O
includes	O
cytokine	O
action	O
,	O
intestinal	O
inflammation	O
,	O
sequestration	O
of	O
red	O
blood	O
cells	O
,	O
apoptosis	B-PATH
and	O
increased	O
permeability	O
of	O
endothelial	O
cells	O
in	O
the	O
gut	O
microvasculature	O
,	O
and	O
direct	O
invasion	O
of	O
gut	O
epithelial	O
cells	O
by	O
various	O
infectious	O
agents	O
.	O

Gas	O
transfer	O
was	O
significantly	O
impaired	O
in	O
patients	O
with	O
severe	O
malaria	B-PATH
.	O

In	O
patients	O
with	O
uncomplicated	O
malaria	B-PATH
,	O
Vc	O
was	O
reduced	O
at	O
presentation	O
but	O
improved	O
thereafter	O
.	O

In	O
patients	O
with	O
severe	O
malaria	B-PATH
,	O
Vc	O
decreased	O
with	O
treatment	O
and	O
was	O
lowest	O
at	O
day	O
7	O
.	O

Expression	O
of	O
one	O
of	O
these	O
subgroup	O
-	O
specific	O
genes	O
,	O
ORF7a	O
,	O
resulted	O
in	O
apoptosis	B-PATH
via	O
a	O
caspase	O
-	O
dependent	O
pathway	O
.	O

The	O
caveolae	O
engulfed	O
SV40	O
virions	O
begin	O
budding	B-PATH
from	O
plasma	O
membrane	O
depending	O
on	O
dynamin	O
.	O

TITLE	O
:	O
Adenovirus	O
-	O
mediated	O
expression	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
is	O
sufficient	O
to	O
induce	O
apoptosis	B-PATH
in	O
Vero	O
E6	O
cells	O
.	O

Pretreatment	O
of	O
cells	O
with	O
a	O
caspase	O
-	O
9	O
inhibitor	O
completely	O
blocked	O
caspase	O
-	O
9	O
activation	O
and	O
partially	O
inhibited	O
the	O
apoptosis	B-PATH
mediated	O
by	O
MHV	O
infection	O
.	O

These	O
results	O
thus	O
establish	O
the	O
involvement	O
of	O
the	O
mitochondrial	O
pathway	O
in	O
MHV	O
-	O
induced	O
oligodendrocyte	O
apoptosis	B-PATH
.	O

ABSTRACT	O
:	O
Severe	O
pulmonary	O
involvement	O
in	O
malaria	B-PATH
has	O
been	O
frequently	O
reported	O
in	O
cases	O
of	O
Plasmodium	O
falciparum	O
infection	O
,	O
but	O
rarely	O
in	O
vivax	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
Deregulation	O
of	O
the	O
cell	B-PATH
cycle	I-PATH
is	O
a	O
common	O
strategy	O
employed	O
by	O
many	O
DNA	O
and	O
RNA	O
viruses	O
to	O
trap	O
and	O
exploit	O
the	O
host	O
cell	O
machinery	O
toward	O
their	O
own	O
benefit	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
positive	O
-	O
strand	O
,	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
-	O
utilizing	O
viruses	O
that	O
require	O
a	O
polymerase	O
template	O
switch	O
,	O
characterized	O
as	O
discontinuous	O
transcription	O
,	O
to	O
place	O
a	O
5	O
'-	O
terminal	O
genomic	O
leader	O
onto	O
subgenomic	O
mRNAs	O
(	O
sgmRNAs	O
).	O

Surprisingly	O
,	O
increased	O
viral	O
load	O
in	O
oligodendroglia	O
did	O
not	O
affect	O
the	O
extent	O
of	O
myelin	O
loss	O
,	O
the	O
frequency	O
of	O
oligodendroglial	O
apoptosis	B-PATH
,	O
or	O
CNS	O
recruitment	O
of	O
macrophages	O
.	O

Respiratory	O
complications	O
of	O
chronic	O
renal	O
failure	O
include	O
pulmonary	O
edema	O
,	O
fibrinous	O
pleuritis	O
,	O
pulmonary	O
calcification	O
,	O
and	O
a	O
predisposition	O
to	O
tuberculosis	B-PATH
.	O

Review	O
of	O
the	O
cases	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H5N1	O
reported	O
to	O
date	O
demonstrates	O
that	O
it	O
causes	O
a	O
severe	O
illness	O
,	O
with	O
a	O
high	O
proportion	O
of	O
patients	O
(	O
63	O
%)	O
requiring	O
advanced	O
organ	O
support	O
.	O

Numerous	O
potent	O
inhibitors	O
of	O
helicases	O
encoded	O
by	O
herpes	O
simplex	O
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
Japanese	O
encephalitis	O
virus	O
,	O
West	O
Nile	O
virus	O
,	O
and	O
human	O
papillomavirus	O
have	O
been	O
recently	O
reported	O
in	O
the	O
scientific	O
literature	O
.	O

These	O
new	O
drugs	O
may	O
offer	O
an	O
interesting	O
alternative	O
for	O
Asia	O
where	O
SARS	O
originated	O
and	O
malaria	B-PATH
has	O
remained	O
endemic	O
.	O

ABSTRACT	O
:	O
Infection	O
by	O
different	O
coronaviruses	O
(	O
CoVs	O
)	O
causes	O
alterations	O
in	O
the	O
transcriptional	O
and	O
translational	O
patterns	O
,	O
cell	B-PATH
cycle	I-PATH
,	O
cytoskeleton	O
,	O
and	O
apoptosis	B-PATH
pathways	O
of	O
the	O
host	O
cells	O
.	O

TITLE	O
:	O
M	O
and	O
N	O
proteins	O
of	O
SARS	O
coronavirus	O
induce	O
apoptosis	B-PATH
in	O
HPF	O
cells	O
.	O

RSV	O
was	O
detected	O
in	O
122	O
(	O
23	O
.	O
7	O
%),	O
HBoV	O
in	O
58	O
(	O
11	O
.	O
3	O
%),	O
adenovirus	O
in	O
35	O
(	O
6	O
.	O
8	O
%),	O
PIV	O
-	O
3	O
in	O
32	O
(	O
6	O
.	O
2	O
%),	O
rhinovirus	O
in	O
30	O
(	O
5	O
.	O
8	O
%),	O
hMPV	O
in	O
24	O
(	O
4	O
.	O
7	O
%),	O
influenza	B-PATH
A	I-PATH
in	O
24	O
(	O
4	O
.	O
7	O
%),	O
PIV	O
-	O
1	O
in	O
9	O
(	O
1	O
.	O
7	O
%),	O
influenza	O
B	O
in	O
9	O
(	O
1	O
.	O
7	O
%),	O
and	O
HCoV	O
-	O
NL63	O
in	O
8	O
(	O
1	O
.	O
6	O
%).	O

In	O
this	O
model	O
,	O
AIDS	O
is	O
seen	O
to	O
be	O
the	O
result	O
of	O
the	O
development	O
of	O
resistance	O
of	O
the	O
virus	O
(	O
PTRV	O
)	O
to	O
continuous	O
exposure	O
to	O
pro	O
-	O
apoptotic	O
(	O
schizonticidal	O
)	O
aminoquinoline	O
drugs	O
used	O
to	O
prevent	O
malaria	B-PATH
.	O

In	O
the	O
course	O
of	O
HIV	B-PATH
infection	I-PATH
,	O
other	O
types	O
of	O
immune	O
complex	O
glomerulonephritis	O
can	O
occur	O
,	O
most	O
frequently	O
in	O
whites	O
.	O

ABSTRACT	O
:	O
A	O
negative	O
-	O
pressure	O
operating	O
theater	O
is	O
required	O
to	O
limit	O
the	O
spread	O
of	O
respiratory	O
diseases	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
tuberculosis	B-PATH
,	O
avian	O
influenza	O
,	O
or	O
similar	O
infectious	O
diseases	O
.	O

Randomized	O
trials	O
are	O
epidemiologic	O
tools	O
that	O
can	O
sometimes	O
provide	O
erroneous	O
results	O
,	O
and	O
they	O
have	O
not	O
been	O
considered	O
necessary	O
for	O
studying	O
isolation	O
before	O
it	O
is	O
used	O
to	O
control	O
other	O
important	O
infections	O
,	O
such	O
as	O
tuberculosis	B-PATH
,	O
smallpox	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

This	O
prospective	O
study	O
was	O
conducted	O
on	O
patients	O
of	O
severe	O
malaria	B-PATH
admitted	O
in	O
a	O
classified	O
malaria	B-PATH
ward	O
of	O
a	O
tertiary	O
care	O
hospital	O
in	O
Bikaner	O
,	O
Rajasthan	O
(	O
northwest	O
India	O
)	O
during	O
1994	O
and	O
2001	O
.	O

The	O
sharp	O
difference	O
for	O
presence	O
of	O
jaundice	O
and	O
severe	O
anaemia	O
in	O
2001	O
and	O
cerebral	O
malaria	B-PATH
in	O
1994	O
was	O
statistically	O
significant	O
.	O

The	O
observation	O
of	O
changing	O
spectrum	O
of	O
severe	O
malaria	B-PATH
in	O
this	O
study	O
and	O
a	O
significant	O
increase	O
in	O
presentation	O
with	O
jaundice	O
as	O
an	O
important	O
manifestation	O
is	O
highly	O
essential	O
for	O
primary	O
,	O
secondary	O
and	O
tertiary	O
level	O
health	O
care	O
providers	O
for	O
proper	O
diagnosis	O
and	O
management	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
lymphopenia	O
observed	O
in	O
FIP	O
cats	O
was	O
due	O
to	O
apoptosis	B-PATH
,	O
and	O
that	O
the	O
ascitic	O
fluid	O
,	O
plasma	O
,	O
and	O
culture	O
supernatant	O
of	O
peritoneal	O
exudate	O
cells	O
(	O
adherent	O
cells	O
with	O
macrophage	O
morphology	O
,	O
or	O
PEC	O
)	O
from	O
FIP	O
cats	O
readily	O
induced	O
apoptosis	B-PATH
in	O
specific	O
pathogen	O
-	O
free	O
cat	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
particularly	O
CD8	O
+	O
cells	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
TNF	O
-	O
alpha	O
,	O
produced	O
by	O
virus	O
-	O
infected	O
macrophages	O
,	O
is	O
responsible	O
for	O
induction	O
of	O
apoptosis	B-PATH
in	O
uninfected	O
T	O
cells	O
,	O
primarily	O
CD8	O
+	O
T	O
cells	O
.	O

Afterwards	O
,	O
influenza	B-PATH
A	I-PATH
H3N2	O
was	O
detected	O
from	O
bronchial	O
extracts	O
.	O

CONCLUSIONS	O
:	O
Symptomatic	O
rhinovirus	O
infections	O
are	O
an	O
important	O
contributor	O
to	O
asthma	B-PATH
exacerbations	O
in	O
children	O
.	O

Respiratory	O
infections	O
may	O
have	O
a	O
human	O
source	O
such	O
as	O
tuberculosis	B-PATH
or	O
viral	O
diseases	O
or	O
may	O
originate	O
in	O
ventilation	O
systems	O
such	O
as	O
Legionnaire	O
'	O
s	O
disease	O
(	O
Legionella	O
pneumophila	O
pneumonia	O
).	O

A	O
recent	O
trial	O
in	O
adults	O
has	O
shown	O
that	O
intravenous	O
artesunate	O
reduces	O
severe	O
malaria	B-PATH
mortality	O
by	O
a	O
third	O
compared	O
with	O
adults	O
treated	O
with	O
intravenous	O
quinine	O
.	O

Oligonucleotide	O
target	O
sequences	O
specific	O
for	O
human	O
immunodeficiency	O
,	O
hepatitis	B-PATH
C	I-PATH
,	O
and	O
severe	O
acute	O
respiratory	O
viruses	O
were	O
assayed	O
simultaneously	O
in	O
a	O
no	O
-	O
wash	O
,	O
sealed	O
chamber	O
,	O
multiplexed	O
experiment	O
in	O
which	O
each	O
of	O
three	O
probe	O
sequences	O
was	O
attached	O
to	O
a	O
different	O
pattern	O
of	O
encoded	O
nanowires	O
.	O

This	O
was	O
initially	O
established	O
by	O
studies	O
demonstrating	O
that	O
cellular	O
expression	O
of	O
only	O
E	O
protein	O
and	O
the	O
membrane	O
protein	O
(	O
M	O
)	O
was	O
necessary	O
and	O
sufficient	O
for	O
the	O
generation	O
and	O
release	B-PATH
of	O
virus	O
-	O
like	O
particles	O
.	O

Later	O
on	O
,	O
viral	O
nucleocapsids	O
have	O
to	O
be	O
transported	O
to	O
the	O
budding	B-PATH
sites	O
in	O
the	O
Golgi	O
region	O
where	O
the	O
viral	O
glycoproteins	O
accumulate	O
and	O
particle	O
formation	O
occurs	O
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
the	O
tropical	O
disease	O
most	O
commonly	O
imported	O
into	O
the	O
UK	O
,	O
with	O
1500	O
-	O
2000	O
cases	O
reported	O
each	O
year	O
,	O
and	O
10	O
-	O
20	O
deaths	O
.	O

Severe	O
falciparum	O
malaria	B-PATH
,	O
or	O
infections	O
complicated	O
by	O
a	O
relatively	O
high	O
parasite	O
count	O
(	O
more	O
than	O
2	O
%	O
of	O
red	O
blood	O
cells	O
parasitized	O
),	O
should	O
be	O
treated	O
with	O
intravenous	O
therapy	O
until	O
the	O
patient	O
is	O
well	O
enough	O
to	O
continue	O
with	O
oral	O
treatment	O
.	O

Falciparum	O
malaria	B-PATH
in	O
pregnancy	O
is	O
more	O
likely	O
to	O
be	O
severe	O
and	O
complicated	O
:	O
the	O
placenta	O
contains	O
high	O
levels	O
of	O
parasites	O
.	O

TITLE	O
:	O
Canine	O
coronavirus	O
induces	O
apoptosis	B-PATH
in	O
cultured	O
cells	O
.	O

Commonly	O
to	O
other	O
animal	O
coronavirus	O
infection	O
caspase	O
-	O
3	O
is	O
likely	O
to	O
contribute	O
to	O
the	O
execution	O
phase	O
of	O
apoptosis	B-PATH
induced	O
by	O
CCoV	O
in	O
A	O
-	O
72	O
cells	O
since	O
we	O
found	O
activation	O
of	O
enzymatic	O
activity	O
as	O
well	O
as	O
procaspase	O
-	O
3	O
activating	O
cleavage	O
.	O

Therefore	O
in	O
the	O
case	O
of	O
CCoV	O
associated	O
gastroenteritis	O
,	O
apoptosis	B-PATH
of	O
epithelial	O
mucosa	O
cells	O
may	O
be	O
responsible	O
for	O
pathology	O
induced	O
by	O
CCoV	O
infection	O
.	O

ABSTRACT	O
:	O
Avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
are	O
infections	O
that	O
cause	O
a	O
severe	O
viral	O
pneumonia	O
leading	O
to	O
acute	O
respiratory	O
dysfunction	O
syndrome	O
and	O
carry	O
a	O
high	O
case	O
-	O
fatality	O
rate	O
.	O

TITLE	O
:	O
The	O
3a	O
Protein	O
of	O
SARS	O
-	O
coronavirus	O
Induces	O
Apoptosis	B-PATH
in	O
Vero	O
E6	O
Cells	O
.	O

TITLE	O
:	O
The	O
SARS	O
-	O
Coronavirus	O
Membrane	O
protein	O
induces	O
apoptosis	B-PATH
through	O
modulating	O
the	O
Akt	O
survival	O
pathway	O
.	O

We	O
found	O
that	O
the	O
SARS	O
-	O
CoV	O
M	O
protein	O
induced	O
apoptosis	B-PATH
in	O
both	O
HEK293T	O
cells	O
and	O
transgenic	O
Drosophila	O
.	O

ABSTRACT	O
:	O
In	O
the	O
period	O
1991	O
-	O
2005	O
,	O
169	O
patients	O
with	O
the	O
diagnosis	O
of	O
malaria	B-PATH
were	O
hospitalized	O
in	O
the	O
Department	O
of	O
Tropical	O
and	O
Parasitic	O
Diseases	O
,	O
Institute	O
of	O
Maritime	O
and	O
Tropical	O
Medicine	O
in	O
Gdynia	O
(	O
from	O
2003	O
--	O
the	O
Academic	O
Centre	O
of	O
Maritime	O
and	O
Tropical	O
Medicine	O
,	O
Medical	O
University	O
of	O
GdaÅ„sk	O
).	O

China	O
has	O
the	O
world	O
'	O
s	O
second	O
largest	O
tuberculosis	B-PATH
epidemic	O
,	O
but	O
progress	O
in	O
tuberculosis	B-PATH
control	O
was	O
slow	O
during	O
the	O
1990s	O
.	O

Detection	O
of	O
tuberculosis	B-PATH
had	O
stagnated	O
at	O
around	O
30	O
%	O
of	O
the	O
estimated	O
total	O
of	O
new	O
cases	O
,	O
and	O
multidrug	O
-	O
resistant	O
tuberculosis	B-PATH
was	O
a	O
major	O
problem	O
.	O

While	O
this	O
effect	O
on	O
immune	O
cells	O
is	O
usually	O
undesirable	O
,	O
it	O
is	O
exactly	O
what	O
would	O
be	O
useful	O
for	O
activating	O
immune	O
cells	O
,	O
initiating	O
provirus	O
transcription	O
in	O
retrovirus	O
-	O
infected	O
cells	O
,	O
and	O
facilitating	O
selective	O
apoptosis	B-PATH
of	O
these	O
infected	O
cells	O
.	O

The	O
protein	O
also	O
plays	O
roles	O
in	O
viral	O
RNA	O
transcription	O
and	O
/	O
or	O
replication	O
and	O
possibly	O
viral	B-PATH
mRNA	I-PATH
translation	I-PATH
.	O

Severe	O
pneumonitis	O
developed	O
twice	O
at	O
the	O
time	O
of	O
neutrophil	O
recovery	O
and	O
acute	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
.	O

In	O
addition	O
,	O
confocal	O
image	O
analysis	O
has	O
shown	O
release	B-PATH
of	O
mitochondrial	O
apoptogenic	O
apoptosis	B-PATH
-	O
inducing	O
factor	O
and	O
cytochrome	O
c	O
into	O
the	O
cytosol	O
.	O

Our	O
results	O
revealed	O
that	O
SARS	O
CoV	O
3CLpro	O
could	O
be	O
considered	O
to	O
induce	O
mitochondrial	O
-	O
mediated	O
apoptosis	B-PATH
.	O

ABSTRACT	O
:	O
The	O
nucleolus	O
is	O
a	O
dynamic	O
sub	O
-	O
nuclear	O
structure	O
which	O
is	O
involved	O
in	O
ribosome	B-PATH
subunit	O
biogenesis	O
,	O
modulation	O
of	O
cell	O
growth	O
and	O
response	O
to	O
cell	O
stress	O
.	O

The	O
nucleolar	O
proteome	O
varies	O
particularly	O
with	O
regard	O
to	O
the	O
cell	B-PATH
cycle	I-PATH
.	O

TITLE	O
:	O
Induction	O
of	O
apoptosis	B-PATH
by	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
7a	O
protein	O
is	O
dependent	O
on	O
its	O
interaction	O
with	O
the	O
Bcl	O
-	O
XL	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
7a	O
protein	O
,	O
which	O
is	O
not	O
expressed	O
by	O
other	O
known	O
coronaviruses	O
,	O
can	O
induce	O
apoptosis	B-PATH
in	O
various	O
cell	O
lines	O
.	O

Recent	O
studies	O
regarding	O
SARS	O
and	O
SARS	O
-	O
CoV	O
have	O
clarified	O
that	O
activation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
plays	O
important	O
roles	O
in	O
upregulation	O
of	O
cytokine	O
expression	O
and	O
apoptosis	B-PATH
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
NGEN	O
respiratory	O
virus	O
analyte	O
-	O
specific	O
assay	O
(	O
Nanogen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
detects	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
Flu	O
-	O
A	O
)	O
and	O
Flu	O
-	O
B	O
,	O
parainfluenza	O
virus	O
1	O
(	O
PIV	O
-	O
1	O
),	O
PIV	O
-	O
2	O
,	O
and	O
PIV	O
-	O
3	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
while	O
the	O
ResPlex	O
II	O
assay	O
(	O
Genaco	O
Biomedical	O
Products	O
,	O
Inc	O
.,	O
Huntsville	O
,	O
AL	O
)	O
detects	O
Flu	O
-	O
A	O
,	O
Flu	O
-	O
B	O
,	O
PIV	O
-	O
1	O
,	O
PIV	O
-	O
2	O
,	O
PIV	O
-	O
3	O
,	O
PIV	O
-	O
4	O
,	O
RSV	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
rhinoviruses	O
(	O
RhVs	O
),	O
enteroviruses	O
(	O
EnVs	O
),	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
).	O

Second	O
,	O
103	O
nasal	O
-	O
wash	O
samples	O
from	O
5	O
-	O
year	O
-	O
old	O
children	O
with	O
asthma	B-PATH
and	O
respiratory	O
symptoms	O
were	O
analyzed	O
;	O
RMA	O
detected	O
viruses	O
in	O
74	O
specimens	O
(	O
71	O
.	O
8	O
%)	O
compared	O
to	O
only	O
24	O
(	O
23	O
.	O
3	O
%)	O
by	O
traditional	O
culture	O
and	O
immunofluorescent	O
-	O
staining	O
techniques	O
.	O

In	O
conclusion	O
,	O
corticosteroid	O
treatment	O
may	O
have	O
a	O
small	O
role	O
in	O
preschool	O
wheeze	O
,	O
in	O
particular	O
for	O
those	O
thought	O
to	O
have	O
early	O
asthma	B-PATH
,	O
but	O
the	O
uncritical	O
application	O
of	O
recommendations	O
that	O
are	O
appropriate	O
for	O
older	O
children	O
and	O
adults	O
with	O
asthma	B-PATH
has	O
led	O
to	O
widespread	O
overuse	O
of	O
these	O
medications	O
.	O

It	O
is	O
proposed	O
that	O
the	O
syndrome	O
may	O
be	O
caused	O
by	O
either	O
a	O
direct	O
mitochondrial	O
respiratory	O
chain	O
inhibition	O
or	O
impaired	O
mitochondrial	O
fatty	B-PATH
acid	I-PATH
metabolism	I-PATH
mediated	O
by	O
propofol	O
.	O

Viral	O
infection	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
subsequent	O
readmissions	O
or	O
mortality	O
rate	O
over	O
a	O
study	O
period	O
of	O
1	O
year	O
CONCLUSIONS	O
:	O
Influenza	B-PATH
A	I-PATH
and	O
two	O
less	O
-	O
attended	O
viruses	O
,	O
coronavirus	O
OC43	O
and	O
rhinovirus	O
,	O
were	O
the	O
common	O
etiologic	O
agents	O
in	O
patients	O
hospitalized	O
with	O
AECOPD	O
in	O
Hong	O
Kong	O
.	O

Retention	O
of	O
import	O
factors	O
at	O
the	O
ER	O
/	O
Golgi	O
membrane	O
leads	O
to	O
a	O
loss	O
of	O
STAT1	O
transport	O
into	O
the	O
nucleus	O
in	O
response	O
to	O
interferon	B-PATH
signaling	I-PATH
,	O
thus	O
blocking	O
the	O
expression	O
of	O
STAT1	O
-	O
activated	O
genes	O
that	O
establish	O
an	O
antiviral	O
state	O
.	O

TITLE	O
:	O
Pseudomembranous	O
necrotizing	O
tracheobronchitis	O
caused	O
by	O
Aspergillus	O
spp	O
--	O
contribution	O
of	O
one	O
case	O
with	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
.	O

The	O
histopathological	O
diagnosis	O
was	O
congenital	O
lobar	O
emphysema	O
(	O
CLE	O
)	O
(	O
9	O
),	O
congenital	O
cystic	O
adenomatoid	O
malformation	O
(	O
CCAM	O
)	O
(	O
9	O
),	O
bronchiectasis	O
(	O
9	O
),	O
sequestration	O
(	O
3	O
),	O
atelectasis	O
(	O
1	O
),	O
lung	O
abscess	O
(	O
1	O
),	O
unilobar	O
tuberculosis	B-PATH
(	O
1	O
),	O
hydatid	O
cyst	O
(	O
1	O
),	O
and	O
foreign	O
body	O
with	O
collapse	O
(	O
1	O
).	O

Recombinant	O
SARS	O
-	O
CoVs	O
bearing	O
deletions	O
in	O
gene	O
7	O
were	O
used	O
to	O
assess	O
the	O
contribution	O
of	O
gene	O
7	O
to	O
virus	O
replication	O
and	O
apoptosis	B-PATH
in	O
several	O
transformed	O
cell	O
lines	O
,	O
as	O
well	O
as	O
to	O
replication	O
and	O
pathogenesis	O
in	O
golden	O
Syrian	O
hamsters	O
.	O

This	O
process	O
has	O
been	O
reported	O
in	O
some	O
cases	O
to	O
be	O
antiviral	O
,	O
while	O
in	O
other	O
cases	O
it	O
has	O
been	O
reported	O
to	O
be	O
required	O
for	O
efficient	O
viral	O
replication	O
or	O
release	B-PATH
.	O

We	O
investigated	O
the	O
capability	O
of	O
the	O
Virochip	O
,	O
a	O
DNA	O
microarray	O
-	O
based	O
viral	O
detection	O
platform	O
,	O
to	O
characterize	O
viral	O
diversity	O
in	O
RTIs	O
in	O
adults	O
with	O
and	O
without	O
asthma	B-PATH
.	O

Apoptosis	B-PATH
was	O
observed	O
in	O
vitro	O
,	O
while	O
both	O
apoptosis	B-PATH
and	O
necrosis	O
were	O
observed	O
in	O
tissues	O
obtained	O
from	O
SARS	O
patients	O
.	O

Gene	O
expression	O
was	O
profiled	O
at	O
18	O
h	O
post	O
-	O
infection	O
using	O
bovine	O
cDNA	O
microarrays	O
;	O
the	O
majority	O
of	O
differentially	O
expressed	O
significant	O
genes	O
were	O
associated	O
with	O
the	O
cell	B-PATH
cycle	I-PATH
and	O
innate	O
immune	O
responses	O
.	O

Future	O
research	O
needs	O
to	O
explore	O
the	O
potency	O
of	O
compounds	O
derived	O
from	O
licorice	O
in	O
prevention	O
and	O
treatment	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
pneumonia	O
and	O
as	O
an	O
adjuvant	O
treatment	O
in	O
patients	O
infected	O
with	O
HIV	O
resistant	O
to	O
antiretroviral	O
drugs	O
.	O

To	O
further	O
investigate	O
the	O
possible	O
roles	O
of	O
S2	O
in	O
SARS	O
-	O
CoV	O
-	O
induced	O
apoptosis	B-PATH
and	O
pathogenesis	O
of	O
SARS	O
,	O
we	O
characterized	O
the	O
host	O
expression	O
profiles	O
induced	O
upon	O
S2	O
over	O
-	O
expression	O
in	O
Vero	O
E6	O
cells	O
by	O
oligonucleotide	O
microarray	O
analysis	O
.	O

We	O
found	O
that	O
this	O
regulated	O
process	O
follows	O
what	O
is	O
referred	O
as	O
the	O
Phosphorylation	O
-	O
Ubiquitination	O
-	O
Recognition	O
-	O
Endocytosis	B-PATH
-	O
Degradation	O
(	O
PURED	O
)	O
pathway	O
.	O

Northern	O
and	O
Western	O
blot	O
analyzes	O
were	O
performed	O
to	O
investigate	O
antiviral	O
activity	O
in	O
MHV	O
-	O
infected	O
DBT	O
cells	O
,	O
including	O
virus	O
entry	O
,	O
viral	O
RNA	O
and	O
protein	O
expression	O
,	O
and	O
virus	O
release	B-PATH
.	O

Synthesized	O
compounds	O
were	O
screened	O
for	O
cytotoxicity	O
and	O
for	O
antiviral	O
activity	O
against	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
,	O
H3N2	O
and	O
H5N1	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
corona	O
,	O
dengue	O
,	O
yellow	O
fever	O
,	O
Venezuelan	O
equine	O
encephalitis	O
(	O
VEE	O
),	O
Rift	O
Valley	O
fever	O
,	O
and	O
Tacaribe	O
viruses	O
in	O
cell	O
culture	O
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
miliary	O
tuberculosis	B-PATH
showing	O
acute	O
respiratory	O
failure	O
during	O
pregnancy	O
].	O

We	O
emphasize	O
that	O
in	O
this	O
case	O
pregnancy	O
has	O
the	O
risk	O
of	O
to	O
causing	O
disease	O
progression	O
of	O
miliary	O
tuberculosis	B-PATH
and	O
we	O
should	O
treat	O
immediately	O
and	O
intensively	O
for	O
miliary	O
tuberculosis	B-PATH
complicated	O
with	O
ARDS	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
25	O
-	O
year	O
-	O
old	O
woman	O
in	O
the	O
second	O
trimester	O
of	O
pregnancy	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
associated	O
with	O
miliary	O
tuberculosis	B-PATH
.	O

These	O
data	O
suggest	O
a	O
correlation	O
among	O
the	O
replication	O
cycle	O
of	O
SARS	O
-	O
CoV	O
,	O
subcellular	O
localization	O
of	O
N	O
,	O
induction	O
of	O
apoptosis	B-PATH
,	O
and	O
the	O
subsequent	O
activation	O
of	O
caspases	O
leading	O
to	O
cleavage	O
of	O
N	O
.	O

Nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	O
-	O
CoV	O
encapsidates	O
the	O
viral	O
RNA	O
and	O
plays	O
an	O
important	O
role	O
in	O
virus	O
particle	O
assembly	O
and	O
release	B-PATH
.	O

Based	O
on	O
this	O
finding	O
,	O
we	O
investigated	O
whether	O
the	O
ECoV	O
-	O
induced	O
CPE	O
was	O
apoptosis	B-PATH
.	O

Morphologic	O
and	O
biochemical	O
features	O
of	O
apoptosis	B-PATH
,	O
such	O
as	O
nuclear	O
fragmentation	O
and	O
DNA	O
ladder	O
formation	O
,	O
were	O
also	O
detected	O
in	O
ECoV	O
-	O
infected	O
cells	O
.	O

Therefore	O
,	O
it	O
was	O
suggested	O
that	O
ECoV	O
can	O
induce	O
apoptosis	B-PATH
in	O
MDBK	O
cells	O
via	O
a	O
caspase	O
-	O
dependent	O
pathway	O
.	O

But	O
relapses	O
are	O
frequent	O
after	O
stopping	O
corticosteroid	O
treatment	O
,	O
as	O
well	O
as	O
the	O
occurrence	O
of	O
severe	O
asthma	B-PATH
.	O

The	O
clinical	O
picture	O
of	O
OHSS	O
is	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
and	O
laboratory	O
manifestations	O
:	O
increased	O
vascular	O
permeability	O
resulting	O
in	O
the	O
excess	O
release	B-PATH
of	O
liquid	O
into	O
the	O
third	O
space	O
and	O
its	O
storage	O
with	O
the	O
development	O
of	O
hypovolemia	O
,	O
hemoconcentration	O
,	O
oliguria	O
,	O
hypoproteinemia	O
,	O
electrolyte	O
imbalance	O
,	O
polyserositis	O
;	O
in	O
severe	O
cases	O
,	O
acute	O
renal	O
failure	O
,	O
thromboembolic	O
events	O
,	O
and	O
adult	O
respiratory	O
distress	O
syndrome	O
develop	O
.	O

Interestingly	O
,	O
a	O
novel	O
homologue	O
of	O
angiotensin	O
converting	O
-	O
enzyme	O
(	O
ACE	O
),	O
termed	O
angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
has	O
been	O
identified	O
as	O
a	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
ACE	O
and	O
ACE2	O
share	O
homology	O
in	O
their	O
catalytic	O
domain	O
and	O
provide	O
different	O
key	O
functions	O
in	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
.	O

To	O
this	O
complex	O
mix	O
has	O
been	O
added	O
the	O
potential	O
for	O
accidental	O
or	O
malicious	O
release	B-PATH
of	O
agents	O
.	O

In	O
the	O
anti	O
-	O
viral	O
aspect	O
,	O
HC	O
exhibited	O
significant	O
inhibitory	O
effects	O
on	O
SARS	O
-	O
CoV	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
and	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
).	O

All	O
but	O
1	O
pig	O
belonging	O
to	O
group	O
V	O
could	O
be	O
extubated	O
compared	O
with	O
none	O
in	O
groups	O
III	O
and	O
IV	O
(	O
P	O
<	O
.	O
01	O
),	O
and	O
only	O
their	O
lungs	O
normalized	O
cytokine	O
release	B-PATH
(	O
P	O
<	O
.	O
001	O
)	O
and	O
surfactant	O
(	O
P	O
<	O
.	O
03	O
)	O
and	O
displayed	O
fewer	O
parenchymal	O
lesions	O
(	O
P	O
<	O
.	O
05	O
).	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
high	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
combined	O
with	O
exogenous	O
pulmonary	O
surfactant	O
(	O
PS	O
)	O
on	O
apoptosis	B-PATH
of	O
lung	O
tissue	O
in	O
rabbit	O
suffering	O
from	O
steam	O
inhalation	O
injury	O
.	O

Compared	O
with	O
CMV	O
or	O
CMV	O
+	O
PS	O
,	O
HFOV	O
or	O
HFOV	O
+	O
PS	O
can	O
decrease	O
the	O
concentration	O
of	O
caspase	O
-	O
3	O
and	O
p73	O
,	O
reduce	O
the	O
mRNA	O
expression	O
of	O
caspase	O
-	O
3	O
and	O
p73	O
in	O
the	O
lung	O
homogenates	O
,	O
as	O
a	O
result	O
lung	O
tissue	O
apoptosis	B-PATH
in	O
inhalation	O
injury	O
may	O
be	O
suppressed	O
.	O

Thus	O
,	O
MHV	O
-	O
2	O
entry	O
is	O
mediated	O
through	O
clathrin	O
-	O
dependent	O
but	O
Eps15	O
-	O
independent	O
endocytosis	B-PATH
.	O

This	O
is	O
surprising	O
,	O
because	O
the	O
architecture	O
of	O
the	O
HEF	O
site	O
was	O
preserved	O
in	O
influenza	B-PATH
A	I-PATH
HA	O
over	O
a	O
much	O
larger	O
evolutionary	O
distance	O
,	O
a	O
switch	O
in	O
receptor	O
specificity	O
and	O
extensive	O
antigenic	O
variation	O
notwithstanding	O
.	O

Occurance	O
of	O
ARF	O
in	O
severe	O
falciparum	O
malaria	B-PATH
is	O
quite	O
common	O
in	O
southeast	O
Asia	O
and	O
Indian	O
subcontinent	O
where	O
intensity	O
of	O
malaria	B-PATH
transmission	O
is	O
usually	O
low	O
with	O
occasional	O
microfoci	O
of	O
intense	O
transmission	O
.	O

TITLE	O
:	O
Acute	O
Akinesia	O
,	O
an	O
unusual	O
complication	O
in	O
Parkinson	B-PATH
'	I-PATH
s	I-PATH
Disease	I-PATH
:	O
a	O
case	O
report	O
.	O

The	O
ability	O
of	O
the	O
ribosome	B-PATH
to	O
change	O
translational	O
reading	O
frames	O
in	O
the	O
-	O
1	O
direction	O
(-	O
1	O
PRF	O
)	O
is	O
employed	O
by	O
many	O
positive	O
strand	O
RNA	O
viruses	O
,	O
including	O
economically	O
important	O
plant	O
viruses	O
and	O
many	O
human	O
pathogens	O
,	O
such	O
as	O
retroviruses	O
,	O
e	O
.	O
g	O
.,	O
HIV	O
-	O
1	O
,	O
and	O
coronaviruses	O
,	O
e	O
.	O
g	O
.,	O
the	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
in	O
order	O
to	O
properly	O
express	O
their	O
genomes	O
.	O

However	O
,	O
the	O
cellular	O
targets	O
leading	O
to	O
3a	O
protein	O
-	O
mediated	O
apoptosis	B-PATH
have	O
not	O
been	O
fully	O
characterized	O
.	O

The	O
adenovirus	O
-	O
mediated	O
overexpression	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
(	O
S	O
)	O
and	O
its	O
C	O
-	O
terminal	O
domain	O
(	O
S2	O
)	O
induce	O
apoptosis	B-PATH
in	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
The	O
M	O
,	O
E	O
,	O
and	O
N	O
structural	O
proteins	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
are	O
required	O
for	O
efficient	O
assembly	O
,	O
trafficking	O
,	O
and	O
release	B-PATH
of	O
virus	O
-	O
like	O
particles	O
.	O

ABSTRACT	O
:	O
Feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
),	O
a	O
coronavirus	O
that	O
causes	O
a	O
lethal	O
chronic	O
disease	O
in	O
cats	O
,	O
enters	O
feline	O
monocytes	O
via	O
endocytosis	B-PATH
.	O

Overall	O
,	O
the	O
prevalence	O
of	O
detected	O
respiratory	O
viruses	O
was	O
:	O
Respiratory	O
Syncytial	O
Virus	O
55	O
(	O
43	O
%);	O
Rhinovirus	O
30	O
(	O
23	O
%);	O
Metapneumovirus	O
13	O
(	O
10	O
%);	O
Influenza	B-PATH
A	I-PATH
8	O
(	O
6	O
%);	O
Enterovirus	O
6	O
(	O
5	O
%);	O
Bocavirus	O
6	O
(	O
5	O
%);	O
Adenovirus	O
4	O
(	O
3	O
%);	O
Coronavirus	O
3	O
(	O
2	O
%);	O
Parainfluenza	O
1	O
:	O
2	O
(	O
1	O
%);	O
Influenza	O
B	O
,	O
1	O
(	O
1	O
%)	O
and	O
Parainfluenza	O
3	O
:	O
1	O
(	O
1	O
%).	O

TITLE	O
:	O
[	O
Disseminated	O
tuberculosis	B-PATH
with	O
severe	O
multi	O
-	O
organ	O
failure	O
in	O
a	O
patient	O
with	O
AIDS	O
].	O

ABSTRACT	O
:	O
Tuberculosis	B-PATH
is	O
the	O
most	O
common	O
infectious	O
complication	O
in	O
HIV	O
infected	O
patients	O
.	O

This	O
study	O
used	O
a	O
broad	O
capture	O
,	O
rapid	O
and	O
sensitive	O
method	O
(	O
multiplex	O
PCR	O
assay	O
)	O
to	O
detect	O
20	O
different	O
respiratory	O
pathogens	O
including	O
influenza	B-PATH
A	I-PATH
subtypes	O
H1	O
,	O
H3	O
,	O
and	O
H5	O
;	O
influenza	O
B	O
;	O
parainfluenza	O
types	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
;	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
groups	O
A	O
and	O
B	O
;	O
adenoviruses	O
;	O
human	O
rhinoviruses	O
;	O
enteroviruses	O
;	O
human	O
metapneumoviruses	O
;	O
human	O
coronaviruses	O
OC43	O
,	O
229E	O
,	O
and	O
SARS	O
-	O
CoV	O
;	O
Chlamydophila	O
pneumoniae	O
;	O
Legionella	O
pneumophila	O
;	O
and	O
Mycoplasma	O
pneumoniae	O
;	O
from	O
respiratory	O
specimens	O
of	O
475	O
children	O
hospitalized	O
over	O
a	O
12	O
-	O
month	O
period	O
for	O
acute	O
respiratory	O
tract	O
infections	O
.	O

However	O
,	O
virus	O
replication	O
was	O
not	O
impaired	O
by	O
these	O
events	O
,	O
suggesting	O
that	O
SARS	O
-	O
CoV	O
possesses	O
a	O
mechanism	O
to	O
overcome	O
the	O
inhibitory	O
effects	O
of	O
phosphorylated	O
eIF2alpha	O
on	O
viral	B-PATH
mRNA	I-PATH
translation	I-PATH
.	O

Of	O
1	O
,	O
091	O
patients	O
with	O
malaria	B-PATH
,	O
635	O
had	O
P	O
.	O
falciparum	O
malaria	B-PATH
and	O
456	O
had	O
P	O
.	O
vivax	O
malaria	B-PATH
.	O

Among	O
patients	O
with	O
severe	O
manifestations	O
,	O
40	O
had	O
evidence	O
of	O
monoinfection	O
of	O
P	O
.	O
vivax	O
malaria	B-PATH
diagnosed	O
by	O
PBF	O
,	O
RDT	O
,	O
and	O
PCR	O
.	O

Complications	O
observed	O
were	O
hepatic	O
dysfunction	O
and	O
jaundice	O
in	O
23	O
(	O
57	O
.	O
5	O
%)	O
patients	O
,	O
renal	O
failure	O
in	O
18	O
(	O
45	O
%)	O
patients	O
,	O
severe	O
anemia	O
in	O
13	O
(	O
32	O
.	O
5	O
%)	O
patients	O
,	O
cerebral	O
malaria	B-PATH
in	O
5	O
patients	O
(	O
12	O
.	O
5	O
%),	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
4	O
patients	O
(	O
10	O
%),	O
shock	O
in	O
3	O
patients	O
(	O
7	O
.	O
5	O
%),	O
and	O
hypoglycemia	O
in	O
1	O
(	O
2	O
.	O
5	O
%)	O
patient	O
.	O

The	O
URI	O
symptoms	O
that	O
precede	O
BACM	O
are	O
consistent	O
with	O
an	O
uncomplicated	O
viral	O
influenza	B-PATH
infection	I-PATH
and	O
include	O
fever	O
,	O
malaise	O
,	O
cough	O
,	O
sore	O
throat	O
,	O
headache	O
,	O
and	O
rhinitis	O
.	O

To	O
understand	O
the	O
cellular	O
factors	O
that	O
may	O
be	O
involved	O
in	O
virion	O
assembly	O
,	O
budding	B-PATH
and	O
maturation	O
processes	O
,	O
IBV	O
M	O
was	O
used	O
as	O
the	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
resulting	O
in	O
the	O
identification	O
of	O
beta	O
-	O
actin	O
as	O
a	O
potentially	O
interacting	O
partner	O
.	O

Mycobacterium	O
tuberculosis	B-PATH
was	O
also	O
detected	O
in	O
sputum	O
and	O
urine	O
.	O

Miliary	O
tuberculosis	B-PATH
complicated	O
with	O
ARDS	O
is	O
relatively	O
rare	O
and	O
the	O
prognosis	O
is	O
extremely	O
poor	O
.	O

Miliary	O
tuberculosis	B-PATH
should	O
be	O
kept	O
in	O
mind	O
as	O
a	O
cause	O
of	O
ARDS	O
.	O

TITLE	O
:	O
[	O
A	O
discussion	O
about	O
the	O
tactics	O
of	O
mechanical	O
ventilation	O
for	O
acute	O
respiratory	O
distress	O
occurring	O
in	O
the	O
first	O
case	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
in	O
Guizhou	O
Province	O
].	O

Phorbol	O
ester	O
,	O
ionomycin	O
,	O
endotoxin	O
,	O
and	O
IL	O
-	O
1beta	O
and	O
TNFalpha	O
acutely	O
induced	O
ACE2	O
release	B-PATH
,	O
further	O
supporting	O
that	O
ADAM17	O
and	O
ADAM10	O
regulate	O
ACE2	O
cleavage	O
.	O

Mice	O
that	O
died	O
also	O
showed	O
unique	O
transcriptional	O
profiles	O
of	O
immune	O
response	O
,	O
apoptosis	B-PATH
,	O
cell	B-PATH
cycle	I-PATH
control	O
,	O
and	O
stress	O
.	O

The	O
SARS	O
-	O
CoV	O
genome	O
is	O
devoid	O
of	O
G	O
-	O
stretches	O
longer	O
than	O
5	O
-	O
6	O
nucleotides	O
,	O
but	O
more	O
extended	O
G	O
-	O
stretches	O
are	O
found	O
in	O
the	O
3	O
'-	O
nontranslated	O
regions	O
of	O
mRNAs	O
coding	O
for	O
certain	O
host	O
-	O
cell	O
proteins	O
involved	O
in	O
apoptosis	B-PATH
or	O
signal	O
transduction	O
,	O
and	O
have	O
been	O
shown	O
to	O
bind	O
to	O
SUD	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Arbidol	O
is	O
an	O
antiviral	O
drug	O
indicated	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
all	O
types	O
of	O
influenza	B-PATH
infection	I-PATH
and	O
some	O
other	O
kinds	O
of	O
acute	O
respiratory	O
infections	O
,	O
specifically	O
against	O
influenza	O
groups	O
A	O
and	O
B	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

It	O
is	O
used	O
to	O
help	O
prevent	O
influenza	B-PATH
infection	I-PATH
as	O
long	O
as	O
necessary	O
with	O
little	O
risk	O
for	O
influenza	O
mutation	O
rendering	O
it	O
less	O
effective	O
.	O

The	O
case	O
records	O
of	O
all	O
confirmed	O
cases	O
of	O
malaria	B-PATH
over	O
the	O
period	O
of	O
one	O
year	O
(	O
September	O
2005	O
-	O
August	O
2006	O
)	O
were	O
studied	O
.	O

The	O
results	O
of	O
rapid	O
diagnostic	O
test	O
for	O
malaria	B-PATH
(	O
OptiMAL	O
test	O
,	O
Diamed	O
AG	O
,	O
Switzerland	O
)	O
were	O
correlated	O
with	O
the	O
peripheral	O
blood	O
smear	O
findings	O
in	O
the	O
patients	O
in	O
whom	O
it	O
was	O
requested	O
.	O

This	O
paper	O
is	O
presented	O
to	O
highlight	O
that	O
P	O
.	O
vivax	O
malaria	B-PATH
though	O
considered	O
to	O
be	O
a	O
benign	O
entity	O
can	O
also	O
have	O
a	O
severe	O
and	O
complicated	O
course	O
which	O
is	O
usually	O
associated	O
with	O
P	O
.	O
falciparum	O
malaria	B-PATH
.	O

There	O
was	O
also	O
strong	O
induction	O
of	O
TNF	O
-	O
related	O
apoptosis	B-PATH
-	O
inducing	O
ligand	O
(	O
TRAIL	O
),	O
but	O
not	O
Fas	O
ligand	O
gene	O
expression	O
in	O
SARS	O
-	O
CoV	O
infected	O
DCs	O
.	O

The	O
diversity	O
of	O
coronaviruses	O
is	O
a	O
result	O
of	O
the	O
infidelity	O
of	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
,	O
high	O
frequency	O
of	O
homologous	O
RNA	O
recombination	O
,	O
and	O
the	O
large	O
genomes	O
of	O
coronaviruses	O
.	O

In	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
70	O
wheezing	O
children	O
attending	O
the	O
emergency	O
department	O
for	O
nebulisation	O
and	O
80	O
stable	O
control	O
subjects	O
(	O
2	O
to	O
16	O
yr	O
of	O
age	O
)	O
in	O
the	O
asthma	B-PATH
clinic	O
,	O
nasal	O
specimens	O
were	O
collected	O
during	O
the	O
dry	O
(	O
n	O
=	O
38	O
,	O
January	O
to	O
May	O
)	O
and	O
rainy	O
(	O
n	O
=	O
112	O
,	O
June	O
to	O
December	O
)	O
seasons	O
.	O

In	O
those	O
models	O
,	O
vagal	O
nerve	O
transaction	O
and	O
splenectomy	O
decreased	O
cytokine	O
release	B-PATH
and	O
protected	O
against	O
lung	O
injury	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
Ribosomal	O
preparations	O
(	O
ribosome	B-PATH
-	O
component	O
immune	O
modulators	O
[	O
RCIMs	O
])	O
do	O
not	O
contain	O
attenuated	O
bacteria	O
and	O
,	O
in	O
contrast	O
to	O
live	O
bacterial	O
extracts	O
,	O
which	O
may	O
induce	O
severe	O
side	O
effects	O
,	O
retain	O
immune	O
stimulating	O
activity	O
without	O
infectious	O
capability	O
.	O

This	O
effect	O
was	O
neither	O
associated	O
with	O
changes	O
in	O
the	O
induction	O
or	O
secretion	O
of	O
type	O
I	O
interferon	O
,	O
nor	O
with	O
altered	O
induction	O
of	O
apoptosis	B-PATH
in	O
cell	O
culture	O
.	O

TITLE	O
:	O
[	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
epidemic	O
in	O
Argentina	O
.	O

The	O
children	O
'	O
s	O
median	O
age	O
was	O
11	O
months	O
;	O
61	O
.	O
8	O
%	O
presented	O
comorbidities	O
(	O
prematurity	O
,	O
asthma	B-PATH
,	O
broncho	O
-	O
pulmonary	O
dysplasia	O
and	O
congenital	O
heart	O
disease	O
).	O

TITLE	O
:	O
Critically	O
Ill	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Mexico	O
.	O

Observational	O
study	O
of	O
58	O
critically	O
ill	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
at	O
6	O
hospitals	O
between	O
March	O
24	O
and	O
June	O
1	O
,	O
2009	O
.	O

During	O
June	O
to	O
August	O
2009	O
in	O
Australia	O
and	O
New	O
Zealand	O
,	O
the	O
ICUs	O
at	O
regional	O
referral	O
centers	O
provided	O
mechanical	O
ventilation	O
for	O
many	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
associated	O
respiratory	O
failure	O
,	O
one	O
-	O
third	O
of	O
whom	O
received	O
ECMO	O
.	O

TITLE	O
:	O
The	O
RNA	B-PATH
polymerase	I-PATH
activity	O
of	O
SARS	O
-	O
coronavirus	O
nsp12	O
is	O
primer	O
dependent	O
.	O

The	O
use	O
of	O
NIPPV	O
in	O
vivax	O
-	O
malaria	B-PATH
related	O
ARDS	O
was	O
associated	O
with	O
a	O
good	O
outcome	O
.	O

Other	O
medical	O
concerns	O
include	O
recurrent	O
oral	O
staphylococcal	O
infections	O
,	O
otitis	O
media	O
,	O
ocular	O
herpes	O
simplex	O
virus	O
keratitis	O
,	O
asthma	B-PATH
,	O
steroid	O
-	O
induced	O
gastritis	O
,	O
steroid	O
-	O
induced	O
cataracts	O
,	O
recurrent	O
upper	O
respiratory	O
infections	O
,	O
and	O
acute	O
pharyngitis	O
.	O

TITLE	O
:	O
Expression	O
of	O
beta	O
-	O
defensins	B-PATH
in	O
the	O
canine	O
respiratory	O
tract	O
and	O
antimicrobial	O
activity	O
against	O
Bordetella	O
bronchiseptica	O
.	O

ABSTRACT	O
:	O
Beta	O
-	O
defensins	B-PATH
are	O
cationic	O
peptides	O
which	O
form	O
part	O
of	O
the	O
innate	O
immune	O
response	O
of	O
the	O
respiratory	O
epithelium	O
.	O

A	O
steady	O
number	O
of	O
cases	O
of	O
imported	O
malaria	B-PATH
are	O
also	O
seen	O
in	O
many	O
countries	O
of	O
the	O
developed	O
world	O
.	O

There	O
has	O
been	O
significant	O
progress	O
in	O
the	O
understanding	O
of	O
pathogenesis	O
of	O
severe	O
malaria	B-PATH
over	O
the	O
last	O
decade	O
.	O

TITLE	O
:	O
Calculating	O
the	O
potential	O
for	O
within	O
-	O
flight	O
transmission	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

ABSTRACT	O
:	O
Clearly	O
air	O
travel	O
,	O
by	O
transporting	O
infectious	O
individuals	O
from	O
one	O
geographic	O
location	O
to	O
another	O
,	O
significantly	O
affects	O
the	O
rate	O
of	O
spread	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

ABSTRACT	O
:	O
Two	O
recent	O
viral	O
epidemics	O
producing	O
pneumonitis	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
pandemic	O
influenza	B-PATH
A	I-PATH
H1N1	O
)	O
have	O
highlighted	O
the	O
potential	O
for	O
viral	O
infections	O
to	O
cause	O
respiratory	O
failure	O
with	O
a	O
significant	O
risk	O
of	O
mortality	O
.	O

The	O
current	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
is	O
fortunately	O
not	O
associated	O
with	O
as	O
high	O
a	O
mortality	O
rate	O
as	O
the	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
),	O
another	O
potential	O
pandemic	O
candidate	O
virus	O
.	O

TITLE	O
:	O
[	O
ARDS	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
):	O
patients	O
'	O
characteristics	O
and	O
management	O
in	O
intensive	O
care	O
unit	O
.	O

The	O
fact	O
that	O
this	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
can	O
develop	O
in	O
healthy	O
young	O
patients	O
and	O
evolve	O
in	O
few	O
hours	O
to	O
a	O
severe	O
ARDS	O
with	O
a	O
refractory	O
hypoxemia	O
gave	O
to	O
the	O
foreground	O
the	O
possible	O
interest	O
of	O
the	O
recourse	O
to	O
extracorporeal	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
some	O
selected	O
severe	O
ARDS	O
(	O
5	O
-	O
10	O
%).	O

Obesity	O
,	O
pregnancy	O
and	O
respiratory	O
diseases	O
(	O
asthma	B-PATH
,	O
COPD	O
)	O
seem	O
to	O
be	O
associated	O
to	O
the	O
development	O
of	O
a	O
severe	O
viral	O
pneumonia	O
due	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
often	O
with	O
ARDS	O
.	O

The	O
7a	O
protein	O
is	O
present	O
in	O
the	O
virus	O
particle	O
and	O
has	O
been	O
shown	O
to	O
interact	O
with	O
several	O
host	O
proteins	O
;	O
thereby	O
implicating	O
it	O
as	O
being	O
involved	O
in	O
several	O
pathogenic	O
processes	O
including	O
apoptosis	B-PATH
,	O
inhibition	O
of	O
cellular	O
protein	O
synthesis	O
,	O
and	O
activation	O
of	O
p38	O
mitogen	O
activated	O
protein	O
kinase	O
.	O

Here	O
we	O
demonstrate	O
the	O
self	O
-	O
assembly	O
and	O
release	B-PATH
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
M	O
protein	O
in	O
medium	O
in	O
the	O
form	O
of	O
membrane	O
-	O
enveloped	O
vesicles	O
with	O
densities	O
lower	O
than	O
those	O
of	O
VLPs	O
formed	O
by	O
M	O
plus	O
N	O
.	O
Although	O
efficient	O
N	O
-	O
N	O
interactions	O
require	O
the	O
presence	O
of	O
RNA	O
,	O
we	O
found	O
that	O
M	O
-	O
M	O
interactions	O
were	O
RNA	O
-	O
independent	O
.	O

ABSTRACT	O
:	O
On	O
June	O
11	O
,	O
2009	O
,	O
the	O
World	O
Health	O
Organization	O
declared	O
the	O
outbreak	O
of	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
a	O
pandemic	O
.	O

TITLE	O
:	O
Adult	O
Respiratory	O
Distress	O
Syndrome	O
and	O
alveolar	O
epithelium	O
apoptosis	B-PATH
:	O
an	O
histopathological	O
and	O
immunohistochemical	O
study	O
.	O

Sequence	O
analysis	O
of	O
a	O
405	O
-	O
nucleotide	O
region	O
of	O
the	O
highly	O
conserved	O
RNA	B-PATH
polymerase	I-PATH
gene	O
(	O
pol	O
)	O
showed	O
that	O
all	O
coronaviruses	O
detected	O
in	O
this	O
study	O
are	O
genetically	O
closely	O
related	O
,	O
with	O
99	O
.	O
5	O
-	O
100	O
%	O
nucleotide	O
identity	O
,	O
and	O
belong	O
to	O
group	O
2	O
of	O
the	O
coronaviruses	O
.	O

TITLE	O
:	O
High	O
mortality	O
from	O
respiratory	O
failure	O
secondary	O
to	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
South	O
Africa	O
.	O

CONCLUSIONS	O
:	O
The	O
majority	O
of	O
patients	O
with	O
respiratory	O
failure	O
secondary	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
were	O
young	O
females	O
and	O
had	O
an	O
underlying	O
risk	O
factor	O
for	O
severe	O
disease	O
.	O

TITLE	O
:	O
What	O
have	O
we	O
learned	O
from	O
the	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
in	O
2009	O
for	O
strengthening	O
pandemic	O
influenza	O
preparedness	O
?	O

The	O
current	O
swine	O
-	O
related	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
has	O
also	O
shown	O
that	O
international	O
collaboration	O
remains	O
a	O
critical	O
component	O
to	O
effectively	O
respond	O
to	O
influenza	O
pandemics	O
in	O
the	O
current	O
globalized	O
world	O
.	O

The	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
-	O
336A	O
>	O
G	O
in	O
the	O
CD209	O
promoter	O
has	O
been	O
demonstrated	O
to	O
regulate	O
promoter	O
activity	O
and	O
to	O
be	O
associated	O
with	O
several	O
important	O
infectious	O
diseases	O
,	O
such	O
as	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
),	O
Mycobacterium	O
tuberculosis	B-PATH
,	O
and	O
Dengue	O
fever	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
clinical	O
feature	O
,	O
treatment	O
and	O
outcome	O
of	O
respiratory	O
failure	O
in	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
H1N1	O
infection	O
in	O
critically	O
ill	O
adults	O
.	O

A	O
prospective	O
observational	O
study	O
of	O
18	O
patients	O
with	O
respiratory	O
failure	O
suffering	O
from	O
2009	O
influenza	B-PATH
A	I-PATH
H1N1	O
infection	O
admitted	O
between	O
November	O
22	O
,	O
2009	O
and	O
January	O
16	O
,	O
2010	O
.	O

In	O
Qinghai	O
Province	O
,	O
cases	O
with	O
influenza	B-PATH
A	I-PATH
H1N1	O
peaked	O
early	O
with	O
relative	O
high	O
incidence	O
of	O
severe	O
cases	O
.	O

Patients	O
suffering	O
from	O
influenza	B-PATH
A	I-PATH
H1N1	O
are	O
susceptible	O
to	O
pulmonary	O
complications	O
.	O

TITLE	O
:	O
Tongue	O
swelling	O
complicating	O
management	O
of	O
a	O
ventilated	O
patient	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

TITLE	O
:	O
Extrapulmonary	O
tissue	O
responses	O
in	O
cynomolgus	O
macaques	O
(	O
Macaca	O
fascicularis	O
)	O
infected	O
with	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
.	O

ABSTRACT	O
:	O
Public	O
health	O
concerns	O
such	O
as	O
multi	O
-	O
and	O
extensive	O
drug	O
-	O
resistant	O
tuberculosis	B-PATH
,	O
bioterrorism	O
,	O
pandemic	O
influenza	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
have	O
intensified	O
efforts	O
to	O
prevent	O
transmission	O
of	O
infections	O
that	O
are	O
completely	O
or	O
partially	O
airborne	O
using	O
environmental	O
controls	O
.	O

TITLE	O
:	O
Spectrum	O
of	O
malaria	B-PATH
complications	O
in	O
an	O
intensive	O
care	O
unit	O
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
remains	O
a	O
major	O
health	O
concern	O
in	O
tropical	O
and	O
subtropical	O
countries	O
.	O

Severe	O
falciparum	O
malaria	B-PATH
is	O
an	O
important	O
cause	O
of	O
multiple	O
organ	O
failure	O
in	O
Indian	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
patients	O
.	O

In	O
all	O
,	O
there	O
were	O
301	O
patients	O
with	O
severe	O
malaria	B-PATH
admitted	O
to	O
the	O
ICU	O
during	O
that	O
period	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
clinical	O
features	O
of	O
patients	O
admitted	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
with	O
acute	O
lower	O
respiratory	O
tract	O
infection	O
(	O
LRTI	O
)	O
attributable	O
to	O
influenza	B-PATH
A	I-PATH
pH1N1	O
virus	O
and	O
compare	O
them	O
with	O
those	O
admitted	O
with	O
LRTI	O
due	O
to	O
other	O
viral	O
pathogens	O
.	O

TITLE	O
:	O
Use	O
of	O
therapeutic	O
plasma	O
exchange	O
as	O
a	O
rescue	O
therapy	O
in	O
2009	O
pH1N1	O
influenza	B-PATH
A	I-PATH
--	O
an	O
associated	O
respiratory	O
failure	O
and	O
hemodynamic	O
shock	O
.	O

TITLE	O
:	O
Outbreak	O
of	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
-	O
2009	O
)	O
in	O
Singapore	O
,	O
May	O
to	O
September	O
2009	O
.	O

The	O
most	O
common	O
risk	O
factors	O
among	O
hospitalised	O
adult	O
cases	O
were	O
asthma	B-PATH
and	O
diabetes	O
.	O

p42	O
is	O
a	O
subunit	O
of	O
the	O
26S	O
proteasome	B-PATH
;	O
this	O
large	O
,	O
multi	O
-	O
protein	O
complex	O
is	O
a	O
component	O
of	O
the	O
ubiquitin	O
-	O
proteasome	B-PATH
pathway	O
,	O
which	O
is	O
involved	O
in	O
a	O
variety	O
of	O
basic	O
cellular	O
processes	O
and	O
inflammatory	O
responses	O
.	O

CONCLUSIONS	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
that	O
SARS	O
-	O
CoV	O
NP	O
interacts	O
with	O
the	O
proteasome	B-PATH
subunit	O
p42	O
within	O
host	O
cells	O
.	O

TITLE	O
:	O
The	O
ubiquitin	O
-	O
proteasome	B-PATH
system	O
plays	O
an	O
important	O
role	O
during	O
various	O
stages	O
of	O
the	O
coronavirus	O
infection	O
cycle	O
.	O

Here	O
,	O
we	O
show	O
that	O
DBA	O
/	O
2	O
mice	O
infected	O
with	O
P	O
.	O
berghei	O
ANKA	O
constitute	O
a	O
new	O
model	O
for	O
malaria	B-PATH
-	O
associated	O
ALI	O
.	O

Malaria	B-PATH
-	O
associated	O
ALI	O
correlated	O
with	O
high	O
levels	O
of	O
circulating	O
VEGF	O
,	O
produced	O
de	O
novo	O
in	O
the	O
spleen	O
,	O
and	O
its	O
blockage	O
led	O
to	O
protection	O
of	O
mice	O
from	O
this	O
syndrome	O
.	O

One	O
predicted	O
advantage	O
of	O
this	O
behavior	O
for	O
coronavirus	O
survivability	O
is	O
an	O
increased	O
chance	O
of	O
maintaining	O
genome	O
fitness	O
in	O
the	O
3	O
'	O
one	O
-	O
third	O
of	O
the	O
genome	O
via	O
a	O
homologous	B-PATH
recombination	I-PATH
between	O
the	O
(	O
now	O
independently	O
abundant	O
)	O
WT	O
sgmRNA	O
and	O
a	O
defective	O
genome	O
.	O

TITLE	O
:	O
Exploring	O
determinants	O
of	O
acceptance	O
of	O
the	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
vaccination	O
in	O
nurses	O
.	O

ABSTRACT	O
:	O
This	O
study	O
investigated	O
the	O
anticipated	O
vaccination	O
rate	O
against	O
pandemic	O
human	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
in	O
the	O
health	O
care	O
setting	O
.	O

CXCR2	O
deficient	O
oligodendrocytes	O
were	O
refractory	O
to	O
CXCL1	O
mediated	O
protection	O
from	O
JHMV	O
-	O
induced	O
apoptosis	B-PATH
,	O
readily	O
activating	O
caspase	O
3	O
and	O
down	O
regulating	O
Bcl	O
-	O
2	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
2	O
is	O
a	O
homolog	O
to	O
the	O
carboxypeptidase	O
ACE	O
,	O
which	O
generates	O
angiotensin	O
II	O
,	O
the	O
main	O
active	O
peptide	O
of	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
(	O
RAS	O
).	O

TITLE	O
:	O
Clinical	O
pathological	O
characteristics	O
and	O
management	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
resulting	O
from	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
species	O
barrier	O
is	O
not	O
perfect	O
for	O
Influenza	B-PATH
A	I-PATH
and	O
numerous	O
transmissions	O
of	O
the	O
virus	O
from	O
pigs	O
or	O
poultry	O
to	O
humans	O
have	O
been	O
described	O
these	O
years	O
.	O

Precautions	O
are	O
now	O
being	O
implemented	O
both	O
in	O
airports	O
and	O
in	O
aircraft	O
,	O
in	O
addition	O
to	O
measures	O
intended	O
to	O
prevent	O
the	O
spread	O
of	O
malaria	B-PATH
and	O
arboviral	O
diseases	O
,	O
such	O
as	O
vector	O
eradication	O
,	O
elimination	O
of	O
stagnant	O
water	O
,	O
malaria	B-PATH
prophylaxis	O
,	O
vaccination	O
,	O
and	O
use	O
of	O
repellents	O
.	O

ABSTRACT	O
:	O
We	O
present	O
the	O
successful	O
use	O
of	O
perioperative	O
non	O
-	O
invasive	O
mechanical	O
ventilation	O
in	O
a	O
morbidly	O
obese	O
pregnant	O
woman	O
with	O
bronchial	O
asthma	B-PATH
,	O
severe	O
preeclampsia	O
and	O
pulmonary	O
edema	O
undergoing	O
an	O
emergency	O
cesarean	O
delivery	O
with	O
spinal	O
anesthesia	O
.	O

Northern	O
and	O
western	O
blot	O
analyses	O
were	O
conducted	O
to	O
evaluate	O
antiviral	O
activity	O
on	O
viral	O
entry	O
,	O
viral	O
RNA	O
and	O
protein	O
expression	O
,	O
and	O
release	B-PATH
in	O
MHV	O
-	O
infected	O
DBT	O
cells	O
.	O

Mastadenovirus	O
,	O
bovine	O
coronavirus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
or	O
Chlamydiaceae	O
were	O
not	O
detected	O
.	O

Among	O
these	O
infections	O
,	O
we	O
observed	O
30	O
monoinfections	O
(	O
HRVs	O
[	O
63	O
%],	O
parainfluenza	O
viruses	O
[	O
PIVs	O
]	O
[	O
20	O
%]),	O
influenza	B-PATH
A	I-PATH
/	O
H3N2	O
virus	O
[	O
6	O
%],	O
coronavirus	O
[	O
4	O
%],	O
and	O
HBoV	O
[	O
4	O
%])	O
and	O
5	O
multiple	O
infections	O
,	O
in	O
which	O
HRVs	O
and	O
PIVs	O
were	O
the	O
most	O
frequently	O
detected	O
viruses	O
.	O

Treatment	O
of	O
A	O
/	O
J	O
mice	O
with	O
the	O
proteasome	B-PATH
inhibitor	O
PDTC	O
,	O
MG132	O
,	O
or	O
PS	O
-	O
341	O
led	O
to	O
40	O
%	O
survival	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
with	O
a	O
concomitant	O
improvement	O
of	O
lung	O
histology	O
,	O
reduced	O
pulmonary	O
viral	O
replication	O
,	O
decreased	O
pulmonary	O
STAT	O
phosphorylation	O
,	O
and	O
reduced	O
pulmonary	O
inflammatory	O
cytokine	O
expression	O
.	O

18	O
influenza	O
(	O
influenza	B-PATH
A	I-PATH
=	O
13	O
and	O
influenza	O
B	O
=	O
5	O
)	O
and	O
17	O
parainfluenza	O
admissions	O
were	O
identified	O
over	O
the	O
7	O
-	O
year	O
period	O
.	O

TITLE	O
:	O
Community	O
-	O
acquired	O
respiratory	O
coinfection	O
in	O
critically	O
ill	O
patients	O
with	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
.	O

TITLE	O
:	O
Three	O
cases	O
of	O
ARDS	O
:	O
An	O
emerging	O
complication	O
of	O
Plasmodium	O
vivax	O
malaria	B-PATH
.	O

Due	O
to	O
the	O
severity	O
of	O
her	O
symptoms	O
,	O
she	O
was	O
managed	O
as	O
falciparum	O
malaria	B-PATH
and	O
was	O
started	O
on	O
intravenous	O
quinine	O
and	O
oral	O
doxycycline	O
.	O

The	O
severe	O
cases	O
of	O
new	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
has	O
imaging	O
manifestations	O
of	O
acute	O
pneumonia	O
and	O
interstitial	O
pneumonia	O
.	O

Seropositivity	O
for	O
influenza	B-PATH
A	I-PATH
(	O
p	O
=	O
0	O
.	O
004	O
),	O
B	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
coronaviruses	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
were	O
associated	O
with	O
history	O
of	O
mood	O
disorders	O
but	O
not	O
with	O
the	O
specific	O
diagnosis	O
of	O
unipolar	O
or	O
bipolar	O
depression	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
8b	O
negatively	O
modulates	O
virus	O
replication	O
by	O
down	O
-	O
regulating	O
E	O
via	O
an	O
ubiquitin	O
-	O
independent	O
proteasome	B-PATH
pathway	O
.	O

Under	O
pathological	O
circumstances	O
,	O
however	O
,	O
unregulated	O
release	B-PATH
of	O
these	O
microbicidal	O
compounds	O
into	O
the	O
extracellular	O
space	O
paradoxically	O
can	O
damage	O
host	O
tissues	O
.	O

TITLE	O
:	O
The	O
hydrophobic	O
domain	O
of	O
infectious	O
bronchitis	O
virus	O
E	O
protein	O
alters	O
the	O
host	O
secretory	O
pathway	O
and	O
is	O
important	O
for	O
release	B-PATH
of	O
infectious	O
virus	O
.	O

All	O
assays	O
detect	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
adenovirus	O
,	O
parainfluenza	O
1	O
-	O
3	O
,	O
respiratory	O
syncytial	O
virus	O
A	O
and	O
B	O
,	O
human	O
metapneumovirus	O
and	O
human	O
rhinovirus	O
.	O

The	O
xTAG	O
additionally	O
subtypes	O
influenza	B-PATH
A	I-PATH
as	O
seasonal	O
H1	O
and	O
H3	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
clinical	O
features	O
and	O
treatment	O
of	O
severe	O
pneumonia	O
due	O
to	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
in	O
children	O
with	O
lymphoma	O
during	O
chemotherapy	O
.	O

The	O
most	O
common	O
symptoms	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1v	O
were	O
:	O
high	O
fever	O
(>	O
39	O
Â°	O
C	O
)	O
-	O
96	O
%	O
of	O
patients	O
,	O
dry	O
cough	O
-	O
86	O
%	O
of	O
patients	O
,	O
malaise	O
-	O
78	O
%	O
of	O
patients	O
,	O
headache	O
-	O
66	O
%	O
of	O
patients	O
,	O
and	O
diarrhea	O
or	O
vomiting	O
-	O
28	O
%	O
of	O
patients	O
.	O

ABSTRACT	O
:	O
Exposure	O
of	O
military	O
and	O
civilian	O
populations	O
to	O
inhaled	O
toxic	O
chemicals	O
can	O
take	O
place	O
as	O
a	O
result	O
of	O
deliberate	O
release	B-PATH
(	O
warfare	O
,	O
terrorism	O
)	O
or	O
following	O
accidental	O
releases	O
from	O
industrial	O
concerns	O
or	O
transported	O
chemicals	O
.	O

On	O
the	O
other	O
hand	O
,	O
it	O
is	O
known	O
that	O
cytotoxic	O
T	O
-	O
lymphocyte	O
(	O
CTL	O
)	O
populations	O
directed	O
against	O
internal	O
antigens	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
are	O
broadly	O
cross	O
-	O
reactive	O
to	O
influenza	O
virus	O
subtypes	O
.	O

Transfection	O
of	O
small	O
interfering	O
RNAs	O
targeting	O
either	O
C11orf59	O
or	O
Golgi	O
apparatus	O
glycoprotein	O
1	O
resulted	O
in	O
increased	O
virus	O
replication	O
,	O
whereas	O
depletion	O
of	O
vesicle	O
-	O
trafficking	O
protein	O
vesicle	O
-	O
trafficking	O
protein	O
sec22b	O
enhanced	O
the	O
release	B-PATH
of	O
infectious	O
progeny	O
virus	O
.	O

Myeloperoxidase	O
(	O
MPO	O
)	O
and	O
Î±	O
-	O
defensins	B-PATH
were	O
monitored	O
as	O
indices	O
of	O
neutrophil	O
activity	O
.	O

LTB4	O
produced	O
statistically	O
significant	O
increases	O
in	O
MPO	O
and	O
Î±	O
-	O
defensins	B-PATH
,	O
whereas	O
IL	O
-	O
8	O
,	O
ECP	O
,	O
and	O
Î±	O
(	O
2	O
)-	O
macroglobulin	O
were	O
unaffected	O
.	O

TITLE	O
:	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
vaccine	O
failure	O
in	O
pregnancy	O
.	O

Combination	O
treatment	O
of	O
IFN	O
-	O
Î±	O
and	O
the	O
proteasome	B-PATH
inhibitor	O
MG	O
-	O
132	O
showed	O
a	O
time	O
-	O
dependent	O
restoration	O
of	O
ERK1	O
protein	O
levels	O
and	O
significant	O
increase	O
of	O
ERK1	O
,	O
STAT1	O
and	O
c	O
-	O
Jun	O
phosphorylation	O
in	O
PLpro	O
-	O
expressing	O
cells	O
.	O

ABSTRACT	O
:	O
Individuals	O
infected	O
with	O
HIV	O
are	O
at	O
higher	O
risk	O
for	O
severe	O
cases	O
of	O
seasonal	O
influenza	B-PATH
infection	I-PATH
and	O
should	O
receive	O
annual	O
doses	O
of	O
vaccine	O
.	O

cis	O
-	O
cleavage	O
resulted	O
in	O
release	B-PATH
of	O
SARS	O
S	O
fragments	O
into	O
the	O
cellular	O
supernatant	O
and	O
in	O
inhibition	O
of	O
antibody	O
-	O
mediated	O
neutralization	O
,	O
most	O
likely	O
because	O
SARS	O
S	O
fragments	O
function	O
as	O
antibody	O
decoys	O
.	O

TITLE	O
:	O
Patient	O
-	O
ventilator	O
interaction	O
during	O
acute	O
lung	O
injury	O
,	O
and	O
the	O
role	O
of	O
spontaneous	O
breathing	O
:	O
part	O
2	O
:	O
airway	O
pressure	O
release	B-PATH
ventilation	O
.	O

ABSTRACT	O
:	O
Virus	O
entry	O
into	O
and	O
release	B-PATH
from	O
epithelial	O
cells	O
are	O
polarized	O
as	O
a	O
result	O
of	O
the	O
distribution	O
of	O
the	O
viral	O
receptors	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
baseline	O
characteristics	O
,	O
development	O
of	O
VAHS	O
,	O
related	O
treatments	O
and	O
associated	O
mortality	O
rate	O
of	O
consecutive	O
critically	O
ill	O
patients	O
with	O
confirmed	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
and	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
[	O
Outcomes	O
of	O
severe	O
pandemic	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
/	O
2009	O
].	O

ABSTRACT	O
:	O
To	O
study	O
the	O
outcomes	O
of	O
severe	O
pandemic	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
/	O
2009	O
.	O

TITLE	O
:	O
Fatal	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
a	O
bone	O
marrow	O
transplant	O
recipient	O
.	O

RT	O
-	O
PCR	O
was	O
used	O
to	O
detect	O
the	O
following	O
pathogens	O
:	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
B	O
,	O
parainfluenza	O
1	O
-	O
4	O
,	O
adenovirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
rhinovirus	O
,	O
human	O
metapneumovirus	O
,	O
human	O
coronavirus	O
(	O
OC43	O
,	O
229E	O
,	O
NL63	O
),	O
Chlamydia	O
pneumoniae	O
,	O
Mycoplasma	O
pneumoniae	O
and	O
Legionella	O
species	O
.	O

RESULTS	O
:	O
A	O
respiratory	O
pathogen	O
was	O
detected	O
in	O
41	O
%	O
of	O
tested	O
patient	O
samples	O
;	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
human	O
rhinovirus	O
were	O
both	O
detected	O
in	O
16	O
%.	O

One	O
hundred	O
and	O
fourteen	O
children	O
aged	O
6	O
-	O
14	O
years	O
with	O
chronic	O
stable	O
asthma	B-PATH
and	O
on	O
regular	O
inhaled	O
steroid	O
were	O
monitored	O
for	O
respiratory	O
symptoms	O
over	O
a	O
full	O
calendar	O
year	O
from	O
recruitment	O
.	O

Although	O
newly	O
discovered	O
respiratory	O
viruses	O
were	O
identified	O
in	O
these	O
episodes	O
,	O
rhinovirus	O
was	O
the	O
commonest	O
organism	O
associated	O
with	O
both	O
asthma	B-PATH
exacerbations	O
and	O
non	O
-	O
asthma	B-PATH
related	O
episodes	O
.	O

Dissecting	O
the	O
mechanism	O
of	O
targeting	O
of	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	O
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
its	O
role	O
in	O
the	O
assembly	O
and	O
release	B-PATH
of	O
virions	O
.	O

Complications	O
related	O
to	O
influenza	B-PATH
infection	I-PATH
can	O
be	O
life	O
threatening	O
,	O
particularly	O
in	O
immunocompromised	O
patients	O
.	O

All	O
subjects	O
underwent	O
spirometry	O
and	O
completed	O
a	O
written	O
questionnaire	O
on	O
asthma	B-PATH
symptoms	O
at	O
baseline	O
.	O

CONCLUSIONS	O
:	O
Novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
is	O
most	O
commonly	O
manifested	O
as	O
a	O
mild	O
acute	O
respiratory	O
disease	O
,	O
which	O
usually	O
affects	O
young	O
healthy	O
adults	O
.	O

Children	O
with	O
a	O
higher	O
severity	O
score	O
had	O
greater	O
chance	O
to	O
develop	O
asthma	B-PATH
in	O
the	O
next	O
2	O
years	O
(	O
p	O
=	O
0	O
.	O
042	O
).	O

TITLE	O
:	O
A	O
case	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
associated	O
with	O
novel	O
H1N1	O
treated	O
with	O
intravenous	O
immunoglobulin	O
G	O
.	O
ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
""""	O
novel	O
H1N1	O
""""	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
serious	O
illness	O
that	O
poses	O
a	O
challenge	O
to	O
clinicians	O
managing	O
such	O
cases	O
.	O

ABSTRACT	O
:	O
Comorbidities	O
that	O
promote	O
the	O
progression	O
of	O
Alzheimer	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
(	O
AD	O
)	O
remain	O
to	O
be	O
uncovered	O
and	O
evaluated	O
in	O
animal	O
models	O
.	O

While	O
there	O
were	O
significant	O
differences	O
in	O
the	O
number	O
of	O
host	O
genes	O
differentially	O
regulated	O
during	O
the	O
host	O
responses	O
between	O
the	O
three	O
SARS	O
-	O
CoV	O
strains	O
,	O
the	O
top	O
pathways	O
and	O
functions	O
were	O
similar	O
and	O
only	O
apparent	O
early	O
during	O
infection	O
with	O
the	O
majority	O
of	O
genes	O
associated	O
with	O
interferon	B-PATH
signaling	I-PATH
pathways	O
.	O

We	O
shed	O
light	O
on	O
the	O
diverse	O
conditions	O
commonly	O
encountered	O
in	O
the	O
region	O
,	O
from	O
the	O
centuries	O
-	O
old	O
illnesses	O
of	O
tuberculosis	B-PATH
,	O
to	O
contemporary	O
problems	O
such	O
as	O
lung	O
complications	O
from	O
chemical	O
warfare	O
.	O

The	O
ability	O
of	O
LiCl	O
to	O
inhibit	O
apoptosis	B-PATH
was	O
investigated	O
by	O
IF	O
analysis	O
of	O
caspase	O
-	O
3	O
expression	O
.	O

In	O
addition	O
,	O
treatment	O
of	O
infected	O
Vero	O
/	O
TMPRSS2	O
cells	O
with	O
the	O
protease	O
inhibitor	O
leupeptin	O
strongly	O
blocked	O
the	O
release	B-PATH
of	O
virus	O
into	O
the	O
culture	O
fluid	O
.	O

We	O
found	O
that	O
an	O
export	O
signal	O
deficient	O
SARS	O
-	O
CoV	O
9b	O
protein	O
induces	O
apoptosis	B-PATH
in	O
transiently	O
transfected	O
cells	O
and	O
showed	O
elevated	O
caspase	O
-	O
3	O
activity	O
.	O

TITLE	O
:	O
Pathogenesis	O
of	O
Influenza	B-PATH
A	I-PATH
/	O
H5N1	O
virus	O
infection	O
in	O
ferrets	O
differs	O
between	O
intranasal	O
and	O
intratracheal	O
routes	O
of	O
inoculation	O
.	O

The	O
method	O
of	O
virus	O
inoculation	O
requires	O
careful	O
consideration	O
in	O
the	O
design	O
of	O
ferret	O
experiments	O
as	O
a	O
model	O
for	O
influenza	B-PATH
A	I-PATH
/	O
H5N1	O
in	O
humans	O
.	O

Critical	O
illness	O
from	O
the	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Sfax	O
occurred	O
in	O
young	O
individuals	O
and	O
was	O
associated	O
with	O
severe	O
acute	O
respiratory	O
and	O
additional	O
organ	O
system	O
failure	O
.	O

TITLE	O
:	O
Acute	O
chest	O
syndrome	O
is	O
associated	O
with	O
history	O
of	O
asthma	B-PATH
in	O
hemoglobin	O
SC	O
disease	O
.	O

In	O
comparison	O
to	O
hemoglobin	O
SS	O
patients	O
,	O
a	O
greater	O
proportion	O
of	O
hemoglobin	O
SC	O
patients	O
had	O
a	O
previous	O
history	O
of	O
asthma	B-PATH
or	O
wheezing	O
(	O
50	O
.	O
7	O
vs	O
.	O
33	O
.	O
8	O
%,	O
OR	O
=	O
2	O
.	O
01	O
[	O
1	O
.	O
02	O
-	O
3	O
.	O
96	O
],	O
P	O
=	O
0	O
.	O
041	O
)	O
and	O
a	O
respiratory	O
complaint	O
of	O
wheeze	O
(	O
11	O
.	O
3	O
vs	O
.	O
2	O
.	O
8	O
%,	O
OR	O
=	O
4	O
.	O
38	O
[	O
0	O
.	O
90	O
-	O
21	O
.	O
4	O
],	O
P	O
=	O
0	O
.	O
049	O
).	O

ABSTRACT	O
:	O
A	O
66	O
-	O
year	O
-	O
old	O
woman	O
with	O
hepatitis	B-PATH
C	I-PATH
related	O
liver	O
cirrhosis	O
presented	O
to	O
our	O
hospital	O
for	O
dyspnoea	O
and	O
cyanosis	O
.	O

While	O
avian	O
infectious	O
bronchitis	O
coronavirus	O
(	O
IBV	O
)	O
infection	O
and	O
avian	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
infection	O
both	O
depend	O
on	O
Î±2	O
,	O
3	O
-	O
linked	O
sialic	O
acids	O
,	O
the	O
host	O
tropism	O
of	O
IBV	O
is	O
restricted	O
compared	O
to	O
that	O
of	O
IAV	O
.	O

Mice	O
were	O
intranasally	O
infected	O
with	O
influenza	B-PATH
A	I-PATH
/	O
Puerto	O
Rico	O
/	O
8	O
/	O
34	O
(	O
PR8	O
)	O
virus	O
,	O
and	O
their	O
lungs	O
were	O
examined	O
both	O
macro	O
-	O
and	O
micro	O
-	O
pathologically	O
every	O
2	O
days	O
.	O

There	O
was	O
no	O
difference	O
in	O
plateau	O
pressures	O
,	O
hemodynamic	O
variables	O
,	O
or	O
survival	O
between	O
conventional	O
mechanical	O
ventilation	O
and	O
airway	O
pressure	O
release	B-PATH
ventilation	O
pigs	O
.	O

There	O
are	O
only	O
a	O
few	O
reported	O
cases	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
legionellosis	B-PATH
.	O

It	O
is	O
a	O
condensed	O
version	O
of	O
a	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
Working	O
Paper	O
prepared	O
for	O
the	O
WHO	O
Working	O
Group	O
on	O
Ethics	O
and	O
Tuberculosis	B-PATH
.	O

Clinicians	O
must	O
have	O
an	O
understanding	O
of	O
cardiopulmonary	O
physiology	O
to	O
promptly	O
recognize	O
and	O
treat	O
pregnant	O
women	O
with	O
respiratory	O
conditions	O
ranging	O
from	O
asthma	B-PATH
to	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

These	O
results	O
confirm	O
the	O
presence	O
of	O
influenza	B-PATH
A	I-PATH
H5N1	O
virus	O
,	O
IBV	O
and	O
NDV	O
in	O
domestic	O
and	O
wild	O
birds	O
in	O
Burkina	O
Faso	O
.	O

TITLE	O
:	O
2009	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Panama	O
:	O
a	O
disease	O
affecting	O
children	O
with	O
a	O
benign	O
course	O
.	O

Here	O
we	O
describe	O
the	O
case	O
of	O
a	O
young	O
man	O
,	O
who	O
developed	O
acute	O
severe	O
motor	O
inflammatory	O
demyelinating	O
polyradiculoneuropathy	O
during	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
infection	O
.	O

Administration	O
of	O
E	O
protein	O
in	O
trans	O
reduced	O
the	O
stress	B-PATH
response	I-PATH
in	O
cells	O
infected	O
with	O
rSARS	O
-	O
CoV	O
-	O
Î”E	O
or	O
with	O
respiratory	O
syncytial	O
virus	O
,	O
or	O
treated	O
with	O
drugs	O
,	O
such	O
as	O
tunicamycin	O
and	O
thapsigargin	O
that	O
elicit	O
cell	O
stress	O
by	O
different	O
mechanisms	O
.	O

In	O
addition	O
,	O
SARS	O
-	O
CoV	O
E	O
protein	O
down	O
-	O
regulated	O
the	O
signaling	O
pathway	O
inositol	O
-	O
requiring	O
enzyme	O
1	O
(	O
IRE	O
-	O
1	O
)	O
of	O
the	O
unfolded	O
protein	O
response	O
,	O
but	O
not	O
the	O
PKR	O
-	O
like	O
ER	O
kinase	O
(	O
PERK	O
)	O
or	O
activating	O
transcription	O
factor	O
6	O
(	O
ATF	O
-	O
6	O
)	O
pathways	O
,	O
and	O
reduced	O
cell	O
apoptosis	B-PATH
.	O

TITLE	O
:	O
Clinical	O
presentations	O
of	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
in	O
hospitalized	O
Thai	O
children	O
.	O

In	O
enzyme	O
assays	O
,	O
1m	O
,	O
2h	O
,	O
5m	O
and	O
5n	O
proved	O
to	O
be	O
potent	O
inhibitors	O
of	O
the	O
BVDV	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
while	O
only	O
2h	O
also	O
inhibited	O
the	O
recombinant	O
HCV	O
enzyme	O
.	O

TITLE	O
:	O
[	O
Therapeutic	O
management	O
of	O
malaria	B-PATH
].	O

ABSTRACT	O
:	O
The	O
new	O
strain	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
,	O
often	O
referred	O
to	O
colloquially	O
as	O
""""	O
swine	O
flu	O
""","	O
which	O
was	O
first	O
detected	O
in	O
April	O
2009	O
,	O
raised	O
to	O
a	O
pandemic	O
of	O
which	O
the	O
impact	O
was	O
not	O
completely	O
predictable	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
eight	O
cases	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
admitted	O
to	O
our	O
medical	O
intensive	O
care	O
with	O
severe	O
respiratory	O
failure	O
between	O
November	O
and	O
December	O
2009	O
and	O
in	O
January	O
2011	O
.	O

TITLE	O
:	O
Pandemic	O
H1N1	O
influenza	B-PATH
infection	I-PATH
in	O
children	O
with	O
acute	O
leukemia	O
:	O
a	O
single	O
-	O
center	O
experience	O
.	O

In	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pneumonia	O
,	O
empirical	O
antibiotic	O
therapy	O
should	O
be	O
provided	O
due	O
to	O
the	O
possibility	O
of	O
bacterial	O
coinfection	O
.	O

The	O
treatment	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
must	O
be	O
based	O
on	O
the	O
use	O
of	O
a	O
protective	O
ventilatory	O
strategy	O
(	O
tidal	O
volume	O
<	O
10	O
ml	O
/	O
kg	O
and	O
plateau	O
pressure	O
<	O
35	O
mmHg	O
)	O
and	O
positive	O
end	O
-	O
expiratory	O
pressure	O
set	O
to	O
high	O
patient	O
lung	O
mechanics	O
,	O
combined	O
with	O
the	O
use	O
of	O
prone	O
ventilation	O
,	O
muscle	O
relaxation	O
and	O
recruitment	O
maneuvers	O
.	O

Cardiovascular	O
complications	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
are	O
common	O
.	O

TITLE	O
:	O
Complicated	O
secondary	O
pneumonia	O
after	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
in	O
an	O
immunocompetent	O
patient	O
.	O

The	O
present	O
study	O
was	O
planned	O
to	O
estimate	O
the	O
pulmonary	O
system	O
involvement	O
in	O
patients	O
with	O
malaria	B-PATH
from	O
north	O
-	O
western	O
India	O
(	O
Bikaner	O
).	O

TITLE	O
:	O
Virus	O
-	O
infected	O
alveolar	O
epithelial	O
cells	O
direct	O
neutrophil	O
chemotaxis	O
and	O
inhibit	O
their	O
apoptosis	B-PATH
.	O

In	O
this	O
study	O
we	O
observed	O
that	O
TGEV	O
infection	O
induced	O
apoptosis	B-PATH
in	O
porcine	O
kidney	O
(	O
PK	O
-	O
15	O
)	O
cells	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O

TITLE	O
:	O
Hapivirins	O
and	O
diprovirins	O
:	O
novel	O
Î¸	O
-	O
defensin	O
analogs	O
with	O
potent	O
activity	O
against	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

We	O
previously	O
reported	O
that	O
synthetic	O
Î¸	O
-	O
defensins	B-PATH
called	O
retrocyclins	O
can	O
neutralize	O
and	O
aggregate	O
various	O
strains	O
of	O
IAV	O
and	O
increase	O
IAV	O
uptake	O
by	O
neutrophils	O
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
associated	O
with	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pneumonia	O
which	O
was	O
aggravated	O
by	O
the	O
cessation	O
of	O
corticosteroid	O
therapy	O
].	O

Biflavonoids	O
appeared	O
to	O
be	O
potent	O
inhibitors	O
of	O
DV	O
-	O
NS5	O
RdRp	O
with	O
IC	O
(	O
50	O
)	O
s	O
between	O
0	O
.	O
26	O
and	O
3	O
.	O
12	O
ÂµM	O
.	O
Inhibitory	O
activity	O
evaluations	O
against	O
the	O
RNA	B-PATH
polymerase	I-PATH
from	O
other	O
Flaviviridae	O
viruses	O
allowed	O
us	O
to	O
conclude	O
that	O
these	O
compounds	O
are	O
specific	O
inhibitors	O
of	O
the	O
DV	O
RNA	B-PATH
polymerase	I-PATH
.	O

The	O
case	O
records	O
of	O
all	O
confirmed	O
cases	O
of	O
malaria	B-PATH
over	O
the	O
period	O
of	O
one	O
year	O
were	O
studied	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
emergence	O
of	O
virulent	O
respiratory	O
infectious	O
diseases	O
such	O
as	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
and	O
Influenza	B-PATH
A	I-PATH
/	O
H1N1	O
viruses	O
predisposes	O
nurses	O
to	O
occupational	O
risks	O
.	O

ABSTRACT	O
:	O
Pneumonia	O
was	O
a	O
common	O
complication	O
among	O
hospitalized	O
patients	O
with	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
H1N1	O
[	O
pH1N1	O
]	O
in	O
the	O
United	O
States	O
in	O
2009	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
indicate	O
that	O
Heme	O
/	O
HO	O
-	O
1	O
,	O
CXCL10	O
/	O
CXCR3	O
and	O
STAT3	O
molecules	O
as	O
well	O
as	O
related	O
signaling	O
pathways	O
play	O
very	O
important	O
roles	O
in	O
the	O
pathogenesis	O
of	O
severe	O
malaria	B-PATH
.	O

Because	O
of	O
a	O
concern	O
for	O
reemergence	O
or	O
a	O
deliberate	O
release	B-PATH
of	O
the	O
SARS	O
coronavirus	O
,	O
vaccine	O
development	O
was	O
initiated	O
.	O

Matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
have	O
been	O
functionally	O
linked	O
with	O
septic	O
and	O
endotoxin	O
shock	O
,	O
with	O
cytokine	O
release	B-PATH
syndromes	O
and	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Finally	O
,	O
the	O
functional	O
consequences	O
of	O
palmitoylation	O
are	O
discussed	O
regarding	O
binding	O
of	O
proteins	O
to	O
membranes	O
or	O
membrane	O
rafts	O
,	O
entry	O
of	O
enveloped	O
viruses	O
into	O
target	O
cells	O
by	O
spike	O
-	O
mediated	O
membrane	O
fusion	O
as	O
well	O
as	O
assembly	O
and	O
release	B-PATH
of	O
virus	O
particles	O
from	O
infected	O
cells	O
.	O

BIT225	O
,	O
developed	O
by	O
Biotron	O
Limited	O
,	O
is	O
the	O
first	O
acylguanidine	O
in	O
clinical	O
trials	O
against	O
HIV	O
type	O
1	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
.	O

The	O
clinical	O
files	O
of	O
women	O
having	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
attending	O
the	O
Monica	O
Pretelini	O
maternal	O
-	O
perinatal	O
hospital	O
'	O
s	O
(	O
HMPMP	O
)	O
intensive	O
care	O
unit	O
in	O
Toluca	O
,	O
Mexico	O
,	O
were	O
reviewed	O
.	O

Past	O
experience	O
during	O
the	O
epidemics	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
-	O
2009	O
)	O
posed	O
several	O
technical	O
challenges	O
in	O
estimating	O
the	O
CFR	O
in	O
real	O
time	O
.	O

TITLE	O
:	O
Intensive	O
care	O
unit	O
patients	O
with	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1pdm09	O
)	O
virus	O
infection	O
-	O
United	O
States	O
,	O
2009	O
.	O

TITLE	O
:	O
Pulmonary	O
manifestation	O
of	O
novel	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
(	O
S	O
-	O
OIV	O
)	O
infection	O
in	O
immunocompromised	O
patients	O
:	O
initial	O
findings	O
with	O
multidetector	O
computed	O
tomography	O
.	O

Retrocyclin	O
-	O
1	O
inhibits	O
the	O
cellular	O
entry	O
of	O
HIV	O
-	O
1	O
,	O
HSV	O
,	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

Owing	O
to	O
this	O
endowment	O
,	O
MPs	O
can	O
effectively	O
interact	O
with	O
other	O
cell	O
types	O
via	O
fusion	O
,	O
receptor	O
-	O
mediated	O
interaction	O
,	O
uptake	O
,	O
or	O
mediator	O
release	B-PATH
,	O
thereby	O
acting	O
as	O
intrinsic	O
stimulators	O
,	O
modulators	O
,	O
or	O
even	O
attenuators	O
in	O
a	O
variety	O
of	O
disease	O
processes	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
critically	O
ill	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
related	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
preliminary	O
experience	O
from	O
a	O
single	O
center	O
.	O

From	O
July	O
to	O
October	O
2009	O
,	O
101	O
cases	O
suspected	O
of	O
suffering	O
from	O
Pandemic	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
were	O
admitted	O
and	O
isolated	O
in	O
Al	O
Nahdha	O
Hospital	O
in	O
Muscat	O
.	O

Risk	O
of	O
mortality	O
in	O
vivax	O
malaria	B-PATH
was	O
highest	O
in	O
patients	O
with	O
ARDS	O
followed	O
by	O
MODS	O
and	O
shock	O
.	O

The	O
nsp1	O
-	O
40S	O
ribosome	B-PATH
complex	O
further	O
induces	O
an	O
endonucleolytic	O
cleavage	O
near	O
the	O
5	O
'	O
UTR	O
of	O
host	O
mRNA	O
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
H1N1	O
induces	O
declines	O
in	O
alveolar	O
gas	O
exchange	O
in	O
mice	O
consistent	O
with	O
rapid	O
post	O
-	O
infection	O
progression	O
from	O
acute	O
lung	O
injury	O
to	O
ARDS	O
.	O

u	O
./	O
mouse	O
influenza	B-PATH
A	I-PATH
/	O
WSN	O
/	O
33	O
.	O

Because	O
early	O
markers	O
of	O
ALI	O
/	O
ARDS	O
are	O
lacking	O
,	O
fluid	O
resuscitation	O
in	O
severe	O
malaria	B-PATH
should	O
follow	O
the	O
old	O
adage	O
to	O
""""	O
keep	O
them	O
dry	O
.	O

Bacteremia	O
and	O
hospital	O
-	O
acquired	O
pneumonia	O
can	O
complicate	O
severe	O
malaria	B-PATH
and	O
may	O
contribute	O
to	O
ALI	O
/	O
ARDS	O
.	O

The	O
use	O
of	O
lung	O
-	O
protective	O
ventilation	O
has	O
helped	O
to	O
reduce	O
mortality	O
from	O
malaria	B-PATH
-	O
induced	O
ALI	O
/	O
ARDS	O
,	O
but	O
permissive	O
hypercapnia	O
in	O
unconscious	O
patients	O
is	O
not	O
recommended	O
because	O
increased	O
intracranial	O
pressure	O
and	O
cerebral	O
swelling	O
may	O
occur	O
in	O
cerebral	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
The	O
occurrence	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
in	O
Hong	O
Kong	O
in	O
1997	O
led	O
to	O
the	O
development	O
of	O
a	O
""""	O
One	O
-	O
Health	O
""""	O
approach	O
to	O
deal	O
with	O
emerging	O
infectious	O
diseases	O
that	O
has	O
been	O
applied	O
to	O
other	O
emergent	O
diseases	O
such	O
as	O
SARS	O
and	O
the	O
pandemic	O
H1N1	O
2009	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
epidemiological	O
features	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
cases	O
in	O
14	O
municipalities	O
of	O
Santa	O
Catarina	O
,	O
Brazil	O
,	O
during	O
the	O
2009	O
pandemic	O
.	O

Those	O
proteins	O
exhibit	O
different	O
functions	O
,	O
such	O
as	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
,	O
helicase	O
,	O
proteases	O
and	O
proteins	O
that	O
regulate	O
cellular	O
functions	O
,	O
mRNAs	O
smaller	O
than	O
mRNA	O
-	O
2	O
translate	O
in	O
general	O
the	O
structural	O
proteins	O
,	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
spike	O
(	O
S	O
)	O
protein	O
,	O
integrated	O
membrane	O
(	O
M	O
)	O
protein	O
and	O
envelope	O
(	O
E	O
)	O
proteins	O
.	O

We	O
studied	O
the	O
severity	O
,	O
outcomes	O
,	O
and	O
hospital	O
charges	O
of	O
patients	O
with	O
ALI	O
/	O
ARDS	O
secondary	O
to	O
pandemic	O
influenza	B-PATH
A	I-PATH
infection	O
compared	O
with	O
ALI	O
and	O
ARDS	O
from	O
other	O
etiologies	O
.	O

ALI	O
/	O
ARDS	O
secondary	O
to	O
pandemic	O
influenza	B-PATH
infection	I-PATH
is	O
associated	O
with	O
more	O
severe	O
respiratory	O
compromise	O
but	O
has	O
lower	O
overall	O
acuity	O
and	O
better	O
survival	O
rates	O
than	O
ALI	O
/	O
ARDS	O
due	O
to	O
other	O
causes	O
.	O

Proteasome	B-PATH
inhibitor	O
MG	O
-	O
132	O
significantly	O
reduced	O
expression	O
of	O
TGF	O
-	O
Î²1	O
and	O
vimentin	O
.	O

ABSTRACT	O
:	O
The	O
whey	O
acidic	O
protein	O
family	O
member	O
,	O
WFDC1	O
/	O
ps20	O
is	O
a	O
permissivity	O
factor	O
in	O
HIV	B-PATH
infection	I-PATH
.	O

ABSTRACT	O
:	O
Programmed	O
-	O
1	O
frameshifting	O
,	O
whereby	O
the	O
reading	O
frame	O
of	O
a	O
ribosome	B-PATH
on	O
messenger	O
RNA	O
is	O
shifted	O
in	O
order	O
to	O
generate	O
an	O
alternate	O
gene	O
product	O
,	O
is	O
often	O
triggered	O
by	O
a	O
pseudoknot	O
structure	O
in	O
the	O
mRNA	O
in	O
combination	O
with	O
an	O
upstream	O
slippery	O
sequence	O
.	O

Most	O
cases	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
swl	O
)	O
are	O
either	O
mild	O
or	O
severe	O
diseases	O
;	O
it	O
may	O
be	O
especially	O
serious	O
in	O
previously	O
unaffected	O
young	O
and	O
middle	O
-	O
aged	O
subjects	O
and	O
develop	O
into	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
the	O
fatal	O
outcome	O
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
:	O
From	O
highly	O
pathogenic	O
H5N1	O
to	O
pandemic	O
2009	O
H1N1	O
.	O

These	O
are	O
the	O
highly	O
pathogenic	O
H5N1	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H5N1	O
)	O
and	O
the	O
Pandemic	O
2009	O
influenza	O
H1N1	O
virus	O
.	O

We	O
estimated	O
that	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
mortality	O
rate	O
per	O
100	O
,	O
000	O
person	O
-	O
years	O
(	O
py	O
)	O
ranged	O
from	O
1	O
.	O
5	O
among	O
persons	O
aged	O
5	O
-	O
44	O
years	O
to	O
5	O
.	O
6	O
among	O
persons	O
aged	O
â‰¥	O
65	O
years	O
.	O

RESULTS	O
:	O
We	O
estimated	O
that	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
mortality	O
rate	O
per	O
100	O
,	O
000	O
person	O
-	O
years	O
(	O
py	O
)	O
ranged	O
from	O
1	O
.	O
5	O
among	O
persons	O
aged	O
5	O
-	O
44	O
years	O
to	O
5	O
.	O
6	O
among	O
persons	O
aged	O
â‰¥	O
65	O
years	O
.	O

CONCLUSIONS	O
:	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
caused	O
a	O
similar	O
burden	O
of	O
disease	O
in	O
Argentina	O
as	O
in	O
other	O
countries	O
.	O

Thirty	O
-	O
five	O
of	O
the	O
patients	O
had	O
a	O
positive	O
malaria	B-PATH
blood	O
smear	O
.	O

We	O
used	O
data	O
from	O
a	O
new	O
sentinel	O
surveillance	O
system	O
to	O
investigate	O
the	O
seasonality	O
and	O
characteristics	O
of	O
influenza	O
,	O
including	O
pandemic	O
(	O
pdm	O
)	O
influenza	B-PATH
A	I-PATH
H1N1	O
,	O
in	O
Zambia	O
.	O

ABSTRACT	O
:	O
The	O
clinical	O
manifestations	O
of	O
severe	O
malaria	B-PATH
are	O
several	O
and	O
occur	O
in	O
different	O
anatomical	O
sites	O
.	O

Using	O
the	O
Respiratory	O
Virus	O
Panel	O
these	O
specimens	O
tested	O
positive	O
for	O
one	O
or	O
more	O
respiratory	O
virus	O
and	O
negative	O
for	O
influenza	B-PATH
A	I-PATH
and	O
B	O
.	O
From	O
our	O
subset	O
hMPV	O
was	O
the	O
fourth	O
most	O
common	O
virus	O
(	O
n	O
=	O
2	O
,	O
561	O
)	O
with	O
373	O
(	O
15	O
%)	O
identified	O
as	O
mixed	O
infection	O
using	O
DIAL	O
.	O

Overall	O
,	O
37	O
respiratory	O
pathogens	O
were	O
detected	O
in	O
34	O
children	O
(	O
10	O
.	O
2	O
%):	O
parainfluenza	O
-	O
1	O
(	O
n	O
=	O
9	O
),	O
human	O
rhinovirus	O
(	O
n	O
=	O
7	O
),	O
parainfluenza	O
-	O
3	O
(	O
n	O
=	O
6	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
,	O
n	O
=	O
6	O
),	O
Streptococcus	O
pneumoniae	O
(	O
n	O
=	O
3	O
),	O
adenovirus	O
(	O
n	O
=	O
2	O
),	O
human	O
coronavirus	O
(	O
n	O
=	O
2	O
),	O
influenza	B-PATH
A	I-PATH
(	O
n	O
=	O
1	O
),	O
and	O
bocavirus	O
(	O
n	O
=	O
1	O
).	O

In	O
in	O
vitro	O
systems	O
,	O
histones	O
damaged	O
endothelial	O
cells	O
,	O
stimulated	O
cytokine	O
release	B-PATH
,	O
and	O
induced	O
neutrophil	O
extracellular	O
trap	O
formation	O
and	O
myeloperoxidase	O
release	B-PATH
.	O

Unfortunately	O
,	O
amantadine	O
forfeited	O
most	O
of	O
its	O
therapeutic	O
potential	O
because	O
of	O
resistance	O
development	O
in	O
recent	O
influenza	B-PATH
A	I-PATH
virus	O
isolates	O
.	O

TITLE	O
:	O
[	O
Clinical	O
and	O
laboratory	O
profile	O
of	O
Plasmodium	O
vivax	O
malaria	B-PATH
patients	O
hospitalized	O
in	O
ApartadÃ³	O
,	O
Colombia	O
].	O

The	O
burden	O
of	O
vivax	O
malaria	B-PATH
is	O
78	O
.	O
7	O
%	O
and	O
the	O
profile	O
of	O
vivax	O
malaria	B-PATH
in	O
this	O
region	O
has	O
scarcely	O
been	O
studied	O
.	O

Of	O
359	O
patients	O
with	O
vivax	O
malaria	B-PATH
who	O
required	O
hospitalization	O
,	O
23	O
.	O
1	O
%	O
(	O
83	O
/	O
359	O
patients	O
)	O
had	O
the	O
following	O
complications	O
:	O
severe	O
anemia	O
,	O
51	O
.	O
8	O
%	O
(	O
43	O
/	O
83	O
);	O
severe	O
thrombocytopenia	O
,	O
15	O
.	O
6	O
%	O
(	O
13	O
/	O
83	O
);	O
hyperbilirubinemia	O
,	O
7	O
.	O
2	O
%	O
(	O
6	O
/	O
83	O
).	O

A	O
total	O
of	O
288	O
samples	O
were	O
tested	O
:	O
165	O
samples	O
were	O
collected	O
from	O
patients	O
with	O
suspected	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infection	O
during	O
the	O
first	O
pandemic	O
wave	O
in	O
2009	O
;	O
and	O
123	O
samples	O
were	O
collected	O
from	O
patients	O
of	O
a	O
hematopoietic	O
stem	O
cell	O
transplantation	O
program	O
in	O
2008	O
-	O
2009	O
.	O

ABSTRACT	O
:	O
Chronic	O
respiratory	O
diseases	O
involve	O
a	O
heterogenous	O
group	O
of	O
diseases	O
,	O
including	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
),	O
asthma	B-PATH
,	O
sleep	O
apnea	O
syndrome	O
,	O
pulmonary	O
hypertension	O
,	O
and	O
many	O
occupational	O
diseases	O
.	O

Activated	O
PMNs	O
release	B-PATH
heparin	O
-	O
binding	O
protein	O
(	O
HBP	O
),	O
a	O
granule	O
protein	O
previously	O
shown	O
to	O
be	O
involved	O
in	O
acute	O
inflammatory	O
reactions	O
.	O

Employing	O
human	O
prostate	B-PATH
cancer	I-PATH
and	O
melanoma	B-PATH
cell	O
models	O
,	O
we	O
found	O
that	O
the	O
intensity	O
and	O
duration	O
of	O
STAT1	O
phosphorylation	O
as	O
well	O
as	O
the	O
downstream	O
activation	O
of	O
pathobiologically	O
relevant	O
genes	O
were	O
dose	O
and	O
particle	O
dependent	O
.	O

Human	O
respiratory	O
syncytial	O
virus	O
was	O
the	O
most	O
common	O
virus	O
in	O
children	O
under	O
5	O
years	O
of	O
age	O
,	O
and	O
the	O
influenza	B-PATH
A	I-PATH
virus	O
was	O
the	O
most	O
prevalent	O
virus	O
in	O
children	O
over	O
5	O
years	O
of	O
age	O
.	O

AKI	O
was	O
associated	O
with	O
oliguria	O
/	O
anuria	O
(	O
48	O
%),	O
anaemia	O
(	O
70	O
%),	O
thrombocytopenia	O
(	O
84	O
%),	O
hepatic	O
dysfunction	O
(	O
48	O
%),	O
gastrointestinal	O
manifestations	O
(	O
33	O
%),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
(	O
14	O
%),	O
cerebral	O
malaria	B-PATH
(	O
6	O
%),	O
disseminated	O
intravascular	O
coagulation	O
(	O
8	O
%)	O
and	O
shock	O
(	O
11	O
%).	O

TITLE	O
:	O
A	O
sign	O
of	O
superspreading	O
in	O
tuberculosis	B-PATH
:	O
highly	O
skewed	O
distribution	O
of	O
genotypic	O
cluster	O
sizes	O
.	O

The	O
Malaria	B-PATH
Score	O
for	O
Adults	O
(	O
MSA	O
)	O
and	O
Coma	O
Acidosis	O
Malaria	B-PATH
(	O
CAM	O
)	O
score	O
have	O
recently	O
been	O
proposed	O
to	O
risk	O
stratify	O
patients	O
with	O
malaria	B-PATH
.	O

Twenty	O
-	O
nine	O
out	O
of	O
150	O
pooled	O
fecal	O
samples	O
tested	O
positive	O
by	O
reverse	O
transcription	O
-	O
PCR	O
contained	O
fragments	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
of	O
coronavirus	O
-	O
related	O
viruses	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
study	O
clinical	O
presentation	O
and	O
complications	O
of	O
patients	O
with	O
complicated	O
P	O
.	O
falciparum	O
malaria	B-PATH
and	O
its	O
outcome	O
.	O

Cerebral	O
malaria	B-PATH
,	O
ARF	O
and	O
ARDS	O
were	O
uncommon	O
presentation	O
.	O

Notably	O
,	O
infection	O
mediated	O
by	O
the	O
entry	O
proteins	O
of	O
Lassa	O
fever	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
and	O
SARS	O
coronavirus	O
was	O
largely	O
unaffected	O
by	O
TIM1	O
expression	O
.	O

ABSTRACT	O
:	O
Infection	O
of	O
poultry	O
with	O
influenza	B-PATH
A	I-PATH
subtype	O
H7	O
viruses	O
occurs	O
worldwide	O
,	O
but	O
the	O
introduction	O
of	O
this	O
subtype	O
to	O
humans	O
in	O
Asia	O
has	O
not	O
been	O
observed	O
previously	O
.	O

In	O
this	O
study	O
,	O
we	O
established	O
an	O
in	O
vitro	O
model	O
to	O
compare	O
the	O
responses	O
of	O
type	O
I	O
(	O
ATI	O
)	O
and	O
type	O
II	O
(	O
ATII	O
)	O
alveolar	O
epithelial	O
cells	O
to	O
infection	O
by	O
respiratory	O
viruses	O
used	O
in	O
murine	O
models	O
:	O
mouse	O
-	O
adapted	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
,	O
v2163	O
),	O
murine	O
coronavirus	O
MHV	O
-	O
1	O
,	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
,	O
strain	O
PR8	O
.	O

Analysis	O
of	O
the	O
pathways	O
downstream	O
of	O
GADD153	O
revealed	O
much	O
more	O
activation	O
of	O
the	O
extracellular	O
signal	O
-	O
related	O
kinase	O
(	O
ERK	O
)	O
pathway	O
in	O
GADD153	O
-	O
knockdown	O
cells	O
during	O
IBV	O
infection	O
,	O
indicating	O
that	O
GADD153	O
may	O
modulate	O
apoptosis	B-PATH
through	O
suppression	O
of	O
the	O
pathway	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
Flu	O
A	O
),	O
human	O
metapneumovirus	O
(	O
hMPV	O
)	O
and	O
human	O
bocavirus	O
(	O
BoCA	O
)	O
were	O
found	O
4	O
.	O
4	O
%,	O
3	O
.	O
7	O
%	O
and	O
2	O
.	O
2	O
%,	O
respectively	O
.	O

We	O
present	O
a	O
case	O
of	O
malaria	B-PATH
with	O
multi	O
organ	O
involvement	O
.	O

Cerebral	O
malaria	B-PATH
should	O
be	O
suspected	O
in	O
any	O
febrile	O
patient	O
from	O
a	O
malaria	B-PATH
-	O
endemic	O
region	O
with	O
loss	O
of	O
consciousness	O
.	O

Influenza	B-PATH
A	I-PATH
virus	O
was	O
the	O
dominant	O
agent	O
(	O
677	O
,	O
61	O
.	O
5	O
%)	O
in	O
all	O
age	O
groups	O
.	O

This	O
was	O
the	O
first	O
case	O
report	O
of	O
fulminant	O
disseminated	O
toxoplasmosis	B-PATH
in	O
South	O
Africa	O
,	O
in	O
which	O
detailed	O
histopathology	O
in	O
an	O
apparently	O
immunocompetent	O
cat	O
was	O
described	O
.	O

TITLE	O
:	O
The	O
study	O
of	O
complications	O
of	O
vivax	O
malaria	B-PATH
in	O
comparison	O
with	O
falciparum	O
malaria	B-PATH
in	O
Mumbai	O
.	O

ABSTRACT	O
:	O
Severe	O
malaria	B-PATH
due	O
to	O
P	O
.	O
vivax	O
infection	O
is	O
increasingly	O
observed	O
now	O
a	O
days	O
.	O

In	O
this	O
study	O
we	O
have	O
compared	O
the	O
complications	O
in	O
vivax	O
malaria	B-PATH
with	O
those	O
in	O
falciparum	O
or	O
mixed	O
malaria	B-PATH
.	O

1	O
)	O
To	O
study	O
various	O
complications	O
in	O
adult	O
inpatients	O
of	O
vivax	O
malaria	B-PATH
.	O

Severe	O
disease	O
was	O
present	O
in	O
162	O
(	O
23	O
.	O
82	O
%)	O
cases	O
of	O
malaria	B-PATH
of	O
which	O
50	O
(	O
31	O
%)	O
had	O
vivax	O
infection	O
,	O
64	O
(	O
39	O
%)	O
had	O
falciparum	O
infection	O
and	O
48	O
(	O
30	O
%)	O
had	O
mixed	O
infection	O
.	O

The	O
complications	O
seen	O
in	O
vivax	O
malaria	B-PATH
were	O
:	O
thrombocytopenia	O
(	O
68	O
%),	O
leukopenia	O
(	O
19	O
%),	O
ARDS	O
(	O
3	O
%),	O
high	O
bilirubin	O
(	O
5	O
%),	O
acute	O
renal	O
failure	O
(	O
3	O
.	O
5	O
%),	O
anemia	O
(	O
3	O
%),	O
mucosal	O
bleeding	O
(	O
8	O
%),	O
cerebral	O
malaria	B-PATH
(	O
3	O
.	O
5	O
%),	O
hypotension	O
(	O
5	O
%),	O
metabolic	O
acidosis	O
(	O
4	O
%)	O
and	O
death	O
(	O
1	O
.	O
77	O
%).	O

ABSTRACT	O
:	O
Exchange	O
transfusion	O
(	O
ET	O
)	O
has	O
biologic	O
plausibility	O
as	O
an	O
adjunct	O
to	O
antimalarial	O
drugs	O
in	O
treating	O
severe	O
malaria	B-PATH
and	O
has	O
been	O
used	O
for	O
decades	O
despite	O
limited	O
evidence	O
of	O
its	O
efficacy	O
in	O
improving	O
survival	O
.	O

We	O
examined	O
the	O
efficacy	O
of	O
ET	O
as	O
an	O
adjunct	O
treatment	O
for	O
severe	O
malaria	B-PATH
using	O
US	O
surveillance	O
data	O
and	O
reviewed	O
the	O
literature	O
to	O
update	O
recommendations	O
.	O

Despite	O
the	O
high	O
prevalence	O
of	O
this	O
disease	O
in	O
our	O
midst	O
,	O
there	O
has	O
been	O
no	O
report	O
on	O
the	O
clinical	O
features	O
in	O
the	O
sickle	O
cell	O
pediatric	O
population	O
suffering	O
from	O
malaria	B-PATH
in	O
our	O
midst	O
.	O

Of	O
the	O
90	O
homozygous	O
sickle	O
cell	O
children	O
with	O
malaria	B-PATH
,	O
fever	O
,	O
pallor	O
,	O
and	O
jaundice	O
were	O
the	O
commonly	O
-	O
found	O
symptoms	O
.	O

No	O
case	O
of	O
cerebral	O
malaria	B-PATH
was	O
found	O
.	O

TITLE	O
:	O
Clinical	O
spectrum	O
and	O
treatment	O
outcome	O
of	O
severe	O
malaria	B-PATH
caused	O
by	O
Plasmodium	O
vivax	O
in	O
18	O
children	O
from	O
northern	O
India	O
.	O

Children	O
diagnosed	O
with	O
'	O
severe	O
malaria	B-PATH
'	O
(	O
World	O
Health	O
Organization	O
,	O
2000	O
),	O
were	O
started	O
on	O
intravenous	O
artesunate	O
followed	O
by	O
artemether	O
-	O
lumefantrine	O
combination	O
.	O

ABSTRACT	O
:	O
Gemcitabine	O
is	O
widely	O
accepted	O
as	O
the	O
standard	O
treatment	O
for	O
pancreatic	B-PATH
cancer	I-PATH
,	O
but	O
it	O
can	O
cause	O
unpredictable	O
side	O
effects	O
.	O

The	O
patient	O
was	O
a	O
76	O
-	O
year	O
-	O
old	O
man	O
with	O
pancreatic	B-PATH
cancer	I-PATH
who	O
was	O
receiving	O
adjuvant	O
gemcitabine	O
chemotherapy	O
after	O
surgery	O
.	O

The	O
most	O
common	O
were	O
influenza	B-PATH
A	I-PATH
strains	O
(	O
17	O
.	O
9	O
%),	O
with	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
and	O
seasonal	O
H3N2	O
strain	O
accounting	O
for	O
52	O
%	O
and	O
43	O
%	O
of	O
these	O
,	O
respectively	O
.	O

The	O
outbreak	O
in	O
2009	O
of	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
strain	O
provided	O
a	O
practical	O
test	O
of	O
the	O
laboratory	O
'	O
s	O
pandemic	O
plan	O
.	O

It	O
seems	O
likely	O
that	O
development	O
of	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
in	O
patient	O
with	O
VHL	O
disease	O
can	O
be	O
related	O
to	O
epigenetic	O
alterations	O
of	O
the	O
VHL	O
gene	O
,	O
but	O
further	O
studies	O
are	O
needed	O
.	O

Data	O
on	O
severe	O
forms	O
of	O
measles	B-PATH
in	O
adults	O
are	O
lacking	O
.	O

Other	O
patients	O
potentially	O
at	O
high	O
risk	O
for	O
severe	O
measles	B-PATH
are	O
young	O
adults	O
and	O
pregnant	O
women	O
.	O

Lessons	O
learned	O
from	O
the	O
SARS	O
epidemic	O
will	O
be	O
especially	O
important	O
in	O
responding	O
to	O
the	O
current	O
emergence	O
of	O
another	O
highly	O
pathogenic	O
human	O
coronavirus	O
,	O
the	O
agent	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
),	O
and	O
to	O
the	O
recently	O
emerging	O
H7N9	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
China	O
.	O

TITLE	O
:	O
Complications	O
associated	O
with	O
Plasmodium	O
vivax	O
malaria	B-PATH
:	O
a	O
retrospective	O
study	O
from	O
a	O
tertiary	O
care	O
hospital	O
based	O
in	O
Western	O
Uttar	O
Pradesh	O
,	O
India	O
.	O

Sixty	O
-	O
two	O
patients	O
met	O
the	O
criteria	O
for	O
severe	O
malaria	B-PATH
during	O
the	O
study	O
period	O
.	O

The	O
epidemiologic	O
factors	O
associated	O
with	O
AVB	O
severity	O
by	O
RSV	O
were	O
prematurity	O
,	O
passive	O
smoking	O
,	O
young	O
age	O
,	O
lack	O
of	O
breastfeeding	O
,	O
chronic	O
lung	O
disease	O
,	O
congenital	O
heart	O
disease	O
,	O
male	O
gender	O
,	O
ethnicity	O
,	O
viral	O
coinfection	O
,	O
low	O
weight	O
at	O
admission	O
,	O
maternal	O
smoking	O
during	O
pregnancy	O
,	O
atopic	O
dermatitis	O
,	O
mechanical	O
ventilation	O
in	O
the	O
neonatal	O
period	O
,	O
maternal	O
history	O
of	O
atopy	O
and	O
/	O
or	O
asthma	B-PATH
during	O
pregnancy	O
,	O
season	O
of	O
birth	O
,	O
low	O
socioeconomic	O
status	O
,	O
Down	O
syndrome	O
,	O
environmental	O
pollution	O
,	O
living	O
at	O
an	O
altitude	O
>	O
2	O
,	O
500	O
meters	O
above	O
sea	O
level	O
,	O
and	O
cesarean	O
section	O
birth	O
.	O

ABSTRACT	O
:	O
The	O
interferon	O
-	O
inducible	O
transmembrane	O
protein	O
(	O
IFITM	O
)	O
family	O
inhibits	O
a	O
growing	O
number	O
of	O
pathogenic	O
viruses	O
,	O
among	O
them	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
dengue	O
virus	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
and	O
Ebola	O
virus	O
.	O

Our	O
previous	O
studies	O
have	O
demonstrated	O
that	O
TGEV	O
infection	O
induces	O
the	O
activation	O
of	O
p53	B-PATH
signaling	I-PATH
pathway	I-PATH
.	O

In	O
addition	O
,	O
TGEV	O
infection	O
of	O
the	O
cells	O
synchronized	O
in	O
various	O
stages	O
of	O
cell	B-PATH
cycle	I-PATH
showed	O
that	O
viral	O
genomic	O
RNA	O
and	O
subgenomic	O
RNA	O
,	O
and	O
virus	O
titer	O
were	O
higher	O
in	O
the	O
cells	O
released	O
from	O
S	O
-	O
phase	O
-	O
or	O
G2	O
/	O
M	O
phase	O
-	O
synchronized	O
cells	O
than	O
that	O
in	O
the	O
cells	O
released	O
from	O
the	O
G0	O
/	O
G1	O
phase	O
-	O
synchronized	O
or	O
asynchronous	O
cells	O
after	O
18h	O
p	O
.	O
i	O
.	O

Immune	O
response	O
to	O
respiratory	O
viral	O
infections	O
,	O
which	O
may	O
be	O
related	O
to	O
the	O
severity	O
of	O
exacerbation	O
in	O
each	O
disease	O
,	O
varies	O
in	O
patients	O
with	O
both	O
COPD	O
and	O
asthma	B-PATH
.	O

In	O
the	O
present	O
report	O
,	O
a	O
series	O
of	O
three	O
cases	O
of	O
imported	O
malaria	B-PATH
complicated	O
by	O
refractory	O
severe	O
ARDS	O
supported	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
presented	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
coincided	O
with	O
the	O
absence	O
of	O
the	O
seasonal	O
influenza	B-PATH
A	I-PATH
of	O
former	O
years	O
.	O

There	O
is	O
a	O
further	O
need	O
to	O
study	O
the	O
pathophysiology	O
,	O
virulence	O
factors	O
and	O
the	O
molecular	O
mechanisms	O
which	O
are	O
involved	O
in	O
malaria	B-PATH
.	O

Complete	O
travel	O
and	O
clinical	O
history	O
of	O
malaria	B-PATH
patient	O
are	O
vital	O
for	O
successful	O
diagnoses	O
and	O
treatment	O
.	O

RESULTS	O
:	O
Sequencing	O
of	O
the	O
malaria	B-PATH
parasite	O
DNA	O
from	O
both	O
cases	O
,	O
followed	O
by	O
multiple	O
sequence	O
alignment	O
and	O
phylogenetic	O
tree	O
construction	O
suggested	O
that	O
the	O
causative	O
agent	O
for	O
both	O
malaria	B-PATH
cases	O
was	O
P	O
.	O
ovale	O
curtisi	O
.	O

Lastly	O
,	O
CAS	O
is	O
complicated	O
by	O
the	O
fact	O
that	O
asthma	B-PATH
care	O
in	O
diverse	O
healthcare	O
settings	O
is	O
haphazard	O
.	O

Non	O
-	O
randomized	O
studies	O
suggest	O
that	O
convalescent	O
plasma	O
appears	O
useful	O
as	O
add	O
-	O
on	O
therapy	O
for	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
),	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	B-PATH
)	O
2009	O
pandemic	O
[	O
A	O
(	O
H1N1	B-PATH
)	O
pdm09	O
),	O
but	O
it	O
is	O
limited	O
by	O
its	O
availability	O
.	O

We	O
now	O
show	O
that	O
memantine	O
,	O
a	O
drug	O
that	O
is	O
used	O
for	O
alleviating	O
symptoms	O
associated	O
with	O
neuropathology	O
,	O
such	O
as	O
Alzheimer	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
,	O
can	O
partially	O
restore	O
the	O
physiological	O
state	O
of	O
infected	O
mice	O
by	O
limiting	O
both	O
neurodegeneration	O
and	O
viral	O
replication	O
.	O

ERGIC	O
-	O
53	O
binds	O
to	O
arenavirus	O
GPs	O
through	O
a	O
lectin	O
-	O
independent	O
mechanism	O
,	O
traffics	O
to	O
arenavirus	O
budding	B-PATH
sites	O
,	O
and	O
is	O
incorporated	O
into	O
virions	O
.	O

Asthma	B-PATH
,	O
one	O
of	O
the	O
most	O
common	O
chronic	O
diseases	O
in	O
children	O
,	O
still	O
accounts	O
for	O
significant	O
mortality	O
and	O
morbidity	O
,	O
as	O
well	O
as	O
high	O
health	O
care	O
costs	O
worldwide	O
.	O

Since	O
the	O
reemergence	O
of	O
indigenous	O
vivax	O
malaria	B-PATH
in	O
1993	O
,	O
cases	O
of	O
severe	O
malaria	B-PATH
have	O
been	O
steadily	O
reported	O
in	O
Korea	O
.	O

TITLE	O
:	O
Atypical	O
clinic	O
presentation	O
of	O
pandemic	O
influenza	B-PATH
A	I-PATH
successfully	O
rescued	O
by	O
extracorporeal	O
membrane	O
oxygenation	O
-	O
Our	O
experience	O
and	O
review	O
of	O
the	O
literature	O
.	O

We	O
demonstrate	O
the	O
causative	O
role	O
of	O
H1N1	O
in	O
refractory	O
ARDS	O
of	O
a	O
previously	O
healthy	O
15	O
-	O
year	O
-	O
old	O
man	O
who	O
presented	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
a	O
hypoxic	O
and	O
persistent	O
cardiogenic	O
shock	O
refractory	O
to	O
conventional	O
management	O
as	O
the	O
leading	O
symptom	O
of	O
influenza	B-PATH
A	I-PATH
.	O
Because	O
of	O
compromised	O
cardiopulmonary	O
function	O
,	O
venovenous	O
ECMO	O
was	O
applied	O
24	O
h	O
after	O
admission	O
.	O

Any	O
virus	O
was	O
detected	O
in	O
320	O
/	O
556	O
(	O
57	O
.	O
6	O
%)	O
ILI	O
episodes	O
:	O
influenza	B-PATH
A	I-PATH
(	O
104	O
/	O
556	O
,	O
18	O
.	O
7	O
%),	O
rhinovirus	O
/	O
enterovirus	O
(	O
82	O
/	O
556	O
,	O
14	O
.	O
7	O
%),	O
coronavirus	O
and	O
human	O
metapneumovirus	O
(	O
each	O
32	O
/	O
556	O
,	O
5	O
.	O
6	O
%).	O

All	O
patients	O
with	O
severe	O
P	O
.	O
vivax	O
malaria	B-PATH
survived	O
,	O
but	O
one	O
child	O
with	O
cerebral	O
malaria	B-PATH
had	O
neurological	O
sequelae	O
.	O

Multiplex	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
was	O
undertaken	O
on	O
archived	O
nasopharyngeal	O
aspirates	O
from	O
HIV	O
-	O
infected	O
and	O
-	O
uninfected	O
children	O
(<	O
2	O
years	O
age	O
)	O
hospitalized	O
for	O
LRTI	O
,	O
who	O
had	O
been	O
previously	O
investigated	O
for	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
parainfluenza	O
I	O
-	O
III	O
,	O
adenovirus	O
and	O
influenza	B-PATH
A	I-PATH
/	O
B	O
.	O
At	O
least	O
one	O
of	O
these	O
viruses	O
were	O
identified	O
in	O
274	O
(	O
53	O
.	O
0	O
%)	O
of	O
517	O
and	O
in	O
509	O
(	O
54	O
.	O
0	O
%)	O
of	O
943	O
LRTI	O
-	O
episodes	O
in	O
HIV	O
-	O
infected	O
and	O
-	O
uninfected	O
children	O
,	O
respectively	O
.	O

We	O
found	O
that	O
TGEV	O
N	O
protein	O
suppressed	O
cell	O
proliferation	O
by	O
causing	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
the	O
S	O
and	O
G2	O
/	O
M	O
phases	O
and	O
apoptosis	B-PATH
.	O

TITLE	O
:	O
The	O
discovery	O
of	O
asunaprevir	O
(	O
BMS	O
-	O
650032	O
),	O
an	O
orally	O
efficacious	O
NS3	O
protease	O
inhibitor	O
for	O
the	O
treatment	O
of	O
hepatitis	B-PATH
C	I-PATH
virus	O
infection	O
.	O

TITLE	O
:	O
Outcome	O
of	O
acute	O
East	O
African	B-PATH
trypanosomiasis	I-PATH
in	O
a	O
Polish	O
traveller	O
treated	O
with	O
pentamidine	O
.	O

TITLE	O
:	O
Unique	O
reassortant	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
associated	O
with	O
severe	O
disease	O
emerging	O
in	O
Hong	O
Kong	O
.	O

The	O
influenza	B-PATH
A	I-PATH
/	O
Hong	O
Kong	O
/	O
470129	O
/	O
2013	O
virus	O
strain	O
was	O
detected	O
in	O
a	O
patient	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
deranged	O
liver	O
function	O
and	O
coagulation	O
profile	O
,	O
cytopenia	O
,	O
and	O
rhabdomyolysis	O
.	O

RESULTS	O
:	O
The	O
influenza	B-PATH
A	I-PATH
/	O
Hong	O
Kong	O
/	O
470129	O
/	O
2013	O
virus	O
strain	O
was	O
detected	O
in	O
a	O
patient	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
deranged	O
liver	O
function	O
and	O
coagulation	O
profile	O
,	O
cytopenia	O
,	O
and	O
rhabdomyolysis	O
.	O

Influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
is	O
a	O
leading	O
pathogen	O
that	O
infects	O
and	O
kills	O
many	O
humans	O
every	O
year	O
.	O

Gram	O
-	O
negative	O
bacteraemia	O
was	O
uncommon	O
among	O
adults	O
with	O
severe	O
malaria	B-PATH
.	O

Acute	O
hippocampal	O
slices	O
of	O
adult	O
mice	O
were	O
incubated	O
with	O
the	O
vitamin	O
E	O
derivative	O
Trolox	O
for	O
3	O
-	O
5	O
h	O
.	O
In	O
Mecp2	O
(-)	O
(/	O
y	O
)	O
slices	O
this	O
treatment	O
dampened	O
neuronal	O
hyperexcitability	O
,	O
improved	O
synaptic	O
short	O
-	O
term	O
plasticity	O
,	O
and	O
fully	O
restored	O
synaptic	O
long	B-PATH
-	I-PATH
term	I-PATH
potentiation	I-PATH
(	O
LTP	O
).	O

In	O
mice	O
susceptible	O
to	O
measles	B-PATH
virus	O
,	O
recombinant	O
MV	O
expressing	O
the	O
anchored	O
full	O
-	O
length	O
S	O
induced	O
the	O
highest	O
titers	O
of	O
neutralizing	O
antibodies	O
and	O
fully	O
protected	O
immunized	O
animals	O
from	O
intranasal	O
infectious	O
challenge	O
with	O
SARS	O
-	O
CoV	O
.	O
As	O
compared	O
to	O
immunization	O
with	O
adjuvanted	O
recombinant	O
Ssol	O
protein	O
,	O
recombinant	O
MV	O
induced	O
stronger	O
and	O
Th1	O
-	O
biased	O
responses	O
,	O
a	O
hallmark	O
of	O
live	O
attenuated	O
viruses	O
and	O
a	O
highly	O
desirable	O
feature	O
for	O
an	O
antiviral	O
vaccine	O
.	O

ABSTRACT	O
:	O
Pathogens	O
such	O
as	O
MERS	O
-	O
CoV	O
,	O
influenza	B-PATH
A	I-PATH
/	O
H5N1	O
and	O
influenza	B-PATH
A	I-PATH
/	O
H7N9	O
are	O
currently	O
generating	O
sporadic	O
clusters	O
of	O
spillover	O
human	O
cases	O
from	O
animal	O
reservoirs	O
.	O

There	O
was	O
an	O
inflammatory	O
syndrome	O
associated	O
with	O
hyponatremia	O
,	O
but	O
malaria	B-PATH
was	O
negative	O
.	O

Deceased	O
donors	O
with	O
previous	O
hepatitis	B-PATH
C	I-PATH
infection	O
may	O
represent	O
a	O
safe	O
resource	O
to	O
expand	O
the	O
donor	O
pool	O
.	O

TITLE	O
:	O
Multi	O
-	O
organ	O
lesions	O
in	O
suckling	O
mice	O
infected	O
with	O
SARS	O
-	O
associated	O
mammalian	O
reovirus	O
linked	O
with	O
apoptosis	B-PATH
induced	O
by	O
viral	O
proteins	O
Î¼1	O
and	O
Ïƒ1	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
apoptosis	B-PATH
induced	O
by	O
BYD1	O
,	O
its	O
outer	O
capsid	O
protein	O
Î¼1	O
,	O
and	O
its	O
cell	O
-	O
attachment	O
protein	O
Ïƒ1	O
to	O
understand	O
the	O
pathogenesis	O
of	O
BYD1	O
.	O

Based	O
on	O
DNA	O
sequences	O
for	O
the	O
3	O
'-	O
untranslated	O
region	O
and	O
the	O
gene	O
encoding	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
,	O
this	O
avian	O
coronaviruses	O
in	O
quail	O
is	O
an	O
IB	O
virus	O
-	O
like	O
gammacoronavirus	O
.	O

TITLE	O
:	O
Anti	O
-	O
inflammatory	O
and	O
antiviral	O
effects	O
of	O
indirubin	O
derivatives	O
in	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
infected	O
primary	O
human	O
peripheral	O
blood	O
-	O
derived	O
macrophages	O
and	O
alveolar	O
epithelial	O
cells	O
.	O

Infusion	O
of	O
AM	O
protected	O
against	O
MV	O
-	O
induced	O
lung	O
injury	O
(	O
66	O
%	O
reduction	O
of	O
pulmonary	O
permeability	O
p	O
<	O
0	O
.	O
01	O
;	O
prevention	O
of	O
pulmonary	O
restriction	O
)	O
and	O
against	O
VILI	O
-	O
induced	O
liver	O
and	O
gut	O
injury	O
in	O
pneumonia	O
(	O
91	O
%	O
reduction	O
of	O
AST	O
levels	O
p	O
<	O
0	O
.	O
05	O
,	O
96	O
%	O
reduction	O
of	O
alanine	O
aminotransaminase	O
(	O
ALT	O
)	O
levels	O
p	O
<	O
0	O
.	O
05	O
,	O
abrogation	O
of	O
histopathological	O
changes	O
and	O
parenchymal	O
apoptosis	B-PATH
in	O
liver	O
and	O
gut	O
).	O

Infusion	O
of	O
AM	O
protected	O
against	O
MV	O
-	O
induced	O
lung	O
injury	O
(	O
66	O
%	O
reduction	O
of	O
pulmonary	O
permeability	O
p	O
<	O
0	O
.	O
01	O
;	O
prevention	O
of	O
pulmonary	O
restriction	O
)	O
and	O
against	O
VILI	O
-	O
induced	O
liver	O
and	O
gut	O
injury	O
in	O
pneumonia	O
(	O
91	O
%	O
reduction	O
of	O
AST	O
levels	O
p	O
<	O
0	O
.	O
05	O
,	O
96	O
%	O
reduction	O
of	O
alanine	O
aminotransaminase	O
(	O
ALT	O
)	O
levels	O
p	O
<	O
0	O
.	O
05	O
,	O
abrogation	O
of	O
histopathological	O
changes	O
and	O
parenchymal	O
apoptosis	B-PATH
in	O
liver	O
and	O
gut	O
).	O

Furthermore	O
,	O
the	O
most	O
active	O
compound	O
2c	O
with	O
SI	O
value	O
higher	O
than	O
165	O
.	O
1	O
inhibiting	O
HBV	O
DNA	B-PATH
replication	I-PATH
was	O
revealed	O
with	O
the	O
optimal	O
logP	O
value	O
of	O
1	O
.	O
78	O
and	O
logD	O
values	O
.	O

TITLE	O
:	O
Severe	O
Plasmodium	O
vivax	O
malaria	B-PATH
complicated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
case	O
associated	O
with	O
focal	O
autochthonous	O
transmission	O
in	O
Greece	O
.	O

In	O
severe	O
Plasmodium	O
falciparum	O
malaria	B-PATH
,	O
ischemic	O
changes	O
may	O
be	O
due	O
to	O
microvascular	O
obstruction	O
,	O
but	O
,	O
in	O
patients	O
with	O
low	O
parasitemia	O
,	O
other	O
endothelial	O
factors	O
may	O
also	O
be	O
involved	O
as	O
observed	O
in	O
other	O
groups	O
of	O
thrombotic	O
microangiopathies	O
.	O

In	O
addition	O
,	O
the	O
data	O
revealed	O
that	O
highly	O
virulent	O
HPAI	O
virus	O
and	O
MERS	O
-	O
CoV	O
induce	O
repressive	O
histone	B-PATH
modifications	I-PATH
,	O
which	O
downregulate	O
expression	O
of	O
ISG	O
subsets	O
.	O

Here	O
we	O
suggest	O
in	O
vivo	O
study	O
of	O
our	O
identified	O
novel	O
peptide	O
antigen	O
in	O
RNA	O
directed	O
RNA	B-PATH
polymerase	I-PATH
protein	O
for	O
universal	O
vaccine	O
--	O
which	O
may	O
be	O
the	O
way	O
to	O
prevent	O
all	O
human	O
coronavirus	O
disease	O
.	O

One	O
hundred	O
and	O
two	O
indoor	O
patients	O
with	O
isolated	O
P	O
vivax	O
malaria	B-PATH
were	O
included	O
in	O
this	O
study	O
with	O
exclusion	O
of	O
other	O
causes	O
of	O
fever	O
including	O
P	O
falciparum	O
malaria	B-PATH
.	O

The	O
upregulated	O
genes	O
were	O
mainly	O
involved	O
in	O
immune	O
system	O
processes	O
,	O
antigen	B-PATH
processing	I-PATH
and	I-PATH
presentation	I-PATH
,	O
the	O
Jak	O
-	O
STAT	O
signalling	O
pathway	O
,	O
the	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
signalling	O
pathway	O
,	O
Toll	O
-	O
like	O
receptor	O
signalling	O
and	O
apoptosis	B-PATH
-	O
related	O
proteases	O
.	O

Early	O
treatment	O
with	O
ceftriaxone	O
and	O
azithromycin	O
,	O
along	O
with	O
oseltamivir	O
in	O
winter	O
months	O
,	O
should	O
be	O
initiated	O
with	O
all	O
cases	O
of	O
severe	O
exacerbations	O
where	O
infection	O
is	O
suspected	O
,	O
and	O
definitely	O
in	O
critical	O
asthma	B-PATH
syndrome	O
until	O
infection	O
is	O
excluded	O
by	O
appropriate	O
diagnostic	O
testing	O
.	O

Notably	O
,	O
some	O
SARS	O
-	O
CoV	O
accessory	O
proteins	O
have	O
been	O
shown	O
to	O
modulate	O
the	O
interferon	B-PATH
signaling	I-PATH
pathways	O
and	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Pre	O
-	O
and	O
post	O
-	O
treatment	O
lymphopenia	O
and	O
pre	O
-	O
treatment	O
serum	O
albumin	O
should	O
be	O
considered	O
in	O
order	O
to	O
minimize	O
the	O
risk	O
of	O
FN	O
when	O
selecting	O
patients	O
with	O
prostate	B-PATH
cancer	I-PATH
for	O
docetaxel	O
therapy	O
,	O
and	O
when	O
considering	O
dose	O
modifications	O
,	O
and	O
the	O
prophylactic	O
use	O
of	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
.	O

Furthermore	O
,	O
direct	O
inhibition	O
of	O
AIF	O
strongly	O
impaired	O
PEDV	O
infection	O
and	O
virus	O
-	O
induced	O
apoptosis	B-PATH
.	O

At	O
that	O
time	O
,	O
the	O
investigation	O
showed	O
a	O
megakaryocytic	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
,	O
treated	O
with	O
MEC	O
without	O
clinical	O
improvement	O
.	O

Heliox	O
may	O
also	O
enhance	O
the	O
bronchodilating	O
effects	O
of	O
Î²	O
-	O
agonist	O
administration	O
for	O
acute	O
asthma	B-PATH
.	O

Moreover	O
,	O
IRE1Î±	O
antagonized	O
IBV	O
-	O
induced	O
apoptosis	B-PATH
by	O
modulating	O
the	O
phosphorylation	O
status	O
of	O
the	O
proapoptotic	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
and	O
the	O
prosurvival	O
RAC	O
-	O
alpha	O
serine	O
/	O
threonine	O
-	O
protein	O
kinase	O
(	O
Akt	O
).	O

Moreover	O
,	O
IRE1Î±	O
is	O
shown	O
to	O
protect	O
the	O
infected	O
cells	O
from	O
apoptosis	B-PATH
by	O
modulating	O
the	O
unfolded	O
-	O
protein	O
response	O
(	O
UPR	O
)	O
and	O
two	O
kinases	O
related	O
to	O
cell	O
survival	O
.	O

We	O
used	O
mock	O
-	O
infected	O
tissue	O
as	O
negative	O
controls	O
for	O
ex	O
-	O
vivo	O
experiments	O
and	O
influenza	B-PATH
A	I-PATH
H5N1	O
as	O
a	O
positive	O
control	O
for	O
cytokine	O
and	O
chemokine	O
induction	O
experiments	O
in	O
Calu	O
-	O
3	O
cells	O
.	O

In	O
the	O
CURB	O
-	O
65	O
model	O
only	O
influenza	B-PATH
infection	I-PATH
was	O
found	O
independently	O
associated	O
with	O
severe	O
disease	O
(	O
CURB	O
-	O
65	O
score	O
â‰¥	O
3	O
)	O
out	O
of	O
variables	O
,	O
including	O
age	O
(	O
years	O
),	O
sex	O
,	O
current	O
smoking	O
status	O
,	O
sick	O
contact	O
with	O
febrile	O
patients	O
,	O
numbers	O
of	O
comorbidity	O
,	O
presence	O
of	O
influenza	B-PATH
infection	I-PATH
,	O
presence	O
of	O
PIV	O
infection	O
,	O
with	O
P	O
=	O
0	O
.	O
021	O
,	O
OR	O
7	O
.	O
86	O
(	O
95	O
%	O
CI	O
1	O
.	O
37	O
-	O
45	O
.	O
04	O
).	O

TITLE	O
:	O
Bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
protect	O
alveolar	O
macrophages	O
from	O
lipopolysaccharide	O
-	O
induced	O
apoptosis	B-PATH
partially	O
by	O
inhibiting	O
the	O
Wnt	O
/	O
Î²	O
-	O
catenin	O
pathway	O
.	O

There	O
is	O
a	O
remarkable	O
dearth	O
of	O
literature	O
on	O
less	O
pronounced	O
outcomes	O
in	O
malaria	B-PATH
,	O
namely	O
prolonged	O
hospitalization	O
and	O
intensive	O
care	O
requirement	O
.	O

Limitations	O
on	O
routine	O
clinical	O
applicability	O
of	O
the	O
World	O
Health	O
Organization	O
'	O
s	O
(	O
WHO	O
)	O
guidelines	O
for	O
determination	O
of	O
severity	O
in	O
malaria	B-PATH
does	O
result	O
in	O
underestimation	O
of	O
the	O
true	O
burden	O
of	O
clinicians	O
'	O
perceived	O
severity	O
in	O
malaria	B-PATH
.	O

For	O
routine	O
clinical	O
settings	O
,	O
severity	O
definition	O
for	O
malaria	B-PATH
needs	O
to	O
be	O
redefined	O
or	O
modified	O
from	O
the	O
existing	O
WHO	O
guidelines	O
.	O

This	O
descriptive	O
study	O
aims	O
to	O
introduce	O
a	O
novel	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H10N8	O
)	O
virus	O
which	O
can	O
infect	O
humans	O
and	O
cause	O
severe	O
diseases	O
.	O

Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
the	O
SARS	O
-	O
CoV	O
M	O
-	O
protein	O
induces	O
apoptosis	B-PATH
through	O
disrupting	O
the	O
interaction	O
of	O
PDK1	O
with	O
PKB	O
/	O
Akt	O
,	O
and	O
this	O
causes	O
the	O
activation	O
of	O
apoptosis	B-PATH
.	O

Our	O
work	O
highlights	O
that	O
the	O
SARS	O
-	O
CoV	O
M	O
protein	O
is	O
highly	O
pro	O
-	O
apoptotic	O
and	O
is	O
capable	O
of	O
simultaneously	O
inducing	O
apoptosis	B-PATH
via	O
initiating	O
caspases	O
8	O
and	O
9	O
.	O

All	O
children	O
aged	O
from	O
2	O
to	O
15	O
years	O
hospitalized	O
for	O
asthma	B-PATH
exacerbation	O
between	O
January	O
2010	O
and	O
December	O
2011	O
in	O
our	O
unit	O
were	O
included	O
in	O
the	O
study	O
.	O

We	O
estimated	O
the	O
mean	O
serial	O
intervals	O
for	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
(	O
2	O
.	O
2	O
days	O
),	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
(	O
2	O
.	O
8	O
days	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
7	O
.	O
5	O
days	O
),	O
measles	B-PATH
(	O
11	O
.	O
7	O
days	O
),	O
varicella	O
(	O
14	O
.	O
0	O
days	O
),	O
smallpox	O
(	O
17	O
.	O
7	O
days	O
),	O
mumps	O
(	O
18	O
.	O
0	O
days	O
),	O
rubella	O
(	O
18	O
.	O
3	O
days	O
),	O
and	O
pertussis	B-PATH
(	O
22	O
.	O
8	O
days	O
).	O

Maximum	O
enrolled	O
children	O
were	O
of	O
viral	O
encephalitis	O
(	O
46	O
.	O
59	O
%)	O
and	O
rest	O
,	O
were	O
of	O
pyogenic	O
meningitis	O
,	O
tuberculosis	B-PATH
meningitis	O
and	O
cerebral	O
malaria	B-PATH
.	O

TITLE	O
:	O
[	O
Severe	O
imported	O
malaria	B-PATH
:	O
case	O
report	O
].	O

Severe	O
malaria	B-PATH
requires	O
fast	O
diagnosis	O
allied	O
to	O
a	O
quick	O
access	O
to	O
an	O
intensive	O
care	O
treatment	O
,	O
since	O
any	O
delay	O
increases	O
the	O
morbid	O
-	O
mortality	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
World	O
Health	O
Organization	O
announced	O
on	O
April	O
2009	O
a	O
public	O
health	O
emergency	O
of	O
international	O
concern	O
caused	O
by	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
.	O

To	O
determine	O
the	O
mechanisms	O
of	O
lung	O
endothelial	O
cell	O
(	O
EC	O
)	O
High	O
Mobility	O
Group	O
Box	O
1	O
(	O
HMGB1	O
)	O
release	B-PATH
following	O
exposure	O
to	O
RBCs	O
and	O
to	O
determine	O
whether	O
RBC	O
transfusion	O
increases	O
susceptibility	O
to	O
lung	O
inflammation	O
in	O
vivo	O
through	O
release	B-PATH
of	O
the	O
danger	O
signal	O
HMGB1	O
.	O

Meanwhile	O
,	O
chain	O
size	O
data	O
for	O
measles	B-PATH
in	O
the	O
United	O
States	O
and	O
Canada	O
reveal	O
statistically	O
significant	O
geographic	O
variation	O
in	O
R	O
eff	O
,	O
suggesting	O
that	O
the	O
timing	O
and	O
coverage	O
of	O
national	O
vaccination	O
programs	O
,	O
as	O
well	O
as	O
contact	O
tracing	O
procedures	O
,	O
may	O
shape	O
the	O
size	O
distribution	O
of	O
observed	O
infection	O
clusters	O
.	O

Using	O
recombinant	O
MHVs	O
expressing	O
reporter	O
genes	O
as	O
well	O
as	O
a	O
novel	O
,	O
replication	O
-	O
independent	O
fusion	O
assay	O
we	O
confirmed	O
the	O
importance	O
of	O
clathrin	O
-	O
mediated	O
endocytosis	B-PATH
and	O
demonstrated	O
that	O
trafficking	O
of	O
MHV	O
to	O
lysosomes	O
is	O
required	O
for	O
fusion	O
and	O
productive	O
entry	O
to	O
occur	O
.	O

ABSTRACT	O
:	O
We	O
present	O
the	O
results	O
of	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
performed	O
in	O
three	O
patients	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pneumonia	O
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

In	O
both	O
studies	O
,	O
virus	O
-	O
confirmed	O
common	O
cold	O
was	O
caused	O
by	O
three	O
main	O
virus	O
subtypes	O
:	O
human	O
rhinovirus	O
(	O
46	O
%),	O
human	O
coronavirus	O
(	O
25	O
%)	O
and	O
influenza	B-PATH
A	I-PATH
(	O
14	O
%)	O
virus	O
.	O

The	O
aim	O
of	O
this	O
article	O
was	O
to	O
review	O
the	O
role	O
of	O
noninvasive	O
ventilation	O
(	O
NIV	O
)	O
in	O
acute	O
pulmonary	O
infectious	O
diseases	O
,	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
H1N1	O
and	O
tuberculosis	B-PATH
,	O
and	O
to	O
assess	O
the	O
risk	O
of	O
disease	O
transmission	O
with	O
the	O
use	O
of	O
NIV	O
from	O
patients	O
to	O
healthcare	O
workers	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
our	O
current	O
understanding	O
of	O
SARS	O
-	O
CoV	O
enzymes	O
involved	O
in	O
RNA	O
biochemistry	O
,	O
such	O
as	O
the	O
in	O
vitro	O
characterization	O
of	O
a	O
highly	O
active	O
and	O
processive	O
RNA	B-PATH
polymerase	I-PATH
complex	O
which	O
can	O
associate	O
with	O
methyltransferase	O
and	O
3	O
'-	O
5	O
'	O
exoribonuclease	O
activities	O
involved	O
in	O
RNA	O
capping	O
,	O
and	O
RNA	O
proofreading	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
viruses	O
,	O
human	O
coronaviruses	O
(	O
hCoV	O
)	O
and	O
human	O
bocavirus	O
(	O
hBoV	O
)	O
are	O
emerging	O
respiratory	O
viruses	O
.	O

RESULTS	O
:	O
Out	O
of	O
the	O
1203	O
examinees	O
,	O
284	O
(	O
23	O
.	O
6	O
%)	O
were	O
influenza	O
-	O
positive	O
:	O
221	O
(	O
77	O
.	O
8	O
%),	O
24	O
(	O
8	O
.	O
5	O
%),	O
and	O
39	O
(	O
13	O
.	O
7	O
%)	O
patients	O
had	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
),	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
,	O
and	O
influenza	O
B	O
,	O
respectively	O
.	O

In	O
addition	O
to	O
its	O
function	O
as	O
a	O
structural	O
protein	O
,	O
N	O
protein	O
is	O
involved	O
in	O
cell	O
apoptosis	B-PATH
or	O
cell	O
-	O
cycle	O
regulation	O
.	O

Recent	O
investigations	O
suggest	O
the	O
possible	O
role	O
of	O
NLRP3	O
inflammasomes	B-PATH
,	O
which	O
regulate	O
IL	O
-	O
1Î²	O
production	O
and	O
lead	O
to	O
inflammatory	O
responses	O
,	O
in	O
the	O
pathophysiology	O
of	O
HALI	O
;	O
however	O
,	O
their	O
role	O
is	O
not	O
fully	O
understood	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
epidemiologic	O
and	O
clinical	O
characteristics	O
of	O
critically	O
ill	O
pregnant	O
and	O
postpartum	O
women	O
with	O
influenza	B-PATH
infection	I-PATH
reported	O
in	O
the	O
2013	O
-	O
2014	O
season	O
.	O

A	O
cross	O
sectional	O
study	O
of	O
839	O
adult	O
African	O
Hajj	O
pilgrims	O
returning	O
to	O
Accra	O
in	O
Ghana	O
,	O
West	O
Africa	O
,	O
was	O
conducted	O
in	O
2013	O
to	O
assess	O
the	O
prevalence	O
of	O
respiratory	O
symptoms	O
as	O
well	O
as	O
of	O
MERS	O
-	O
CoV	O
,	O
human	O
rhinovirus	O
(	O
HRV	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
FLU	O
A	O
)	O
infection	O
.	O

Many	O
current	O
studies	O
have	O
reported	O
possible	O
application	O
of	O
aptamers	O
as	O
a	O
treatment	O
or	O
diagnostic	O
tool	O
in	O
viral	O
infections	O
,	O
e	O
.	O
g	O
.,	O
HIV	O
(	O
Human	O
Immunodeficiency	O
Virus	O
),	O
HBV	O
(	O
Hepatitis	O
B	O
Virus	O
),	O
HCV	O
(	O
Hepatitis	B-PATH
C	I-PATH
Virus	O
),	O
SARS	O
(	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
),	O
H5N1	O
avian	O
influenza	O
and	O
recently	O
spread	O
Ebola	O
.	O

Diagnosis	O
of	O
pulmonary	O
tuberculosis	B-PATH
was	O
made	O
10days	O
after	O
admission	O
on	O
examination	O
of	O
cavitary	O
and	O
diffuse	O
infiltrates	O
on	O
a	O
second	O
CT	O
scan	O
,	O
in	O
addition	O
to	O
presence	O
of	O
acid	O
-	O
fast	O
bacilli	O
on	O
smear	O
examination	O
of	O
bronchial	O
aspirates	O
.	O

On	O
the	O
basis	O
of	O
clinical	O
and	O
epidemiological	O
information	O
,	O
specimens	O
were	O
tested	O
using	O
conventional	O
RT	O
-	O
PCR	O
for	O
the	O
M	O
gene	O
of	O
the	O
influenza	O
viruses	O
and	O
hemagglutinin	O
H5	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
),	O
virus	O
;	O
negative	O
samples	O
were	O
tested	O
for	O
other	O
respiratory	O
viruses	O
.	O

We	O
retrospectively	O
analyzed	O
data	O
from	O
patients	O
reported	O
to	O
the	O
US	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
with	O
a	O
diagnosis	O
of	O
malaria	B-PATH
parasite	O
single	O
-	O
species	O
infection	O
between	O
1985	O
and	O
2011	O
.	O

The	O
primary	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
suggested	O
that	O
the	O
conjugated	O
derivatives	O
of	O
p	O
-	O
HAP	O
glycoside	O
and	O
substituted	O
cinnamic	O
acids	O
(	O
2a	O
-	O
2i	O
)	O
obviously	O
enhanced	O
the	O
activity	O
against	O
HBV	O
DNA	B-PATH
replication	I-PATH
with	O
IC50	O
values	O
ranged	O
from	O
5	O
.	O
8	O
to	O
74	O
.	O
4	O
Î¼M	O
.	O

CONCLUSIONS	O
:	O
Airway	O
pressure	O
release	B-PATH
ventilation	O
may	O
be	O
an	O
important	O
option	O
as	O
a	O
ventilatory	O
mode	O
for	O
management	O
of	O
maternal	O
respiratory	O
failure	O
during	O
pregnancy	O
.	O

Experimental	O
studies	O
on	O
ARDS	O
have	O
shown	O
that	O
inhibition	O
of	O
apoptosis	B-PATH
in	O
the	O
lungs	O
reduces	O
lung	O
epithelial	O
injury	O
.	O

Eight	O
-	O
to	O
11	O
-	O
week	O
-	O
old	O
female	O
C57BL	O
/	O
6OlaHsd	O
mice	O
were	O
inoculated	O
with	O
the	O
rodent	O
-	O
specific	O
pneumovirus	O
pneumonia	O
virus	O
of	O
mice	O
(	O
PVM	O
)	O
strain	O
J3666	O
and	O
received	O
multiple	O
injections	O
of	O
zVAD	O
or	O
vehicle	O
(	O
control	O
)	O
during	O
the	O
course	O
of	O
disease	O
,	O
after	O
which	O
they	O
were	O
studied	O
for	O
markers	O
of	O
apoptosis	B-PATH
,	O
inflammation	O
,	O
and	O
lung	O
injury	O
on	O
day	O
7	O
after	O
infection	O
.	O

TITLE	O
:	O
Severity	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
illness	O
and	O
emergence	O
of	O
D225G	O
variant	O
,	O
2013	O
-	O
14	O
influenza	O
season	O
,	O
Florida	O
,	O
USA	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
and	O
low	O
-	O
pathogenicity	O
influenza	B-PATH
A	I-PATH
viruses	O
(	O
LP	O
IAVs	O
)	O
depend	O
on	O
target	O
cell	O
proteases	O
to	O
cleave	O
their	O
viral	O
glycoproteins	O
and	O
prime	O
them	O
for	O
virus	O
-	O
cell	O
membrane	O
fusion	O
.	O

We	O
conducted	O
a	O
retrospective	O
analysis	O
of	O
a	O
cluster	O
of	O
patients	O
diagnosed	O
with	O
or	O
suspected	O
of	O
influenza	B-PATH
A	I-PATH
H1N1	O
infection	O
in	O
the	O
period	O
from	O
December	O
2010	O
to	O
March	O
2011	O
.	O

Finding	O
timely	O
evidence	O
of	O
the	O
presence	O
the	O
clinical	O
signs	O
of	O
threatening	O
ARDS	O
and	O
underlying	O
diseases	O
like	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
during	O
prehospital	O
period	O
in	O
early	O
stage	O
of	O
disease	O
it	O
is	O
possible	O
introduce	O
early	O
adequate	O
treatment	O
:	O
high	O
flow	O
oxygen	O
,	O
fluid	O
replacement	O
and	O
pharmacological	O
and	O
antiviral	O
therapy	O
.	O

A	O
higher	O
risk	O
of	O
death	O
and	O
poor	O
prognosis	O
were	O
found	O
in	O
children	O
with	O
measles	B-PATH
who	O
needed	O
to	O
be	O
treated	O
in	O
PICU	O
,	O
especially	O
for	O
ARDS	O
with	O
pneumothorax	O
.	O

METHODS	O
:	O
Seventeen	O
cases	O
with	O
measles	B-PATH
with	O
serious	O
complications	O
in	O
ICU	O
in	O
Anhui	O
Provincial	O
Children	O
'	O
s	O
Hospital	O
were	O
recruited	O
from	O
May	O
2012	O
to	O
May	O
2013	O
.	O

The	O
risk	O
of	O
influenza	B-PATH
infection	I-PATH
and	O
mortality	O
was	O
significantly	O
increased	O
in	O
unvaccinated	O
patients	O
(	O
odds	O
ratio	O
37	O
.	O
5	O
[	O
95	O
%	O
CI	O
2	O
.	O
7	O
-	O
507	O
.	O
5	O
,	O
p	O
=	O
0	O
.	O
01	O
]	O
and	O
6	O
.	O
7	O
[	O
95	O
%	O
CI	O
2	O
.	O
3	O
-	O
18	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
003	O
],	O
respectively	O
).	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
serological	O
evidence	O
of	O
influenza	B-PATH
A	I-PATH
viruses	O
other	O
than	O
H17	O
and	O
H18	O
in	O
bats	O
.	O

Our	O
findings	O
support	O
the	O
involvement	O
of	O
NFE2L2	O
gene	O
variants	O
in	O
ARDS	O
susceptibility	O
and	O
reinforce	O
further	O
exploration	O
of	O
the	O
role	O
of	O
oxidant	O
stress	B-PATH
response	I-PATH
as	O
a	O
risk	O
factor	O
for	O
ARDS	O
in	O
critically	O
ill	O
patients	O
.	O

The	O
affected	O
cellular	O
proteins	O
that	O
we	O
identified	O
in	O
this	O
study	O
were	O
classified	O
into	O
the	O
functional	O
groups	O
involved	O
in	O
various	O
cellular	O
processes	O
such	O
as	O
cell	O
division	O
,	O
metabolism	O
,	O
the	O
stress	B-PATH
response	I-PATH
,	O
protein	O
biosynthesis	O
and	O
transport	O
,	O
cytoskeleton	O
networks	O
and	O
cell	O
communication	O
.	O

Within	O
the	O
endocytic	O
compartment	O
,	O
reovirus	O
undergoes	O
stepwise	O
disassembly	O
,	O
which	O
is	O
followed	O
by	O
release	B-PATH
of	O
the	O
transcriptionally	O
active	O
viral	O
core	O
into	O
the	O
cytoplasm	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
assemble	O
by	O
budding	B-PATH
into	O
the	O
lumen	O
of	O
the	O
early	O
Golgi	O
complex	O
prior	O
to	O
exocytosis	O
.	O

Polymorphisms	O
at	O
OAS1	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
differential	O
susceptibility	O
to	O
several	O
infections	O
of	O
great	O
public	O
health	O
significance	O
,	O
including	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
SARS	O
coronavirus	O
,	O
and	O
West	O
Nile	O
virus	O
.	O

All	O
FDA	O
-	O
approved	O
immunoadhesins	O
are	O
designed	O
to	O
modulate	O
the	O
interaction	O
of	O
a	O
human	O
receptor	O
with	O
its	O
normal	O
ligand	O
,	O
such	O
as	O
Etanercept	O
(	O
Enbrel	O
(Â®)	O
),	O
which	O
interferes	O
with	O
the	O
binding	O
of	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
to	O
the	O
TNF	O
-	O
alpha	O
receptor	O
and	O
is	O
used	O
to	O
treat	O
inflammatory	O
diseases	O
such	O
as	O
rheumatoid	B-PATH
arthritis	I-PATH
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
the	O
most	O
important	O
parasitic	O
diseases	O
of	O
humans	O
and	O
one	O
of	O
the	O
leading	O
causes	O
of	O
morbidity	O
and	O
mortality	O
in	O
tropical	O
countries	O
.	O

We	O
also	O
observed	O
similar	O
effects	O
in	O
influenza	B-PATH
A	I-PATH
virus	O
-	O
infected	O
middle	O
-	O
aged	O
Pla2g2d	O
(-/-)	O
mice	O
.	O

Airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
and	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
are	O
2	O
different	O
open	O
-	O
lung	O
strategies	O
that	O
have	O
been	O
proposed	O
to	O
treat	O
refractory	O
hypoxemic	O
respiratory	O
failure	O
while	O
preventing	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
A	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)-	O
based	O
biosensor	O
was	O
developed	O
for	O
specific	O
detection	O
of	O
nine	O
common	O
respiratory	O
virus	O
,	O
including	O
influenza	B-PATH
A	I-PATH
and	O
influenza	O
B	O
,	O
H1N1	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenza	O
virus	O
1	O
-	O
3	O
(	O
PIV1	O
,	O
2	O
,	O
3	O
),	O
adenovirus	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
).	O

TITLE	O
:	O
Arterivirus	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
:	O
Vital	O
enzymatic	O
activity	O
remains	O
elusive	O
.	O

TITLE	O
:	O
Clinical	O
report	O
of	O
serious	O
complications	O
associated	O
with	O
measles	B-PATH
pneumonia	O
in	O
children	O
hospitalized	O
at	O
Shengjing	O
hospital	O
,	O
China	O
.	O

We	O
also	O
detected	O
an	O
association	O
of	O
TLR2	O
gene	O
with	O
tuberculosis	B-PATH
(	O
rs5743708	O
;	O
3	O
.	O
19	O
[	O
2	O
.	O
03	O
-	O
5	O
.	O
02	O
]).	O

TITLE	O
:	O
Rapid	O
genome	O
sequencing	O
and	O
characterization	O
of	O
novel	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
H7N9	O
virus	O
directly	O
from	O
clinical	O
sample	O
by	O
semiconductor	O
sequencing	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
novel	O
respiratory	O
viruses	O
such	O
as	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
and	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
highlights	O
the	O
importance	O
of	O
understanding	O
determinants	O
of	O
transmission	O
to	O
healthcare	O
workers	O
(	O
HCWs	O
)	O
and	O
the	O
public	O
.	O

Among	O
174	O
nasopharyngeal	O
aspirates	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
was	O
detected	O
in	O
39	O
samples	O
(	O
22	O
.	O
41	O
%),	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
34	O
(	O
19	O
.	O
54	O
%),	O
metapneumovirus	O
(	O
MPV	O
)	O
in	O
19	O
(	O
10	O
.	O
92	O
%),	O
coronaviruses	O
in	O
14	O
(	O
8	O
.	O
05	O
%),	O
and	O
parainfluenza	O
viruses	O
(	O
PIVs	O
)	O
in	O
11	O
(	O
6	O
.	O
32	O
%).	O

Compared	O
to	O
M41	O
,	O
885	O
and	O
QX	O
caused	O
greater	O
induction	O
of	O
toll	O
like	O
receptor	O
3	O
(	O
TLR3	O
),	O
melanoma	B-PATH
differentiation	O
associated	O
protein	O
5	O
(	O
MDA5	O
)	O
and	O
interferon	O
beta	O
(	O
IFN	O
-	O
Î²	O
)	O
in	O
CEKC	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
improve	O
the	O
selection	O
and	O
treatment	O
of	O
individual	O
release	B-PATH
candidates	O
by	O
detecting	O
possible	O
pathogen	O
carriers	O
using	O
samples	O
taken	O
before	O
and	O
during	O
release	B-PATH
.	O

More	O
specifically	O
,	O
lung	O
histology	O
,	O
mRNA	O
levels	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
,	O
and	O
protein	O
expression	O
levels	O
of	O
tight	B-PATH
junction	I-PATH
proteins	O
were	O
determined	O
.	O

Mutations	O
of	O
gap	B-PATH
junction	I-PATH
proteins	O
,	O
connexins	O
(	O
Cxs	O
),	O
cause	O
dysmyelination	O
and	O
leukoencephalopathy	O
.	O

After	O
infection	O
,	O
Cx43	O
did	O
not	O
traffic	O
normally	O
to	O
the	O
membrane	O
to	O
form	O
gap	B-PATH
junction	I-PATH
plaques	O
,	O
and	O
that	O
could	O
be	O
the	O
basis	O
of	O
reduced	O
functional	O
gap	B-PATH
junction	I-PATH
coupling	O
between	O
astrocytes	O
.	O

Thus	O
,	O
PDCoV	O
does	O
not	O
induce	O
apoptosis	B-PATH
in	O
the	O
infected	O
intestinal	O
enterocytes	O
in	O
vivo	O
,	O
but	O
in	O
two	O
infected	O
cell	O
lines	O
of	O
swine	O
origin	O
,	O
LLC	O
-	O
PK	O
and	O
ST	O
cells	O
.	O

In	O
children	O
with	O
SCD	O
,	O
there	O
is	O
a	O
high	O
prevalence	O
of	O
AHR	O
that	O
is	O
not	O
associated	O
with	O
asthma	B-PATH
-	O
like	O
symptoms	O
.	O

AHR	O
may	O
be	O
a	O
distinct	O
entity	O
in	O
children	O
with	O
SCD	O
,	O
existing	O
in	O
the	O
absence	O
of	O
concomitant	O
asthma	B-PATH
.	O

The	O
top	O
three	O
underlying	O
medical	O
conditions	O
were	O
bronchial	O
asthma	B-PATH
(	O
14	O
.	O
3	O
%),	O
cardiac	O
disease	O
(	O
10	O
.	O
4	O
%)	O
and	O
neurological	O
disorder	O
(	O
11	O
.	O
7	O
%).	O

Many	O
studies	O
have	O
focused	O
on	O
hypercytokinemia	O
during	O
avian	O
influenza	B-PATH
infection	I-PATH
.	O

In	O
the	O
ICU	O
,	O
patients	O
with	O
sepsis	O
,	O
ARDS	O
,	O
community	O
-	O
acquired	O
pneumonia	O
,	O
exacerbation	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
severe	O
asthma	B-PATH
,	O
or	O
trauma	O
may	O
receive	O
corticosteroids	O
.	O

These	O
molecules	O
are	O
able	O
to	O
directly	O
inhibit	O
many	O
viruses	O
such	O
as	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	O
),	O
Hepatitis	B-PATH
C	I-PATH
Virus	O
(	O
HCV	O
),	O
Dengue	O
Virus	O
,	O
Ebola	O
Virus	O
or	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
through	O
binding	O
to	O
envelope	O
protein	O
N	O
-	O
glycans	O
.	O

Approximately	O
three	O
quarters	O
of	O
reported	O
malaria	B-PATH
cases	O
in	O
the	O
UK	O
are	O
caused	O
by	O
Plasmodium	O
falciparum	O
,	O
which	O
is	O
capable	O
of	O
invading	O
a	O
high	O
proportion	O
of	O
red	O
blood	O
cells	O
and	O
rapidly	O
leading	O
to	O
severe	O
or	O
life	O
-	O
threatening	O
multi	O
-	O
organ	O
disease	O
.	O

There	O
are	O
no	O
typical	O
clinical	O
features	O
of	O
malaria	B-PATH
;	O
even	O
fever	O
is	O
not	O
invariably	O
present	O
.	O

Management	O
of	O
malaria	B-PATH
depends	O
on	O
awareness	O
of	O
the	O
diagnosis	O
and	O
on	O
performing	O
the	O
correct	O
diagnostic	O
tests	O
:	O
the	O
diagnosis	O
cannot	O
be	O
excluded	O
until	O
more	O
than	O
one	O
blood	O
specimen	O
has	O
been	O
examined	O
.	O

Falciparum	O
malaria	B-PATH
in	O
pregnancy	O
is	O
more	O
likely	O
to	O
be	O
complicated	O
:	O
the	O
placenta	O
contains	O
high	O
levels	O
of	O
parasites	O
,	O
stillbirth	O
or	O
early	O
delivery	O
may	O
occur	O
and	O
diagnosis	O
can	O
be	O
difficult	O
if	O
parasites	O
are	O
concentrated	O
in	O
the	O
placenta	O
and	O
scanty	O
in	O
the	O
blood	O
.	O

Melatonin	O
inhibits	O
the	O
activation	O
of	O
the	O
NLRP3	O
inflammasome	O
by	O
both	O
suppressing	O
the	O
release	B-PATH
of	O
extracellular	O
histones	O
and	O
directly	O
blocking	O
histone	O
-	O
induced	O
NLRP3	O
inflammasome	O
activation	O
.	O

TITLE	O
:	O
The	O
C	O
-	O
Terminal	O
Tail	O
of	O
TRIM56	O
Dictates	O
Antiviral	O
Restriction	O
of	O
Influenza	B-PATH
A	I-PATH
and	O
B	O
Viruses	O
by	O
Impeding	O
Viral	O
RNA	O
Synthesis	O
.	O

Therefore	O
,	O
dyspnoea	O
in	O
patients	O
with	O
malaria	B-PATH
should	O
alert	O
clinicians	O
,	O
as	O
the	O
development	O
of	O
respiratory	O
distress	O
is	O
a	O
poor	O
prognostic	O
factor	O
.	O

Most	O
people	O
who	O
arrive	O
in	O
Sweden	O
with	O
suspicious	O
symptoms	O
will	O
likely	O
have	O
other	O
diseases	O
than	O
Ebola	O
/	O
MERS	O
,	O
for	O
example	O
malaria	B-PATH
or	O
pneumococci	O
,	O
but	O
we	O
still	O
need	O
to	O
take	O
care	O
of	O
these	O
patients	O
and	O
be	O
able	O
to	O
provide	O
optimal	O
treatment	O
of	O
electrolyte	O
disturbances	O
,	O
kidney	O
failure	O
,	O
bleedings	O
etc	O
.	O

Data	O
from	O
the	O
GO	O
analysis	O
indicated	O
that	O
the	O
target	O
genes	O
of	O
ribavirin	O
and	O
interferon	O
-	O
Î±	O
as	O
well	O
as	O
the	O
genes	O
from	O
the	O
microarray	O
were	O
mainly	O
enriched	O
in	O
10	O
biological	O
processes	O
,	O
including	O
cellular	O
process	O
,	O
metabolic	O
process	O
,	O
immune	O
system	O
process	O
and	O
biological	O
regulation	O
,	O
et	O
al	O
.	O
Data	O
on	O
drug	O
target	O
genes	O
,	O
first	O
and	O
second	O
cluster	O
of	O
microarray	O
would	O
involve	O
9	O
,	O
3	O
and	O
23	O
signaling	O
pathways	O
respectively	O
,	O
and	O
only	O
the	O
former	O
two	O
showed	O
7	O
common	O
pathways	O
,	O
which	O
were	O
related	O
to	O
pathogen	O
recognition	O
,	O
cytokine	O
release	B-PATH
and	O
autoimmune	O
response	O
.	O

TITLE	O
:	O
Responses	O
of	O
the	O
Toll	O
-	O
like	O
receptor	O
and	O
melanoma	B-PATH
differentiation	O
-	O
associated	O
protein	O
5	O
signaling	O
pathways	O
to	O
avian	O
infectious	O
bronchitis	O
virus	O
infection	O
in	O
chicks	O
.	O

ABSTRACT	O
:	O
Plasmodium	O
Vivax	O
malaria	B-PATH
is	O
generally	O
considered	O
as	O
a	O
benign	O
self	O
-	O
limiting	O
illness	O
and	O
is	O
less	O
often	O
associated	O
with	O
more	O
severe	O
disease	O
and	O
complications	O
.	O

Antituberculous	O
drugs	O
were	O
administered	O
because	O
a	O
previous	O
blood	O
interferon	O
-	O
gamma	O
release	B-PATH
assay	O
was	O
positive	O
,	O
however	O
,	O
the	O
patient	O
died	O
of	O
severe	O
respiratory	O
failure	O
within	O
several	O
days	O
,	O
and	O
cultures	O
of	O
her	O
blood	O
,	O
urine	O
and	O
bone	O
marrow	O
posthumously	O
revealed	O
Mycobacterium	O
tuberculosis	B-PATH
.	O

TITLE	O
:	O
Characteristics	O
and	O
outcomes	O
of	O
patients	O
treated	O
with	O
airway	O
pressure	O
release	B-PATH
ventilation	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O

N475	O
forms	O
the	O
base	O
of	O
the	O
P1	O
binding	O
site	O
and	O
likely	O
orients	O
the	O
substrate	O
for	O
nucleophilic	O
attack	O
or	O
plays	O
a	O
role	O
in	O
product	O
release	B-PATH
.	O

ABSTRACT	O
:	O
Highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
H5N6	O
virus	O
has	O
caused	O
four	O
human	O
infections	O
in	O
China	O
.	O

TITLE	O
:	O
[	O
Successful	O
Treatment	O
of	O
Seasonal	O
Influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
infection	O
-	O
related	O
Hemophagocytic	O
Lymphocytosis	O
in	O
an	O
Elderly	O
Man	O
].	O

Under	O
LPS	O
-	O
induced	O
injured	O
lung	O
,	O
the	O
release	B-PATH
of	O
sRAGE	O
into	O
the	O
alveolar	O
space	O
was	O
increased	O
,	O
whereas	O
the	O
expression	O
of	O
RAGE	O
was	O
decreased	O
with	O
alveolar	O
disruption	O
.	O

In	O
this	O
study	O
,	O
coronavirus	O
sequences	O
were	O
detected	O
using	O
a	O
nested	O
RT	O
-	O
PCR	O
targeting	O
440	O
bp	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
in	O
six	O
of	O
79	O
fecal	O
samples	O
collected	O
from	O
an	O
urban	O
colony	O
of	O
E	O
.	O
helvum	O
in	O
Ibadan	O
,	O
Nigeria	O
.	O

The	O
H7N9	O
virus	O
was	O
detected	O
by	O
the	O
influenza	B-PATH
A	I-PATH
virus	O
matrix	O
gene	O
target	O
,	O
while	O
other	O
influenza	B-PATH
A	I-PATH
virus	O
subtyping	O
gene	O
targets	O
in	O
the	O
panel	O
remained	O
negative	O
.	O

There	O
is	O
recently	O
,	O
a	O
considerable	O
increase	O
in	O
malaria	B-PATH
infections	O
especially	O
in	O
tropical	O
areas	O
.	O

Results	O
showed	O
that	O
in	O
high	O
dose	O
LPS	O
(	O
30mg	O
/	O
kg	O
and	O
40mg	O
/	O
kg	O
)	O
-	O
induced	O
severe	O
ARDS	O
,	O
RIP3	O
protein	O
was	O
increased	O
significantly	O
,	O
accompanied	O
by	O
increases	O
of	O
p	O
-	O
RIP3	O
and	O
MLKL	O
,	O
while	O
in	O
low	O
dose	O
LPS	O
(	O
10mg	O
/	O
kg	O
and	O
20mg	O
/	O
kg	O
)	O
-	O
induced	O
mild	O
ARDS	O
,	O
apoptosis	B-PATH
was	O
remarkably	O
increased	O
.	O

Insight	O
from	O
successful	O
approaches	O
of	O
targeting	O
viral	O
ncRNA	O
in	O
HIV	O
,	O
HCV	O
,	O
SARS	O
CoV	O
,	O
and	O
influenza	B-PATH
A	I-PATH
will	O
provide	O
a	O
basis	O
for	O
the	O
future	O
exploration	O
of	O
RNA	O
targets	O
for	O
therapeutic	O
intervention	O
in	O
other	O
viral	O
pathogens	O
which	O
create	O
urgent	O
,	O
unmet	O
medical	O
needs	O
.	O

ABSTRACT	O
:	O
In	O
an	O
epidemiological	O
study	O
of	O
ferret	O
coronaviruses	O
(	O
FRCoVs	O
),	O
novel	O
FRCoV	O
strains	O
(	O
Saitama	O
-	O
1	O
and	O
Aichi	O
-	O
1	O
)	O
were	O
detected	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
nucleotide	O
sequence	O
analysis	O
of	O
partial	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
genes	O
.	O

TITLE	O
:	O
Clinical	O
research	O
about	O
airway	O
pressure	O
release	B-PATH
ventilation	O
for	O
moderate	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

He	O
was	O
also	O
administered	O
anti	O
-	O
tuberculosis	B-PATH
drugs	O
and	O
received	O
systemic	O
corticosteroid	O
therapy	O
.	O

ECMO	O
should	O
be	O
considered	O
one	O
of	O
the	O
treatment	O
options	O
for	O
the	O
management	O
of	O
ARDS	O
due	O
to	O
severe	O
pulmonary	O
tuberculosis	B-PATH
.	O

Patient	O
cells	O
showed	O
chromosome	O
rearrangements	O
,	O
micronuclei	O
,	O
sensitivity	O
to	O
replication	O
stress	O
and	O
DNA	O
damage	O
,	O
and	O
defective	O
homologous	B-PATH
recombination	I-PATH
.	O

ABSTRACT	O
:	O
Asthma	B-PATH
is	O
a	O
prevalent	O
and	O
serious	O
health	O
problem	O
in	O
Korea	O
.	O

Recently	O
,	O
the	O
Korean	O
Asthma	B-PATH
Guideline	O
has	O
been	O
updated	O
by	O
The	O
Korean	O
Academy	O
of	O
Tuberculosis	B-PATH
and	O
Respiratory	O
Diseases	O
(	O
KATRD	O
)	O
in	O
an	O
effort	O
to	O
improve	O
the	O
clinical	O
management	O
of	O
asthma	B-PATH
.	O

For	O
this	O
purpose	O
,	O
this	O
guideline	O
was	O
updated	O
following	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
recent	O
studies	O
and	O
adapting	O
some	O
points	O
of	O
international	O
guidelines	O
(	O
Global	O
Initiative	O
for	O
Asthma	B-PATH
[	O
GINA	O
]	O
report	O
2014	O
,	O
National	O
Asthma	B-PATH
Education	O
and	O
Prevention	O
Program	O
[	O
NAEPP	O
]	O
2007	O
,	O
British	O
Thoracic	O
Society	O
[	O
BTS	O
/	O
SIGN	O
]	O
asthma	B-PATH
guideline	O
2012	O
,	O
and	O
Canadian	O
asthma	B-PATH
guideline	O
2012	O
).	O

RESULTS	O
:	O
This	O
work	O
examines	O
the	O
available	O
strategies	O
for	O
overcoming	O
the	O
obstacles	O
of	O
assembling	O
the	O
long	O
and	O
complex	O
RNA	O
genomes	O
of	O
coronaviruses	O
and	O
reports	O
one	O
-	O
step	O
construction	O
of	O
an	O
infectious	O
clone	O
system	O
for	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
by	O
homologous	B-PATH
recombination	I-PATH
in	O
S	O
.	O
cerevisiae	O
.	O

Virus	O
replication	O
takes	O
place	O
within	O
the	O
host	O
cell	O
cytosol	O
,	O
whereas	O
assembly	O
and	O
budding	B-PATH
occur	O
at	O
the	O
endoplasmic	O
reticulum	O
-	O
Golgi	O
intermediate	O
compartment	O
.	O

Current	O
antiviral	O
developments	O
have	O
focused	O
targets	O
on	O
viral	O
entry	O
,	O
replication	O
,	O
release	B-PATH
,	O
and	O
intercellular	O
pathways	O
essential	O
for	O
viral	O
life	O
cycle	O
.	O

Children	O
with	O
enterovirus	O
D68	O
were	O
more	O
likely	O
to	O
have	O
asthma	B-PATH
(	O
62	O
%	O
vs	O
23	O
%;	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
present	O
with	O
reactive	O
airway	O
disease	O
exacerbations	O
,	O
with	O
greater	O
receipt	O
of	O
albuterol	O
(	O
94	O
%	O
vs	O
49	O
%)	O
and	O
steroids	O
(	O
89	O
%	O
vs	O
40	O
%;	O
p	O
<	O
0	O
.	O
0001	O
for	O
both	O
).	O

ABSTRACT	O
:	O
In	O
cells	O
,	O
positive	O
strand	O
RNA	O
viruses	O
,	O
such	O
as	O
Retroviridae	O
,	O
must	O
selectively	O
recognize	O
their	O
full	O
-	O
length	O
RNA	O
genome	O
among	O
abundant	O
cellular	O
RNAs	O
to	O
assemble	O
and	O
release	B-PATH
particles	O
.	O

Two	O
influenza	O
outbreaks	O
were	O
reported	O
in	O
two	O
NHs	O
,	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
strains	O
belonging	O
to	O
cluster	O
3C	O
.	O
3	O
and	O
3C	O
.	O
2a	O
.	O

ABSTRACT	O
:	O
The	O
discovery	O
of	O
a	O
back	O
-	O
up	O
to	O
the	O
hepatitis	B-PATH
C	I-PATH
virus	O
NS3	O
protease	O
inhibitor	O
asunaprevir	O
(	O
2	O
)	O
is	O
described	O
.	O

ABSTRACT	O
:	O
In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
setting	O
high	O
airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
pressure	O
guided	O
by	O
an	O
expiratory	O
inflection	O
point	O
of	O
pressure	O
-	O
volume	O
(	O
PV	O
)	O
curve	O
following	O
lung	O
recruitment	O
maneuver	O
(	O
RM	O
)	O
on	O
oxygen	O
delivery	O
(	O
DO	O

Many	O
studies	O
have	O
reported	O
on	O
the	O
release	B-PATH
,	O
transport	O
,	O
and	O
exposure	O
of	O
expiratory	O
droplets	O
because	O
of	O
respiratory	O
activities	O
.	O

Grade	O
3	O
-	O
4	O
cytokine	O
release	B-PATH
syndrome	O
occurred	O
in	O
46	O
%	O
of	O
patients	O
following	O
T	O
cell	O
therapy	O
for	O
relapsed	O
/	O
refractory	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
an	O
important	O
cause	O
of	O
morbidity	O
during	O
the	O
2009	O
pandemic	O
.	O

Ctsl	O
-/-	O
mice	O
infected	O
with	O
influenza	B-PATH
A	I-PATH
/	O
Puerto	O
Rico	O
/	O
8	O
/	O
34	O
(	O
H1N1	O
)	O
had	O
larger	O
lung	O
viral	O
loads	O
and	O
higher	O
mortality	O
than	O
infected	O
Ctsl	O
+/+	O
mice	O
.	O

Furthermore	O
,	O
Ctsl	O
-/-	O
mice	O
had	O
profound	O
deficits	O
in	O
CD4	O
+	O
lymphocytes	O
before	O
and	O
after	O
infection	O
and	O
weaker	O
production	O
of	O
pathogen	O
-	O
specific	O
IgG	O
.	O
Thus	O
,	O
CTSL	O
appears	O
to	O
support	O
innate	O
as	O
well	O
as	O
adaptive	O
responses	O
,	O
which	O
confer	O
a	O
survival	O
advantage	O
on	O
mice	O
infected	O
with	O
the	O
orthomyxovirus	O
influenza	B-PATH
A	I-PATH
.	O

Many	O
enveloped	O
viruses	O
enter	O
cells	O
through	O
endocytosis	B-PATH
.	O

Children	O
with	O
symptoms	O
suggestive	O
of	O
pulmonary	O
tuberculosis	B-PATH
(	O
PTB	O
)	O
may	O
have	O
tuberculosis	B-PATH
,	O
other	O
respiratory	O
tract	O
infections	O
or	O
co	O
-	O
infection	O
with	O
Mycobacterium	O
tuberculosis	B-PATH
and	O
other	O
pathogens	O
.	O

Other	O
bacteria	O
detected	O
included	O
Mycoplasma	O
pneumoniae	O
(	O
9	O
%),	O
Bordetella	O
pertussis	B-PATH
(	O
7	O
%)	O
and	O
Chlamydophila	O
pneumoniae	O
(	O
4	O
%).	O

By	O
transiently	O
expressing	O
the	O
MERS	O
-	O
CoV	O
accessory	O
proteins	O
individually	O
,	O
we	O
identified	O
a	O
role	O
of	O
protein	O
4a	O
(	O
p4a	O
)	O
in	O
preventing	O
activation	O
of	O
the	O
stress	B-PATH
response	I-PATH
pathway	O
.	O

However	O
,	O
a	O
recombinant	O
MERS	O
-	O
CoV	O
deficient	O
in	O
p4a	O
expression	O
still	O
suppressed	O
SG	O
formation	O
,	O
indicating	O
the	O
expression	O
of	O
at	O
least	O
one	O
other	O
stress	B-PATH
response	I-PATH
antagonist	O
.	O

ABSTRACT	O
:	O
Glucocorticoid	O
-	O
induced	O
leucine	O
zipper	O
(	O
GILZ	O
)	O
is	O
a	O
potent	O
anti	O
-	O
inflammatory	O
protein	O
involved	O
in	O
neutrophil	O
apoptosis	B-PATH
and	O
the	O
resolution	O
of	O
inflammation	O
.	O

In	O
addition	O
,	O
common	O
directional	O
changes	O
in	O
human	O
influenza	B-PATH
A	I-PATH
viruses	O
were	O
observed	O
for	O
three	O
subtypes	O
,	O
whose	O
epidemics	O
started	O
independently	O
.	O

Very	O
few	O
studies	O
on	O
influenza	B-PATH
A	I-PATH
H1N1pdm09	O
in	O
post	O
-	O
pandemic	O
periods	O
exist	O
,	O
and	O
there	O
is	O
no	O
information	O
on	O
the	O
severity	O
of	O
both	O
seasonal	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
A	O
(	O
H3N2	O
)	O
from	O
the	O
same	O
season	O
,	O
adjusting	O
for	O
potential	O
confounders	O
,	O
including	O
vaccine	O
.	O

Our	O
findings	O
suggest	O
that	O
seasonal	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
maintains	O
some	O
features	O
of	O
pandemic	O
viruses	O
,	O
and	O
recommend	O
wider	O
use	O
of	O
vaccination	O
in	O
younger	O
adult	O
high	O
-	O
risk	O
patients	O
.	O

Because	O
no	O
cases	O
were	O
reported	O
in	O
the	O
United	O
States	O
during	O
2015	O
,	O
the	O
following	O
diseases	O
do	O
not	O
appear	O
in	O
this	O
early	O
release	B-PATH
table	O
:	O
anthrax	O
;	O
dengue	O
hemorrhagic	O
fever	O
;	O
diphtheria	O
;	O
eastern	O
equine	O
encephalitis	O
virus	O
disease	O
,	O
nonneuroinvasive	O
;	O
poliomyelitis	O
,	O
paralytic	O
;	O
poliovirus	O
infection	O
,	O
nonparalytic	O
;	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
disease	O
(	O
SARS	O
-	O
CoV	O
);	O
smallpox	O
;	O
western	O
equine	O
encephalitis	O
virus	O
disease	O
,	O
neuroinvasive	O
and	O
nonneuroinvasive	O
;	O
yellow	O
fever	O
;	O
and	O
viral	O
hemorrhagic	O
fevers	O
.	O

IL	O
-	O
17	O
is	O
associated	O
with	O
neutrophilic	O
inflammation	O
,	O
steroid	O
resistance	O
and	O
severe	O
asthma	B-PATH
,	O
but	O
its	O
importance	O
in	O
the	O
association	O
between	O
asthma	B-PATH
and	O
obesity	O
is	O
unknown	O
.	O

In	O
acute	O
asthma	B-PATH
,	O
IL	O
-	O
17	O
expression	O
,	O
like	O
most	O
other	O
clinical	O
measures	O
,	O
was	O
similar	O
among	O
lean	O
,	O
overweight	O
and	O
obese	O
groups	O
,	O
but	O
was	O
higher	O
in	O
acute	O
versus	O
stable	O
asthma	B-PATH
subjects	O
,	O
with	O
sputum	O
IL	O
-	O
17	O
correlating	O
positively	O
with	O
sputum	O
neutrophils	O
and	O
negatively	O
with	O
FEV	O
IL	O
-	O
17	O
contributes	O
to	O
worse	O
disease	O
control	O
in	O
obese	O
asthma	B-PATH
through	O
enhancing	O
airway	O
neutrophilia	O
and	O
depression	O
,	O
and	O
may	O
implicate	O
in	O
asthma	B-PATH
exacerbations	O
.	O

ABSTRACT	O
:	O
Inflammatory	O
lung	O
diseases	O
like	O
asthma	B-PATH
bronchiale	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
allergic	O
airway	O
inflammation	O
are	O
widespread	O
public	O
diseases	O
that	O
constitute	O
an	O
enormous	O
burden	O
to	O
the	O
health	O
systems	O
.	O

When	O
manifesting	O
in	O
the	O
lungs	O
,	O
severe	O
malaria	B-PATH
causes	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ALI	O
/	O
ARDS	O
).	O

The	O
depletion	O
of	O
neutrophils	O
,	O
treatment	O
with	O
AMD3100	O
(	O
a	O
CXCR4	O
antagonist	O
),	O
Pulmozyme	O
(	O
human	O
recombinant	O
DNase	O
)	O
or	O
Sivelestat	O
(	O
inhibitor	O
of	O
neutrophil	O
elastase	O
)	O
decreased	O
the	O
development	O
of	O
malaria	B-PATH
-	O
associated	O
ALI	O
/	O
ARDS	O
and	O
significantly	O
increased	O
mouse	O
survival	O
.	O

A	O
43	O
-	O
year	O
-	O
old	O
man	O
with	O
liver	O
cirrhosis	O
due	O
to	O
hepatitis	B-PATH
C	I-PATH
virus	O
underwent	O
living	O
-	O
donor	O
liver	O
transplantation	O
.	O

ABSTRACT	O
:	O
Griffithsin	O
(	O
GRFT	O
)	O
is	O
a	O
red	O
alga	O
-	O
derived	O
lectin	O
with	O
demonstrated	O
broad	O
spectrum	O
antiviral	O
activity	O
against	O
enveloped	O
viruses	O
,	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
Japanese	O
encephalitis	O
virus	O
(	O
JEV	O
),	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
),	O
and	O
herpes	O
simplex	O
virus	O
-	O
2	O
(	O
HSV	O
-	O
2	O
).	O

ABSTRACT	O
:	O
The	O
lipid	O
kinase	O
phosphatidylinositol	O
4	O
-	O
kinase	O
IIIÎ²	O
(	O
PI4KB	O
)	O
is	O
an	O
essential	O
host	O
factor	O
for	O
many	O
positive	O
-	O
sense	O
single	O
-	O
stranded	O
RNA	O
(+	O
RNA	O
)	O
viruses	O
including	O
human	O
pathogens	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
),	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
coxsackie	O
viruses	O
,	O
and	O
rhinoviruses	O
.	O

Lung	O
function	O
and	O
the	O
percentages	O
of	O
eosinophils	O
in	O
induced	O
sputum	O
samples	O
were	O
determined	O
,	O
and	O
the	O
frequencies	O
of	O
severe	O
asthma	B-PATH
exacerbations	O
during	O
the	O
previous	O
year	O
were	O
evaluated	O
in	O
the	O
group	O
of	O
patients	O
with	O
asthma	B-PATH
.	O

Concurrent	O
infections	O
of	O
dengue	O
and	O
malaria	B-PATH
are	O
rare	O
due	O
to	O
the	O
different	O
habitats	O
of	O
its	O
vectors	O
and	O
activities	O
of	O
different	O
carrier	O
mosquitoes	O
.	O

TITLE	O
:	O
Takotsubo	O
cardiomyopathy	O
:	O
A	O
known	O
unknown	O
foe	O
of	O
asthma	B-PATH
.	O

Clinicians	O
should	O
re	O
-	O
evaluate	O
asthma	B-PATH
management	O
and	O
be	O
aware	O
of	O
the	O
complications	O
associated	O
with	O
asthma	B-PATH
attacks	O
such	O
as	O
stress	O
-	O
induced	O
cardiomyopathy	O
.	O

Multiple	O
recombinant	O
MVA	O
currently	O
undergo	O
clinical	O
testing	O
for	O
vaccination	O
against	O
human	O
immunodeficiency	O
viruses	O
,	O
Mycobacterium	O
tuberculosis	B-PATH
or	O
Plasmodium	O
falciparum	O
.	O

CASE	O
REPORT	O
A	O
47	O
-	O
year	O
-	O
old	O
nonsmoking	O
Hispanic	O
man	O
with	O
advanced	O
HIV	B-PATH
infection	I-PATH
presented	O
with	O
severe	O
acute	O
necrotizing	O
pneumonia	O
secondary	O
to	O
R	O
.	O
equi	O
.	O

However	O
,	O
TMPRSS2	O
overexpression	O
decreased	O
MHV	O
structural	O
protein	O
expression	O
,	O
release	B-PATH
of	O
infectious	O
particles	O
,	O
and	O
syncytium	O
formation	O
,	O
and	O
endogenous	O
serine	O
protease	O
activity	O
did	O
not	O
contribute	O
greatly	O
to	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
shrinking	O
lung	O
syndrome	O
(	O
SLS	O
)	O
is	O
a	O
rare	O
complication	O
of	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
performed	O
as	O
an	O
acceptable	O
life	O
-	O
saving	O
bridging	O
procedure	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O
To	O
patients	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)-	O
associated	O
ARDS	O
,	O
ECMO	O
could	O
be	O
adopted	O
as	O
a	O
feasible	O
therapeutic	O
solution	O
.	O

ABSTRACT	O
:	O
Autophagy	O
is	O
a	O
basic	O
biological	O
metabolic	O
process	O
involving	O
in	O
intracellular	O
membrane	O
transport	O
pathways	O
that	O
recycle	O
cellular	O
components	O
and	O
eliminate	O
intracellular	O
microorganisms	O
within	O
the	O
lysosome	B-PATH
.	O

We	O
examine	O
the	O
relationship	O
between	O
epidemic	O
containment	O
and	O
the	O
disease	O
dynamics	O
of	O
symptoms	O
and	O
infectiousness	O
for	O
seven	O
case	O
-	O
study	O
diseases	O
with	O
diverse	O
natural	O
histories	O
,	O
including	O
Ebola	O
,	O
influenza	B-PATH
A	I-PATH
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

TITLE	O
:	O
The	O
Impact	O
of	O
the	O
Interferon	O
/	O
TNF	O
-	O
Related	O
Apoptosis	B-PATH
-	O
Inducing	O
Ligand	O
Signaling	O
Axis	O
on	O
Disease	O
Progression	O
in	O
Respiratory	O
Viral	O
Infection	O
and	O
Beyond	O
.	O

First	O
described	O
as	O
an	O
apoptosis	B-PATH
-	O
inducing	O
agent	O
in	O
transformed	O
cells	O
,	O
it	O
is	O
now	O
also	O
well	O
established	O
to	O
rapidly	O
evoke	O
cellular	O
stress	O
pathways	O
in	O
epithelial	O
cells	O
,	O
finally	O
leading	O
to	O
caspase	O
-	O
dependent	O
or	O
-	O
independent	O
cell	O
death	O
.	O

The	O
infectious	O
diseases	O
with	O
the	O
highest	O
yearly	O
incidence	O
were	O
hand	O
,	O
foot	O
,	O
and	O
mouth	O
disease	O
(	O
114	O
Â·	O
48	O
per	O
100	O
000	O
),	O
hepatitis	O
B	O
(	O
81	O
Â·	O
57	O
per	O
100	O
000	O
),	O
and	O
tuberculosis	B-PATH
(	O
80	O
Â·	O
33	O
per	O
100	O
000	O
).	O

By	O
combining	O
these	O
substrate	O
profiling	O
and	O
structural	O
data	O
,	O
we	O
were	O
able	O
to	O
design	O
a	O
selective	O
peptide	O
inhibitor	O
of	O
APN	O
that	O
was	O
an	O
effective	O
therapeutic	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
against	O
APN	O
-	O
expressing	O
prostate	B-PATH
cancer	I-PATH
models	O
.	O

The	O
assessed	O
BDR	O
criteria	O
included	O
the	O
Global	O
Initiative	O
for	O
Chronic	O
Obstructive	O
Lung	O
Disease	O
(	O
GOLD	O
),	O
American	O
Thoracic	O
Society	O
(	O
ATS	O
),	O
American	O
College	O
of	O
Chest	O
Physicians	O
,	O
(	O
ACCP	O
),	O
major	O
criteria	O
of	O
the	O
Spanish	O
definition	O
of	O
asthma	B-PATH
-	O
COPD	O
overlap	O
syndrome	O
(	O
ACOS	O
),	O
criteria	O
compatible	O
with	O
ACOS	O
in	O
the	O
Global	O
Initiative	O
for	O
Asthma	B-PATH
(	O
GINA	O
),	O
and	O
European	O
Respiratory	O
Society	O
(	O
ERS	O
).	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
and	O
septic	O
shock	O
in	O
a	O
cat	O
with	O
disseminated	O
toxoplasmosis	B-PATH
.	O

TITLE	O
:	O
ABSTRACT	O
:	O
Malaria	B-PATH
during	O
pregnancy	O
can	O
cause	O
various	O
feto	O
-	O
maternal	O
complications	O
.	O

We	O
used	O
microarray	O
analysis	O
to	O
compare	O
changes	O
in	O
gene	O
expression	O
of	O
murine	O
lung	O
epithelial	O
cells	O
infected	O
individually	O
by	O
three	O
respiratory	O
viruses	O
causing	O
mild	O
(	O
rhinovirus	O
,	O
RV1B	O
),	O
moderate	O
(	O
coronavirus	O
,	O
MHV	O
-	O
1	O
),	O
and	O
severe	O
(	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
PR8	O
)	O
disease	O
in	O
mice	O
.	O

In	O
2	O
(	O
15	O
%)	O
CoV	O
-	O
HKU1	O
-	O
positive	O
adults	O
,	O
the	O
only	O
viral	O
coinfection	O
detected	O
was	O
influenza	B-PATH
A	I-PATH
.	O

TITLE	O
:	O
Infants	O
hospitalized	O
for	O
Bordetella	O
pertussis	B-PATH
infection	O
commonly	O
have	O
respiratory	O
viral	O
coinfections	O
.	O

ABSTRACT	O
:	O
Whether	O
viral	O
coinfections	O
cause	O
more	O
severe	O
disease	O
than	O
Bordetella	O
pertussis	B-PATH
(	O
B	O
.	O
pertussis	B-PATH
)	O
alone	O
remains	O
unclear	O
.	O

Asthma	B-PATH
is	O
a	O
heterogeneous	O
clinical	O
syndrome	O
primarily	O
affecting	O
the	O
lower	O
respiratory	O
tract	O
,	O
characterized	O
by	O
episodic	O
or	O
persistent	O
symptoms	O
of	O
wheezing	O
,	O
dyspnea	O
,	O
and	O
cough	O
.	O

Management	O
of	O
persistent	O
asthma	B-PATH
requires	O
avoidance	O
of	O
aggravating	O
environmental	O
factors	O
,	O
use	O
of	O
short	O
-	O
acting	O
Î²2	O
-	O
agonists	O
for	O
rapid	O
relief	O
of	O
symptoms	O
,	O
and	O
daily	O
use	O
of	O
inhaled	O
corticosteroids	O
.	O

TITLE	O
:	O
Respiratory	O
Complications	O
of	O
ABSTRACT	O
:	O
Malaria	B-PATH
,	O
a	O
major	O
global	O
public	O
health	O
problem	O
,	O
is	O
mainly	O
caused	O
by	O

The	O
best	O
examples	O
are	O
the	O
recurring	O
outbreaks	O
of	O
dengue	O
and	O
chikungunya	O
fever	O
in	O
tropical	O
and	O
sub	O
-	O
tropical	O
regions	O
,	O
the	O
recent	O
epidemic	O
of	O
Zika	O
in	O
the	O
Americas	O
and	O
the	O
Caribbean	O
,	O
and	O
the	O
SARS	O
,	O
MERS	O
,	O
and	O
influenza	B-PATH
A	I-PATH
outbreaks	O
across	O
the	O
globe	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
as	O
well	O
as	O
influenza	B-PATH
A	I-PATH
viruses	O
are	O
widely	O
spread	O
in	O
pig	O
fattening	O
and	O
can	O
cause	O
high	O
economical	O
loss	O
.	O

Although	O
T	O
helper	O
cell	O
type	O
2	O
(	O
Th2	O
)	O
cytokines	O
were	O
proven	O
to	O
play	O
critical	O
roles	O
in	O
atopic	O
asthma	B-PATH
,	O
IL	O
-	O
17A	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
severe	O
refractory	O
asthma	B-PATH
.	O

Otherwise	O
,	O
a	O
novel	O
variation	O
(	O
16	O
-	O
20	O
aa	O
deletion	O
and	O
an	O
L25P	O
mutation	O
)	O
in	O
the	O
transmembrane	O
domain	O
of	O
the	O
E	O
protein	O
affected	O
multiple	O
infection	O
processes	O
,	O
including	O
up	O
-	O
regulation	O
of	O
the	O
production	O
of	O
the	O
ER	O
stress	O
indicator	O
GRP78	O
,	O
improving	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
,	O
and	O
promoting	O
apoptosis	B-PATH
.	O

No	O
cross	O
-	O
reactivity	O
to	O
influenza	B-PATH
A	I-PATH
or	O
B	O
was	O
detected	O
.	O

The	O
aim	O
of	O
the	O
study	O
is	O
to	O
assess	O
the	O
evolution	O
of	O
malaria	B-PATH
cases	O
in	O
the	O
area	O
as	O
well	O
as	O
its	O
clinical	O
management	O
over	O
the	O
10	O
years	O
of	O
its	O
implementation	O
.	O

Ninety	O
-	O
five	O
drills	O
(	O
53	O
measles	B-PATH
and	O
42	O
MERS	O
)	O
were	O
conducted	O
in	O
49	O
EDs	O
with	O
patients	O
masked	O
and	O
isolated	O
in	O
78	O
%	O
of	O
drills	O
.	O

Then	O
,	O
IBV	O
-	O
induced	O
apoptosis	B-PATH
was	O
observed	O
through	O
a	O
cell	O
viability	O
assay	O
,	O
morphological	O
changes	O
,	O
and	O
flow	O
cytometry	O
.	O

During	O
the	O
study	O
period	O
in	O
2015	O
,	O
the	O
index	O
case	O
was	O
a	O
30	O
-	O
year	O
-	O
old	O
Filipino	O
nurse	O
who	O
had	O
a	O
history	O
of	O
unprotected	O
exposure	O
to	O
a	O
MERS	O
-	O
CoV	O
-	O
positive	O
case	O
on	O
May	O
15	O
,	O
2015	O
,	O
and	O
had	O
multiple	O
negative	O
tests	O
for	O
MERS	O
-	O
CoV	O
.	O
Weeks	O
later	O
,	O
she	O
was	O
diagnosed	O
with	O
pulmonary	O
tuberculosis	B-PATH
and	O
MERS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
pneumonia	O
.	O

Release	B-PATH
assay	O
in	O
vitro	O
showed	O
that	O
both	O
NDV	O
and	O
IBV	O
could	O
be	O
sustainably	O
released	O
from	O
the	O
nanoparticles	O
after	O
an	O
initial	O
burst	O
release	B-PATH
.	O

None	O
of	O
the	O
patients	O
had	O
MERS	O
-	O
CoV	O
but	O
influenza	O
viruses	O
were	O
detected	O
in	O
12	O
.	O
7	O
%	O
with	O
high	O
circulation	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
(	O
47	O
.	O
1	O
%).	O

Pandemic	O
H1N1	O
was	O
the	O
most	O
common	O
influenza	O
in	O
2015	O
with	O
a	O
peak	O
in	O
peaked	O
October	O
to	O
December	O
and	O
influenza	B-PATH
A	I-PATH
other	O
than	O
H1N1	O
was	O
more	O
common	O
in	O
2016	O
with	O
a	O
peak	O
in	O
August	O
and	O
then	O
October	O
to	O
December	O
.	O

With	O
the	O
ongoing	O
outbreaks	O
of	O
measles	B-PATH
in	O
Europe	O
,	O
it	O
is	O
recommended	O
that	O
all	O
pilgrims	O
have	O
an	O
updated	O
immunization	O
against	O
vaccine	O
-	O
preventable	O
diseases	O
(	O
diphtheria	O
,	O
tetanus	O
,	O
pertussis	B-PATH
,	O
polio	O
,	O
measles	B-PATH
and	O
mumps	O
).	O

Presence	O
of	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
parainfluenza	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
,	O
human	O
adeno	O
-,	O
boca	O
-,	O
corona	O
-,	O
metapneumo	O
-,	O
rhino	O
-	O
and	O
respiratory	O
syncytial	O
viruses	O
was	O
determined	O
by	O
real	O
-	O
time	O
PCR	O
.	O

In	O
EMR	O
,	O
several	O
infectious	O
disease	O
outbreaks	O
were	O
detected	O
,	O
investigated	O
,	O
and	O
rapidly	O
contained	O
over	O
the	O
past	O
5	O
years	O
including	O
:	O
yellow	O
fever	O
in	O
Sudan	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
in	O
Bahrain	O
,	O
Oman	O
,	O
Qatar	O
,	O
Saudi	O
Arabia	O
,	O
United	O
Arab	O
Emirates	O
,	O
and	O
Yemen	O
,	O
cholera	O
in	O
Iraq	O
,	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
infection	O
in	O
Egypt	O
,	O
and	O
dengue	O
fever	O
in	O
Yemen	O
,	O
Sudan	O
,	O
and	O
Pakistan	O
.	O

Plasmodium	O
falciparum	O
accounts	O
for	O
most	O
cases	O
,	O
although	O
P	O
vivax	O
is	O
increasingly	O
found	O
to	O
cause	O
severe	O
malaria	B-PATH
in	O
Asia	O
.	O

Cerebral	O
malaria	B-PATH
is	O
common	O
in	O
children	O
in	O
Africa	O
,	O
manifests	O
as	O
coma	O
and	O
seizures	O
,	O
and	O
has	O
a	O
high	O
morbidity	O
and	O
mortality	O
.	O

These	O
viruses	O
can	O
interfere	O
with	O
the	O
specific	O
steps	O
of	O
viral	O
life	O
cycle	O
by	O
blocking	O
the	O
binding	O
between	O
virus	O
and	O
host	O
cells	O
,	O
disrupting	O
viral	O
endocytosis	B-PATH
,	O
disturbing	O
membrane	O
fusion	O
,	O
and	O
interrupting	O
viral	O
RNA	O
replication	O
and	O
translation	O
,	O
thereby	O
demonstrating	O
potent	O
therapeutic	O
effect	O
against	O
various	O
emerging	O
and	O
re	O
-	O
emerging	O
viruses	O
.	O

TITLE	O
:	O
Immune	O
responses	O
in	O
influenza	B-PATH
A	I-PATH
virus	O
and	O
human	O
coronavirus	O
infections	O
:	O
an	O
ongoing	O
battle	O
between	O
the	O
virus	O
and	O
host	O
.	O

ABSTRACT	O
:	O
Respiratory	O
viruses	O
,	O
especially	O
influenza	B-PATH
A	I-PATH
viruses	O
and	O
coronaviruses	O
such	O
as	O
MERS	O
-	O
CoV	O
,	O
represent	O
continuing	O
global	O
threats	O
to	O
human	O
health	O
.	O

In	O
addition	O
,	O
17Î²	O
-	O
estradiol	O
significantly	O
prevented	O
the	O
ex	O
-	O
vivo	O
release	B-PATH
of	O
IL	O
-	O
1Î²	O
and	O
VEGF	O
from	O
lung	O
tissue	O
.	O

ABSTRACT	O
:	O
In	O
the	O
past	O
twenty	O
years	O
,	O
numerous	O
novel	O
zoonotic	O
viral	O
agents	O
with	O
pandemic	O
potential	O
have	O
emerged	O
in	O
China	O
,	O
such	O
as	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
and	O
,	O
more	O
recently	O
,	O
the	O
avian	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
/	O
H7N9	O
virus	O
,	O
which	O
have	O
caused	O
outbreaks	O
among	O
humans	O
with	O
high	O
morbidity	O
and	O
mortality	O
.	O

In	O
P	O
.	O
berghei	O
NK65	O
infected	O
mice	O
,	O
which	O
concomitantly	O
develop	O
lethal	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
the	O
liver	O
tissue	O
is	O
characterized	O
by	O
an	O
excess	O
oxidative	O
stress	B-PATH
response	I-PATH
and	O
reduced	O
antioxidant	O
defenses	O
while	O
in	O
P	O
.	O
chabaudi	O
AS	O
infected	O
mice	O
hepatopathy	O
does	O
not	O
lead	O
to	O
lipid	O
alterations	O
or	O
reduction	O
of	O
antioxidant	O
enzymes	O
,	O
but	O
rather	O
to	O
inflammation	O
and	O
cytokine	O
burst	O
,	O
as	O
shown	O
earlier	O
,	O
that	O
may	O
favour	O
parasite	O
killing	O
and	O
clearance	O
of	O
the	O
infection	O
.	O

ABSTRACT	O
:	O
Most	O
patients	O
with	O
severe	O
infection	O
with	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
progress	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
even	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
).	O

The	O
primary	O
focus	O
was	O
on	O
the	O
prevalence	O
of	O
respiratory	O
viruses	O
,	O
including	O
AdV	O
(	O
adenovirus	O
),	O
BoV	O
(	O
bocavirus	O
),	O
CoV	O
(	O
coronavirus	O
),	O
CMV	O
(	O
cytomegalovirus	O
),	O
EnV	O
(	O
enterovirus	O
),	O
HSV	O
(	O
herpes	O
simplex	O
virus	O
),	O
IfV	O
(	O
influenza	O
virus	O
),	O
MpV	O
(	O
metapneumovirus	O
),	O
PiV	O
(	O
parainfluenzavirus	O
),	O
RV	O
(	O
rhinovirus	O
)	O
and	O
RSV	O
(	O
respiratory	O
syncytial	O
virus	O
)	O
during	O
asthma	B-PATH
exacerbations	O
.	O

In	O
total	O
,	O
188	O
episodes	O
of	O
ARI	O
were	O
reported	O
,	O
being	O
rhinovirus	O
the	O
most	O
frequently	O
detected	O
(	O
n	O
=	O
53	O
),	O
followed	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H3	O
)	O
(	O
n	O
=	O
19	O
)	O
and	O
HBoV	O
(	O
n	O
=	O
14	O
).	O

mTOR	B-PATH
signaling	I-PATH
pathway	I-PATH
activator	O
-	O
MHY1485	O
,	O
and	O
inhibitor	O
-	O
PP242	O
were	O
used	O
to	O
study	O
the	O
antiviral	O
function	O
.	O

Results	O
indicated	O
that	O
the	O
mTOR	B-PATH
signaling	I-PATH
pathway	I-PATH
played	O
a	O
vital	O
role	O
in	O
the	O
PEDV	O
antiviral	O
regulation	O
in	O
the	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
Characteristics	O
of	O
early	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
newly	O
diagnosed	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
.	O

A	O
25	O
-	O
year	O
-	O
old	O
pregnant	O
woman	O
was	O
initiated	O
with	O
ECMO	O
due	O
to	O
severe	O
ARDS	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
.	O

The	O
negative	O
regulators	O
of	O
interferon	B-PATH
signaling	I-PATH
,	O
the	O
suppressors	O
of	O
cytokine	O
signaling	O
,	O
SOCS	O
-	O
1	O
and	O
SOCS	O
-	O
3	O
,	O
were	O
found	O
to	O
be	O
markedly	O
up	O
-	O
regulated	O
in	O
the	O
initial	O
round	O
of	O
H5N1	O
virus	O
replication	O
.	O

Our	O
results	O
showed	O
that	O
the	O
nsp7	O
protein	O
is	O
localized	O
in	O
the	O
cytoplasm	O
and	O
has	O
no	O
effect	O
on	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
)	O
growth	O
,	O
cell	B-PATH
cycle	I-PATH
,	O
and	O
cyclin	O
A	O
expression	O
.	O

TITLE	O
:	O
Transfusion	O
-	O
transmitted	O
malaria	B-PATH
masquerading	O
as	O
sickle	O
cell	O
crisis	O
with	O
multisystem	O
organ	O
failure	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
transfusion	O
-	O
transmitted	O
malaria	B-PATH
in	O
a	O
patient	O
with	O
SCD	O
presenting	O
with	O
acute	O
vaso	O
-	O
occlusive	O
crisis	O
and	O
rapidly	O
decompensating	O
to	O
multisystem	O
organ	O
failure	O
(	O
MSOF	O
).	O

The	O
history	O
is	O
loaded	O
by	O
chronic	O
pathologies	O
:	O
myeloma	O
disease	O
,	O
prostate	B-PATH
cancer	I-PATH
,	O
ciliary	O
arrhythmia	O
,	O
heart	O
failure	O
;	O
received	O
several	O
courses	O
of	O
polichemotherapy	O
,	O
last	O
ten	O
days	O
has	O
been	O
treated	O
for	O
pneumonia	O
with	O
antibiotics	O
of	O
ceftriaxone	O
group	O
in	O
outpatient	O
setting	O
.	O

ABSTRACT	O
:	O
Although	O
Plasmodium	O
ovale	O
is	O
considered	O
the	O
cause	O
of	O
only	O
mild	O
malaria	B-PATH
,	O
a	O
case	O
of	O
severe	O
malaria	B-PATH
due	O
to	O
P	O
.	O
ovale	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
is	O
reported	O
.	O

TITLE	O
:	O
Risk	O
factors	O
for	O
severe	O
influenza	B-PATH
A	I-PATH
virus	O
infections	O
in	O
post	O
-	O
2009	O
pandemic	O
period	O
.	O

The	O
recovery	O
of	O
pulmonary	O
functions	O
,	O
exercise	O
capacity	O
,	O
and	O
HRQoL	O
in	O
the	O
survivors	O
of	O
ARDS	O
due	O
to	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
H1N1	O
pneumonitis	O
(	O
H1N1	O
-	O
ARDS	O
)	O
was	O
evaluated	O
in	O
a	O
tertiary	O
teaching	O
hospital	O
in	O
northern	O
Taiwan	O
between	O
May	O
2010	O
and	O
June	O
2011	O
.	O

Further	O
research	O
results	O
showed	O
that	O
inhibition	O
of	O
p53	B-PATH
signaling	I-PATH
pathway	I-PATH
can	O
reverse	O
the	O
cell	B-PATH
cycle	I-PATH
arrest	O
in	O
G0	O
/	O
G1	O
phase	O
induced	O
by	O
PEDV	O
infection	O
and	O
cancel	O
out	O
the	O
up	O
-	O
regulation	O
of	O
p21	O
and	O
corresponding	O
Cyclin	O
/	O
cdk	O
mentioned	O
above	O
.	O

Furthermore	O
APN	O
and	O
EGFR	O
synergistically	O
stimulate	O
PI3K	O
/	O
AKT	O
as	O
well	O
as	O
MEK	O
/	O
ERK1	O
/	O
2	O
endocytosis	B-PATH
signaling	O
pathways	O
.	O

Fully	O
differentiated	O
3D	O
nasal	O
epithelium	O
cultures	O
were	O
inoculated	O
with	O
picornaviruses	O
,	O
a	O
coronavirus	O
and	O
influenza	B-PATH
A	I-PATH
viruses	O
in	O
the	O
absence	O
or	O
in	O
the	O
presence	O
of	O
reference	O
antiviral	O
drugs	O
.	O

Of	O
these	O
,	O
P	O
.	O
falciparum	O
and	O
P	O
.	O
vivax	O
are	O
the	O
most	O
prevalent	O
and	O
account	O
for	O
the	O
majority	O
of	O
the	O
global	O
malaria	B-PATH
cases	O
.	O

Although	O
,	O
P	O
.	O
vivax	O
infection	O
has	O
long	O
been	O
considered	O
to	O
be	O
benign	O
,	O
recent	O
studies	O
have	O
reported	O
life	O
-	O
threatening	O
consequences	O
,	O
including	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
cerebral	O
malaria	B-PATH
,	O
multi	O
-	O
organ	O
failure	O
,	O
dyserythropoiesis	O
and	O
anaemia	O
.	O

TITLE	O
:	O
Prolonged	O
Evolution	O
of	O
Virus	O
-	O
Specific	O
Memory	O
T	O
Cell	O
Immunity	O
after	O
Severe	O
Avian	O
Influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
Virus	O
Infection	O
.	O

ABSTRACT	O
:	O
The	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
caused	O
a	O
worldwide	O
pandemic	O
in	O
2009	O
-	O
2010	O
and	O
has	O
since	O
remained	O
in	O
seasonal	O
circulation	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
any	O
variations	O
in	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
status	O
according	O
to	O
sex	O
,	O
age	O
group	O
,	O
sample	O
type	O
,	O
or	O
location	O
within	O
the	O
Eastern	O
Province	O
of	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O

The	O
incidence	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
was	O
higher	O
in	O
Ras	O
Tanura	O
city	O
compared	O
to	O
other	O
locations	O
in	O
the	O
Eastern	O
Province	O
.	O

Treatment	O
with	O
cyclosporin	O
A	O
(	O
CsA	O
),	O
an	O
inhibitor	O
of	O
mitochondrial	O
permeability	O
transition	O
pore	O
(	O
MPTP	O
)	O
opening	O
,	O
significantly	O
suppressed	O
PDCoV	O
-	O
triggered	O
apoptosis	B-PATH
and	O
viral	O
replication	O
.	O

The	O
estimation	O
approach	O
is	O
general	O
and	O
may	O
be	O
applicable	O
to	O
zoonotic	O
pathogens	O
such	O
as	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
related	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
as	O
well	O
as	O
vaccine	O
-	O
preventable	O
diseases	O
like	O
measles	B-PATH
.	O

Besides	O
anti	O
-	O
MDA5	O
autoantibodies	O
,	O
patients	O
with	O
CADM	O
may	O
have	O
myositis	O
-	O
associated	O
autoantibodies	O
(	O
MAAs	O
),	O
which	O
characterize	O
other	O
connective	O
tissue	O
diseases	O
such	O
as	O
rheumatoid	B-PATH
arthritis	I-PATH
and	O
SjÃ¶gren	O
'	O
s	O
syndrome	O
.	O

A	O
74	O
-	O
year	O
-	O
old	O
man	O
,	O
with	O
a	O
history	O
of	O
advanced	O
stage	O
melanoma	B-PATH
and	O
treatment	O
with	O
ipilimumab	O
,	O
pembrolizumab	O
and	O
nivolumab	O
,	O
was	O
admitted	O
to	O
the	O
hospital	O
due	O
to	O
respiratory	O
failure	O
with	O
hypoxemia	O
and	O
dyspnoea	O
.	O

Although	O
preventive	O
measures	O
and	O
the	O
development	O
of	O
drugs	O
have	O
provided	O
some	O
relief	O
from	O
the	O
burden	O
of	O
malaria	B-PATH
,	O
dengue	O
,	O
and	O
HIV	O
,	O
the	O
US	O
military	O
continues	O
to	O
fund	O
research	O
and	O
development	O
of	O
prophylactic	O
vaccines	O
that	O
will	O
contribute	O
to	O
force	O
health	O
protection	O
and	O
global	O
health	O
.	O

Influenza	B-PATH
A	I-PATH
""""	O
equivocal	O
""""	O
and	O
""""	O
no	O
-	O
subtype	O
""""	O
samples	O
by	O
FilmArray	O
were	O
further	O
compared	O
to	O
a	O
laboratory	O
-	O
developed	O
Influenza	B-PATH
A	I-PATH
/	O
B	O
test	O
.	O

Cyclophilins	O
have	O
been	O
reported	O
to	O
play	O
an	O
essential	O
role	O
in	O
the	O
replication	O
of	O
several	O
other	O
RNA	O
viruses	O
,	O
including	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

This	O
study	O
addressed	O
factors	O
related	O
to	O
treatment	O
outcomes	O
in	O
subjects	O
of	O
complicated	O
influenza	B-PATH
infection	I-PATH
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
during	O
the	O
Taiwan	O
epidemic	O
in	O
the	O
Spring	O
of	O
2016	O
.	O

Patients	O
with	O
virology	O
-	O
proven	O
influenza	B-PATH
infection	I-PATH
admitted	O
to	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
between	O
January	O
and	O
March	O
2016	O
were	O
included	O
for	O
analysis	O
.	O

TITLE	O
:	O
Characteristics	O
and	O
outcome	O
of	O
ill	O
critical	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
infection	O
.	O

TITLE	O
:	O
Structurally	O
Diverse	O
Polyketides	O
From	O
the	O
Mangrove	O
-	O
Derived	O
Fungus	O
ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
is	O
a	O
severe	O
worldwide	O
threat	O
to	O
public	O
health	O
and	O
economic	O
development	O
due	O
to	O
its	O
high	O
morbidity	O
and	O
mortality	O
.	O

Mice	O
were	O
immunized	O
intranasally	O
with	O
the	O
inactivated	O
split	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
(	O
A	O
/	O
Shanghai	O
/	O
02	O
/	O
2013	O
)	O
vaccine	O
with	O
or	O
without	O
JY	O
.	O

ABSTRACT	O
:	O
Pertussis	B-PATH
is	O
a	O
severe	O
respiratory	O
disease	O
caused	O
by	O

TITLE	O
:	O
Characterization	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
pseudotyped	O
with	O
the	O
spike	O
protein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

We	O
report	O
a	O
case	O
of	O
ARDS	O
after	O
an	O
infection	O
with	O
H1N1	O
influenza	B-PATH
A	I-PATH
in	O
a	O
33	O
-	O
year	O
-	O
old	O
patient	O
pregnant	O
at	O
27	O
-	O
weeks	O
.	O

The	O
decline	O
of	O
the	O
vaccine	O
-	O
preventable	O
diseases	O
has	O
contributed	O
to	O
a	O
recognition	O
of	O
the	O
potential	O
for	O
using	O
vaccines	O
to	O
prevent	O
other	O
infectious	O
diseases	O
,	O
including	O
human	O
immunodeficiency	O
virus	O
/	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
HIV	O
/	O
AIDS	O
),	O
tuberculosis	B-PATH
(	O
TB	O
),	O
malaria	B-PATH
,	O
hepatitis	B-PATH
C	I-PATH
,	O
and	O
a	O
variety	O
of	O
neglected	O
tropical	O
diseases	O
(	O
NTDs	O
).	O

TITLE	O
:	O
A	O
review	O
on	O
current	O
trends	O
in	O
the	O
treatment	O
of	O
human	O
infection	O
with	O
H7N9	O
-	O
avian	O
influenza	B-PATH
A	I-PATH
.	O
ABSTRACT	O
:	O
The	O
H7N9	O
subtype	O
of	O
avian	O
influenza	O
is	O
an	O
enzootic	O
and	O
airborne	O
virus	O
which	O
caused	O
an	O
influenza	O
outbreak	O
in	O
China	O
.	O

A	O
respiratory	O
multiplex	O
array	O
was	O
performed	O
to	O
detect	O
for	O
influenza	B-PATH
A	I-PATH
and	O
B	O
;	O
respiratory	O
syncytial	O
virus	O
A	O
and	O
B	O
;	O
human	O
parainfluenza	O
virus	O
1	O
-	O
2	O
-	O
3	O
and	O
4	O
;	O
human	O
coronavirus	O
229E	O
and	O
OC43	O
;	O
human	O
rhinovirus	O
;	O
human	O
enterovirus	O
;	O
human	O
adenovirus	O
;	O
human	O
bocavirus	O
;	O
human	O
metapneumovirus	O
.	O

TITLE	O
:	O
p53	O
-	O
and	O
ROS	O
-	O
mediated	O
AIF	O
pathway	O
involved	O
in	O
TGEV	O
-	O
induced	O
apoptosis	B-PATH
.	O

Normalised	O
metabolic	O
,	O
circulatory	O
and	O
ventilatory	O
demands	O
will	O
allow	O
one	O
to	O
single	O
out	O
the	O
oxygenation	O
defect	O
managed	O
with	O
high	O
PEEP	O
(	O
diffuse	O
recruitable	O
ARDS	O
)	O
under	O
early	O
spontaneous	O
ventilation	O
(	O
airway	O
pressure	O
release	B-PATH
ventilation	O
+	O
SV	O
or	O
low	O
-	O
pressure	O
support	O
).	O

TITLE	O
:	O
Lung	O
Repair	O
and	O
Regeneration	O
in	O
ARDS	O
:	O
Role	O
of	O
PECAM1	O
and	O
Wnt	B-PATH
Signaling	I-PATH
.	O

Although	O
PEDV	O
induced	O
cell	O
apoptosis	B-PATH
has	O
been	O
established	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
the	O
functional	O
protein	O
that	O
contributes	O
to	O
this	O
event	O
remains	O
unclear	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
the	O
S1	O
proteins	O
from	O
various	O
coronavirus	O
family	O
members	O
such	O
as	O
TGEV	O
,	O
IBV	O
,	O
CCoV	O
,	O
SARS	O
and	O
MERS	O
could	O
also	O
induce	O
Vero	O
-	O
E6	O
cells	O
apoptosis	B-PATH
.	O

RESULTS	O
:	O
PEDV	O
could	O
infect	O
various	O
host	O
cells	O
including	O
Vero	O
,	O
Vero	O
-	O
E6	O
and	O
Marc	O
-	O
145	O
and	O
cause	O
obvious	O
cytopathic	O
effects	O
,	O
including	O
roundup	O
,	O
cell	O
fusion	O
,	O
cell	O
membrane	O
vacuolation	O
,	O
syncytium	O
formation	O
and	O
cause	O
apparent	O
apoptosis	B-PATH
.	O

TITLE	O
:	O
Deletion	O
of	O
both	O
the	O
Tyrosine	O
-	O
Based	O
Endocytosis	B-PATH
Signal	O
and	O
the	O
Endoplasmic	O
Reticulum	O
Retrieval	O
Signal	O
in	O
the	O
Cytoplasmic	O
Tail	O
of	O
Spike	O
Protein	O
Attenuates	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
in	O
Pigs	O
.	O

Clinical	O
studies	O
identifying	O
the	O
factors	O
associated	O
with	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
in	O
malaria	B-PATH
are	O
lacking	O
.	O

Usually	O
,	O
CNS	O
pathologies	O
are	O
caused	O
by	O
known	O
neurotropic	O
viruses	O
such	O
as	O
measles	B-PATH
virus	O
(	O
MV	O
),	O
herpes	O
virus	O
and	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
among	O
others	O
.	O

ClinicalTrials	O
.	O
gov	O
NCT01666834	O
;	O
date	O
of	O
registration	O
release	B-PATH
:	O
August	O
14	O

This	O
case	O
illustrates	O
that	O
tuberculosis	B-PATH
should	O
always	O
be	O
suspected	O
in	O
patients	O
from	O
high	O
-	O
incidence	O
countries	O
in	O
case	O
of	O
lung	O
involvement	O
and	O
that	O
an	O
interdisciplinary	O
approach	O
including	O
long	O
-	O
term	O
intensive	O
care	O
management	O
can	O
enable	O
successful	O
treatment	O
of	O
tuberculosis	B-PATH
with	O
severe	O
,	O
near	O
-	O
fatal	O
complications	O
.	O

Pregnant	O
women	O
infected	O
with	O
influenza	B-PATH
A	I-PATH
virus	O
were	O
at	O
increased	O
risk	O
of	O
hospitalization	O
and	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
which	O
is	O
associated	O
with	O
high	O
mortality	O
,	O
while	O
their	O
newborns	O
had	O
an	O
increased	O
risk	O
of	O
pre	O
-	O
term	O
birth	O
or	O
low	O
birth	O
weight	O
.	O

The	O
analysis	O
of	O
a	O
fragment	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
showed	O
the	O
correlation	O
of	O
the	O
Italian	O
strains	O
with	O
CoVs	O
that	O
was	O
only	O
detected	O
in	O
the	O
bat	O
Pipistrellus	O
genera	O
(	O
Pipistrellus	O
kuhlii	O
and	O
Pipistrellus	O
Pipistrellus	O
)	O
in	O
European	O
countries	O
.	O

Our	O
previous	O
studies	O
showed	O
that	O
TGEV	O
infection	O
activated	O
p53	O
signaling	O
to	O
induce	O
host	O
cell	O
apoptosis	B-PATH
,	O
which	O
might	O
influence	O
virus	O
replication	O
.	O

This	O
risk	O
has	O
been	O
recently	O
reinforced	O
by	O
human	O
epidemics	O
in	O
Singapore	O
of	O
SARS	O
coronavirus	O
,	O
2009	O
pandemic	O
H1N1	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
and	O
enterovirus	O
71	O
.	O

Among	O
the	O
influenza	B-PATH
A	I-PATH
-	O
positive	O
cases	O
,	O
25	O
(	O
20	O
.	O
8	O
%)	O
were	O
A	O
/	O
H1N1	O
pdm09	O
and	O
95	O
(	O
79	O
.	O
2	O
%)	O
were	O
A	O
/	O
H3	O
subtypes	O
.	O

TITLE	O
:	O
Small	O
Animal	O
Models	O
of	O
Respiratory	O
Viral	O
Infection	O
Related	O
to	O
Asthma	B-PATH
.	O

Asthma	B-PATH
development	O
has	O
been	O
modeled	O
by	O
administration	O
of	O
virus	O
to	O
immature	O
animals	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
has	O
been	O
purported	O
to	O
have	O
several	O
physiological	O
benefits	O
.	O

Tripartite	O
motif	O
8	O
(	O
TRIM8	O
)	O
contains	O
an	O
N	O
-	O
terminal	O
RING	O
finger	O
,	O
which	O
is	O
followed	O
by	O
two	O
B	O
-	O
boxes	O
and	O
a	O
coiled	O
-	O
coil	O
domain	O
,	O
belonging	O
to	O
the	O
TRIM	O
/	O
RBCC	O
family	O
and	O
playing	O
significant	O
role	O
in	O
meditating	O
inflammation	O
,	O
oxidative	O
stress	O
and	O
apoptosis	B-PATH
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
point	O
-	O
of	O
-	O
care	O
lung	O
ultrasound	O
as	O
a	O
novel	O
tool	O
to	O
determine	O
the	O
prevalence	O
and	O
early	O
signs	O
of	O
ARDS	O
in	O
a	O
resource	O
-	O
limited	O
setting	O
among	O
patients	O
with	O
severe	O
malaria	B-PATH
or	O
sepsis	O
.	O

RESULTS	O
:	O
Of	O
102	O
patients	O
enrolled	O
,	O
71	O
had	O
sepsis	O
and	O
31	O
had	O
malaria	B-PATH
.	O

This	O
variant	O
was	O
located	O
in	O
the	O
C3b	O
-	O
binding	O
site	O
and	O
functional	O
tests	O
revealed	O
that	O
it	O
perturbed	O
the	O
regulatory	O
activity	O
of	O
factor	O
H	O
.	O
This	O
case	O
suggests	O
that	O
pertussis	B-PATH
is	O
a	O
strong	O
trigger	O
of	O
HUS	O
and	O
that	O
complement	O
investigations	O
are	O
necessary	O
to	O
guide	O
treatment	O
and	O
understand	O
the	O
pathophysiology	O
.	O

ABSTRACT	O
:	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
and	O
Influenza	B-PATH
A	I-PATH
virus	O
Subtype	O
H7N9	O
(	O
H7N9	O
)	O
have	O
both	O
had	O
a	O
great	O
impact	O
on	O
China	O
in	O
the	O
21	O
This	O
article	O
explores	O
communication	O
for	O
emergency	O
management	O
of	O
SARS	O
in	O
2003	O
and	O
H7N9	O
in	O
2013	O
in	O
China	O
,	O
to	O
provide	O
useful	O
evidence	O
for	O
government	O
and	O
practitioner	O
on	O
management	O
improvement	O
for	O
infectious	O
disease	O
outbreaks	O
response	O
in	O
China	O
and	O
international	O
community	O
in	O
the	O
future	O
.	O

HIV	B-PATH
infection	I-PATH
increased	O
from	O
13	O
,	O
258	O
in	O
2004	O
(	O
RI	O
1	O
.	O
02	O
per	O
100	O
,	O
000	O
person	O
years	O
)	O
to	O
74	O
,	O
048	O
in	O
2014	O
(	O
RI	O
5	O
.	O
46	O
per	O
100	O
,	O
000	O
).	O

A	O
significant	O
association	O
was	O
found	O
between	O
influenza	B-PATH
infection	I-PATH
and	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
).	O

All	O
respiratory	O
specimens	O
from	O
patients	O
enrolled	O
through	O
SARI	O
surveillance	O
were	O
also	O
routinely	O
tested	O
by	O
multiplex	O
reverse	O
transcription	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
for	O
adenovirus	O
;	O
enterovirus	O
;	O
human	O
metapneumovirus	O
;	O
parainfluenza	O
virus	O
types	O
1	O
,	O
2	O
,	O
and	O
3	O
;	O
respiratory	O
syncytial	O
virus	O
;	O
rhinovirus	O
;	O
influenza	B-PATH
A	I-PATH
,	O
and	O
influenza	O
B	O
.	O
Human	O
bocavirus	O
,	O
hCoV	O
-	O
229E	O
,	O
and	O
hPyV	O
-	O
WU	O
were	O
detected	O
in	O
3	O
.	O
7	O
%	O
(	O
25	O
/	O
680	O
),	O
4	O
.	O
1	O
%	O
(	O
28	O
/	O
680	O
),	O
and	O
4	O
.	O
1	O
%	O
(	O
28	O
/	O
680	O
)	O
of	O
respiratory	O
specimens	O
,	O
respectively	O
.	O

TITLE	O
:	O
Lactobacillus	O
acidophilus	O
S	O
-	O
layer	O
protein	O
-	O
mediated	O
inhibition	O
of	O
PEDV	O
-	O
induced	O
apoptosis	B-PATH
of	O
Vero	O
cells	O
.	O

In	O
Vero	O
cells	O
infected	O
with	O
PEDV	O
,	O
we	O
found	O
that	O
apoptosis	B-PATH
was	O
mediated	O
by	O
activation	O
of	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
3	O
in	O
the	O
late	O
stage	O
of	O
infection	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
customs	O
officers	O
'	O
occupational	O
risk	O
towards	O
environmental	O
and	O
infectious	O
factors	O
,	O
including	O
viral	O
infections	O
,	O
tuberculosis	B-PATH
and	O
psittacosis	O
.	O

There	O
are	O
many	O
diseases	O
that	O
are	O
evaluated	O
using	O
an	O
ABG	O
which	O
include	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
severe	O
sepsis	O
,	O
septic	O
shock	O
,	O
hypovolemic	O
shock	O
,	O
diabetic	O
ketoacidosis	O
,	O
renal	O
tubular	O
acidosis	O
,	O
acute	O
respiratory	O
failure	O
,	O
heart	O
failure	O
,	O
cardiac	O
arrest	O
,	O
asthma	B-PATH
and	O
inborn	O
errors	O
of	O
metabolism	O
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
caused	O
by	O
Plasmodium	O
parasites	O
and	O
is	O
one	O
of	O
the	O
most	O
life	O
-	O
threatening	O
infectious	O
diseases	O
in	O
humans	O
.	O

Infection	O
can	O
result	O
in	O
severe	O
complications	O
such	O
as	O
cerebral	O
malaria	B-PATH
,	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
acute	O
renal	O
injury	O
.	O

Specimens	O
were	O
examined	O
at	O
our	O
collaborating	O
institutions	O
with	O
a	O
panel	O
of	O
molecular	O
assays	O
for	O
viral	O
pathogens	O
including	O
influenza	B-PATH
A	I-PATH
(	O
IAV	O
),	O
IBV	O
,	O
ICV	O
,	O
and	O
IDV	O
,	O
human	O
adenovirus	O
(	O
AdV	O
),	O
human	O
enterovirus	O
(	O
EV	O
),	O
human	O
coronavirus	O
(	O
CoV	O
),	O
respiratory	O
syncytial	O
virus	O
subtype	O
A	O
(	O
RSV	O
-	O
A	O
)	O
or	O
RSV	O
-	O
B	O
,	O
and	O
parainfluenza	O
virus	O
(	O
PIV	O
)	O
types	O
1	O
-	O
4	O
.	O
Of	O
599	O
samples	O
examined	O
,	O
288	O
(	O
48	O
%)	O
had	O
molecular	O
evidence	O
of	O
1	O
or	O
more	O
respiratory	O
viruses	O
.	O

Other	O
pathogens	O
covered	O
in	O
this	O
review	O
series	O
are	O
considered	O
to	O
be	O
re	O
-	O
emerging	O
,	O
such	O
as	O
multi	O
-	O
drug	O
resistant	O
tuberculosis	B-PATH
.	O

ROS	O
and	O
p53	O
play	O
key	O
roles	O
in	O
regulating	O
many	O
kinds	O
of	O
cell	O
process	O
during	O
viral	O
infection	O
,	O
however	O
,	O
the	O
exact	O
function	O
in	O
PEDV	O
-	O
induced	O
apoptosis	B-PATH
remains	O
unclear	O
.	O

However	O
,	O
treatment	O
with	O
the	O
p38	O
MAPK	O
inhibitor	O
SB203580	O
,	O
and	O
the	O
SAPK	O
/	O
JNK	O
inhibitor	O
SP600125	O
reversed	O
PEDV	O
-	O
induced	O
apoptosis	B-PATH
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
frequency	O
of	O
infections	O
caused	O
by	O
Influenza	O
viruses	O
,	O
i	O
.	O
e	O
.	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
,	O
Influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
and	O
Influenza	O
B	O
in	O
patients	O
presenting	O
with	O
respiratory	O
tract	O
infections	O
,	O
i	O
.	O
e	O
.	O
influenza	O
-	O
like	O
illness	O
(	O
ILI	O
)	O
and	O
severe	O
acute	O
respiratory	O
illness	O
(	O
SARI	O
).	O

Based	O
on	O
his	O
presentation	O
and	O
age	O
,	O
there	O
was	O
a	O
high	O
suspicion	O
of	O
viral	B-PATH
myocarditis	I-PATH
.	O

Common	O
tropical	O
infections	O
that	O
can	O
be	O
severe	O
,	O
such	O
as	O
malaria	B-PATH
,	O
dengue	O
,	O
and	O
enteric	O
fever	O
,	O
should	O
always	O
be	O
considered	O
in	O
the	O
diagnostic	O
evaluation	O
.	O

TITLE	O
:	O
Porcine	O
Reproductive	O
and	O
Respiratory	O
Syndrome	O
Virus	O
nsp11	O
Antagonizes	O
Type	O
I	O
Interferon	B-PATH
Signaling	I-PATH
by	O
Targeting	O
IRF9	O
.	O

IFI	O
included	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
adenovirus	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
and	O
parainfluenza	O
.	O

Plasmodium	O
berghei	O
NK65	O
-	O
E	O
(	O
PbNK65	O
)	O
parasites	O
were	O
injected	O
in	O
Vwf	O
In	O
accordance	O
with	O
patients	O
with	O
severe	O
malaria	B-PATH
,	O
plasma	O
VWF	O
levels	O
were	O
increased	O
and	O
ADAMTS13	O
activity	O
levels	O
were	O
reduced	O
in	O
experimental	O
MA	O
-	O
ARDS	O
.	O

A	O
total	O
of	O
30	O
.	O
4	O
%	O
of	O
patients	O
tested	O
positive	O
for	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
.	O

Antiviral	O
treatment	O
started	O
more	O
than	O
two	O
days	O
after	O
onset	O
of	O
symptoms	O
was	O
more	O
frequently	O
associated	O
with	O
ARDS	O
and	O
death	O
and	O
,	O
having	O
had	O
vaccine	O
against	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
a	O
factor	O
independently	O
related	O
to	O
survival	O
.	O

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
the	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
SARS	O
-	O
Nsp12	O
,	O
can	O
enhance	O
the	O
helicase	O
activity	O
of	O
SARS	O
-	O
Nsp13	O
through	O
interacting	O
with	O
it	O
directly	O
.	O

Moreover	O
,	O
the	O
absence	O
of	O
SIRT1	O
notably	O
inhibited	O
NBP	O
-	O
induced	O
protective	O
effects	O
against	O
LPS	O
-	O
induced	O
increase	O
of	O
W	O
/	O
D	O
ratio	O
of	O
lung	O
,	O
histological	O
injury	O
of	O
lung	O
,	O
infiltration	O
of	O
inflammatory	O
cells	O
,	O
release	B-PATH
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
and	O
oxidative	B-PATH
damage	I-PATH
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
knowledge	O
of	O
host	O
factors	O
co	O
-	O
opted	O
and	O
signaling	O
pathways	O
activated	O
during	O
HCoV	O
infection	O
,	O
with	O
an	O
emphasis	O
on	O
HCoV	O
-	O
infection	O
-	O
induced	O
stress	B-PATH
response	I-PATH
,	O
autophagy	O
,	O
apoptosis	B-PATH
,	O
and	O
innate	O
immunity	O
.	O

The	O
frequency	O
of	O
detection	O
of	O
HRV	O
,	O
RSV	O
,	O
Influenza	B-PATH
A	I-PATH
virus	O
,	O
HMPV	O
,	O
parainfluenza	O
virus	O
,	O
adenovirus	O
,	O
M	O
.	O
pneumoniae	O
,	O
coronavirus	O
,	O
bocavirus	O
and	O
C	O
.	O
pneumoniae	O
in	O
sputa	O
was	O
higher	O
than	O
that	O
of	O
OPSs	O
(	O
all	O
p	O
<	O
.	O
001	O
).	O

Here	O
,	O
we	O
used	O
whole	O
-	O
transcriptome	O
sequencing	O
(	O
RNASeq	O
)	O
and	O
ribosome	B-PATH
profiling	O
(	O
RiboSeq	O
)	O
to	O
delineate	O
gene	O
expression	O
in	O
the	O
IBV	O
M41	O
-	O
CK	O
and	O
Beau	O
-	O
R	O
strains	O
at	O
subcodon	O
resolution	O
.	O

We	O
aimed	O
to	O
evaluate	O
clinical	O
characteristics	O
and	O
mortality	O
of	O
CA	O
-	O
RVI	O
except	O
seasonal	O
influenza	B-PATH
A	I-PATH
/	O
B	O
in	O
transplant	O
recipients	O
and	O
non	O
-	O
transplant	O
critically	O
ill	O
patients	O
in	O
ICU	O
.	O

We	O
demonstrated	O
that	O
the	O
U937	O
cell	O
model	O
is	O
robust	O
and	O
suitable	O
for	O
the	O
high	O
-	O
throughput	O
screening	O
of	O
immunomodulators	O
and	O
antivirals	O
against	O
influenza	B-PATH
infection	I-PATH
.	O

Although	O
indistinguishable	O
proinflammatory	O
genes	O
were	O
induced	O
,	O
the	O
wild	O
-	O
type	O
strain	O
activated	O
higher	O
levels	O
of	O
C5a	O
in	O
lung	O
tissue	O
accompanied	O
by	O
elevated	O
albumin	O
instillation	O
and	O
increased	O
lactate	O
dehydrogenase	O
release	B-PATH
in	O
bronchoalveolar	O
lavage	O
fluid	O
compared	O
with	O
the	O
plc	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
in	O
ICH	O
differs	O
from	O
non	O
-	O
ICH	O
in	O
terms	O
of	O
clinical	O
features	O
,	O
range	O
of	O
complications	O
,	O
radiological	O
features	O
,	O
treatment	O
response	O
,	O
and	O
outcome	O
.	O

In	O
vitro	O
,	O
endocan	O
inhibited	O
human	O
leukocyte	B-PATH
transendothelial	I-PATH
migration	I-PATH
as	O
well	O
as	O
ICAM	O
-	O
1	O
-	O
dependent	O
migration	O
but	O
had	O
a	O
very	O
mild	O
effect	O
on	O
ICAM	O
-	O
1	O
-	O
dependent	O
adhesion	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
association	O
between	O
GBS	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
infection	O
has	O
been	O
rarely	O
reported	O
.	O

HCV	O
infection	O
should	O
be	O
screened	O
in	O
high	O
-	O
risk	O
patients	O
to	O
prevent	O
silent	O
progression	O
of	O
the	O
chronic	O
hepatitis	B-PATH
C	I-PATH
and	O
its	O
potentially	O
severe	O
extra	O
-	O
hepatic	O
manifestations	O
.	O

ABSTRACT	O
:	O
Tuberculosis	B-PATH
(	O
TB	O
)	O
is	O
a	O
rare	O
but	O
known	O
cause	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
with	O
a	O
high	O
mortality	O
.	O

In	O
contrast	O
,	O
conversion	O
of	O
LC3	O
-	O
I	O
/	O
LC3	O
-	O
II	O
could	O
be	O
significantly	O
inhibited	O
by	O
4	O
-	O
PBA	O
,	O
an	O
ER	O
stress	O
inhibitor	O
,	O
indicating	O
that	O
ORF3	O
-	O
induced	O
autophagy	O
is	O
dependent	O
on	O
ER	O
stress	B-PATH
response	I-PATH
.	O

TITLE	O
:	O
Respiratory	O
viral	O
infections	O
and	O
the	O
risk	O
of	O
rheumatoid	B-PATH
arthritis	I-PATH
.	O

ABSTRACT	O
:	O
We	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
ambient	O
respiratory	O
viral	O
infections	O
in	O
the	O
general	O
population	O
on	O
rheumatoid	B-PATH
arthritis	I-PATH
(	O
RA	O
)	O
development	O
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
virus	O
infection	O
induces	O
liver	O
injury	O
in	O
mice	O
.	O

Homologous	B-PATH
recombination	I-PATH
was	O
clearly	O
involved	O
in	O
the	O
molecular	O
evolution	O
of	O
HAdV	O
-	O
A	O
,	O
B	O
,	O
and	O
D	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
molecular	O
evolution	O
of	O
HAdV	O
-	O
C	O
.	O
From	O
2000	O
to	O
2016	O
,	O
201	O
HAdV	O
-	O
C	O
strains	O
were	O
collected	O
from	O
nine	O
provinces	O
covering	O
six	O
administrative	O
regions	O
of	O
mainland	O
of	O
China	O
via	O
3	O
existing	O
surveillance	O
programs	O
,	O
namely	O
the	O
febrile	O
respiratory	O
syndrome	O
surveillance	O
,	O
the	O
acute	O
flaccid	O
paralysis	O
surveillance	O
,	O
and	O
the	O
hand	O
,	O
foot	O
,	O
and	O
mouth	O
disease	O
surveillance	O
system	O
.	O

Although	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
have	O
a	O
top	O
priority	O
regarding	O
prevention	O
and	O
treatment	O
,	O
recent	O
molecular	O
diagnostic	O
tests	O
detecting	O
an	O
array	O
of	O
other	O
CARVs	O
in	O
real	O
time	O
have	O
dramatically	O
expanded	O
our	O
knowledge	O
about	O
the	O
epidemiology	O
,	O
diversity	O
,	O
and	O
impact	O
of	O
CARV	O
infections	O
in	O
the	O
general	O
population	O
and	O
in	O
allogeneic	O
HCT	O
and	O
SOT	O
patients	O
.	O

Nasopharyngeal	O
swabs	O
collected	O
from	O
patients	O
with	O
ILI	O
from	O
week	O
46	O
/	O
2017	O
to	O
week	O
17	O
/	O
2018	O
were	O
tested	O
to	O
identify	O
influenza	B-PATH
A	I-PATH
viruses	O
(	O
IAV	O
)	O
and	O
influenza	O
B	O
viruses	O
(	O
IBV	O
).	O

TITLE	O
:	O
Lung	O
endothelial	O
cell	O
antigen	O
cross	O
-	O
presentation	O
to	O
CD8	O
ABSTRACT	O
:	O
Malaria	B-PATH
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
are	O
life	O
-	O
threatening	O
manifestations	O
of	O
severe	O
malaria	B-PATH
infections	O
.	O

ABSTRACT	O
:	O
In	O
a	O
multicenter	O
cohort	O
study	O
including	O
22	O
oseltamivir	O
-	O
treated	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
prevalence	O
of	O
the	O
H275Y	O
substitution	O
in	O
the	O
neuraminidase	O
,	O
responsible	O
for	O
highly	O
reduced	O
sensitivity	O
to	O
oseltamivir	O
,	O
was	O
23	O
%.	O

TITLE	O
:	O
Anti	O
-	O
influenza	O
immune	O
plasma	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
:	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
phase	O
3	O
trial	O
.	O

Children	O
and	O
adults	O
with	O
PCR	O
-	O
confirmed	O
influenza	B-PATH
A	I-PATH
infection	O
,	O
a	O
National	O
Early	O
Warning	O
score	O
of	O
3	O
or	O
greater	O
,	O
and	O
onset	O
of	O
illness	O
within	O
6	O
days	O
before	O
randomisation	O
were	O
eligible	O
.	O

ABSTRACT	O
:	O
To	O
report	O
an	O
outbreak	O
of	O
measles	B-PATH
with	O
epidemiological	O
link	O
between	O
Hong	O
Kong	O
International	O
Airport	O
(	O
HKIA	O
)	O
and	O
a	O
hospital	O
.	O

Epidemiological	O
investigations	O
,	O
patients	O
'	O
measles	B-PATH
serology	O
,	O
and	O
phylogenetic	O
analysis	O
of	O
the	O
hemagglutinin	O
(	O
H	O
)	O
and	O
nucleoprotein	O
(	O
N	O
)	O
genes	O
of	O
measles	B-PATH
virus	O
isolates	O
were	O
conducted	O
.	O

Furthermore	O
,	O
1	O
airport	O
baggage	O
handler	O
who	O
was	O
admitted	O
to	O
hospital	O
A	O
before	O
rash	O
onset	O
infected	O
2	O
healthcare	O
workers	O
(	O
HCWs	O
)	O
known	O
to	O
have	O
2	O
doses	O
of	O
MMR	O
vaccination	O
with	O
positive	O
measles	B-PATH
IgG	O
and	O
lower	O
viral	O
loads	O
in	O
respiratory	O
specimens	O
.	O

Chandelia	O
S	O
,	O
Kishore	O
S	O
,	O
Nandan	O
D	O
.	O
Successful	O
Ventilation	O
of	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Complicated	O
by	O
Pneumothorax	O
Using	O
Airway	O
Pressure	O
Release	B-PATH
Ventilation	O
:	O
A	O
Case	O
Report	O
.	O

ABSTRACT	O
:	O
Miliary	O
tuberculosis	B-PATH
is	O
a	O
serious	O
and	O
uncommon	O
form	O
of	O
tuberculosis	B-PATH
due	O
to	O
hematogenous	O
dissemination	O
of	O
This	O
study	O
aimed	O
to	O
describe	O
the	O
epidemiological	O
and	O
clinical	O
features	O
of	O
miliary	O
tuberculosis	B-PATH
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
profile	O
,	O
severity	O
and	O
complications	O
of	O
patients	O
suffering	O
from	O
malaria	B-PATH
in	O
Mangaluru	O
,	O
a	O
southwestern	O
coastal	O
city	O
in	O
India	O
.	O

Among	O
these	O
,	O
506	O
(	O
87	O
.	O
4	O
%)	O
had	O
mild	O
malaria	B-PATH
,	O
whereas	O
73	O
(	O
12	O
.	O
6	O
%)	O
had	O
severe	O
malaria	B-PATH
.	O

All	O
the	O
patients	O
with	O
severe	O
malaria	B-PATH
recruited	O
in	O
our	O
study	O
were	O
successfully	O
treated	O
and	O
discharged	O
.	O

Majority	O
of	O
patients	O
had	O
mild	O
malaria	B-PATH
,	O
likely	O
due	O
to	O
seeking	O
treatment	O
soon	O
after	O
experiencing	O
symptoms	O
and	O
/	O
or	O
having	O
preexisting	O
immune	O
protection	O
.	O

Implementing	O
effective	O
surveillance	O
and	O
vector	O
control	O
measures	O
in	O
malaria	B-PATH
hotspot	O
locations	O
in	O
the	O
city	O
and	O
educating	O
people	O
about	O
preventive	O
measures	O
are	O
likely	O
to	O
reduce	O
the	O
malaria	B-PATH
burden	O
in	O
this	O
endemic	O
region	O
.	O

The	O
former	O
triggers	O
the	O
release	B-PATH
inflammatory	O
cytokines	O
and	O
the	O
latter	O
promotes	O
exocytosis	O
of	O
unusually	O
large	O
von	O
Willebrand	O
factor	O
multimers	O
(	O
ULVWF	O
)	O
and	O
platelet	O
activation	O
.	O

In	O
this	O
study	O
,	O
a	O
chimeric	O
DNA	O
construct	O
was	O
designed	O
to	O
encode	O
an	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
NA	O
protein	O
which	O
is	O
flanking	O
immunogenic	O
amino	O
acids	O
(	O
aa	O
)	O
736	O
-	O
761	O
of	O
MERS	O
-	O
CoV	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
severe	O
form	O
of	O
acute	O
lung	O
injury	O
during	O
which	O
severe	O
inflammatory	O
responses	O
induce	O
cell	O
apoptosis	B-PATH
,	O
necrosis	O
,	O
and	O
fibrosis	O
.	O

ABSTRACT	O
:	O
The	O
long	O
-	O
term	O
dynamics	O
of	O
antibody	O
responses	O
in	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
infection	O
are	O
not	O
well	O
understood	O
.	O

Hospitalized	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
were	O
significantly	O
younger	O
,	O
more	O
frequently	O
had	O
class	O
III	O
obesity	O
,	O
and	O
had	O
a	O
higher	O
risk	O
for	O
pneumonia	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
than	O
patients	O
infected	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
or	O
B	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

The	O
nasopharyngeal	O
or	O
throat	O
swabs	O
of	O
these	O
six	O
patients	O
were	O
negative	O
for	O
known	O
respiratory	O
microbes	O
by	O
point	O
-	O
of	O
-	O
care	O
multiplex	O
RT	O
-	O
PCR	O
,	O
but	O
five	O
patients	O
(	O
four	O
adults	O
and	O
the	O
child	O
)	O
were	O
RT	O
-	O
PCR	O
positive	O
for	O
genes	O
encoding	O
the	O
internal	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
and	O
surface	O
Spike	O
protein	O
of	O
this	O
novel	O
coronavirus	O
,	O
which	O
were	O
confirmed	O
by	O
Sanger	O
sequencing	O
.	O

The	O
radical	O
operation	O
of	O
colorectal	B-PATH
cancer	I-PATH
is	O
confine	O
operation	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
),	O
one	O
of	O
the	O
causes	O
of	O
the	O
common	O
cold	O
,	O
exacerbates	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
bronchial	O
asthma	B-PATH
.	O

It	O
revealed	O
that	O
the	O
sizes	O
of	O
tumours	O
in	O
C6	O
glioma	B-PATH
-	O
bearing	O
rats	O
were	O
smaller	O
after	O
treatment	O
with	O
AVNP2	O
.	O

TITLE	O
:	O
Airway	O
Pressure	O
Release	B-PATH
Ventilation	O
as	O
a	O
Rescue	O
Therapy	O
in	O
Pediatric	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

TITLE	O
:	O
Radiation	O
induced	O
apoptosis	B-PATH
and	O
pulmonary	O
fibrosis	O
:	O
curcumin	O
an	O
effective	O
intervention	O
?	O

This	O
study	O
investigated	O
prevalence	O
of	O
10	O
respiratory	O
viruses	O
;	O
Adenovirus	O
,	O
influenza	B-PATH
A	I-PATH
,	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
Parainfluenza	O
virus	O
(	O
PIV	O
)	O
type	O
1	O
-	O
4	O
,	O
enterovirus	O
,	O
and	O
human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
among	O
children	O
in	O
Alexandria	O
,	O
Egypt	O
presenting	O
with	O
acute	O
lower	O
respiratory	O
tract	O
infections	O
.	O

We	O
show	O
a	O
broad	O
spectrum	O
of	O
fusion	O
inhibition	O
by	O
GA	O
of	O
all	O
three	O
classes	O
of	O
fusion	O
proteins	O
including	O
HIV	O
,	O
Ebola	O
virus	O
(	O
EBOV	O
),	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
and	O
Epstein	O
Barr	O
virus	O
(	O
EBV	O
).	O

In	O
this	O
work	O
,	O
we	O
searched	O
the	O
homologous	O
templates	O
of	O
all	O
nonstructural	O
and	O
structural	O
proteins	O
of	O
2019	O
-	O
nCoV	O
.	O
Among	O
the	O
nonstructural	O
proteins	O
,	O
the	O
leader	O
protein	O
(	O
nsp1	O
),	O
the	O
papain	O
-	O
like	O
protease	O
(	O
nsp3	O
),	O
the	O
nsp4	O
,	O
the	O
3C	O
-	O
like	O
protease	O
(	O
nsp5	O
),	O
the	O
nsp7	O
,	O
the	O
nsp8	O
,	O
the	O
nsp9	O
,	O
the	O
nsp10	O
,	O
the	O
RNA	O
-	O
directed	O
RNA	B-PATH
polymerase	I-PATH
(	O
nsp12	O
),	O
the	O
helicase	O
(	O
nsp13	O
),	O
the	O
guanine	O
-	O
N7	O
methyltransferase	O
(	O
nsp14	O
),	O
the	O
uridylate	O
-	O
specific	O
endoribonuclease	O
(	O
nsp15	O
),	O
the	O
2	O
'-	O
O	O
-	O
methyltransferase	O
(	O
nsp16	O
),	O
and	O
the	O
ORF7a	O
protein	O
could	O
be	O
built	O
on	O
the	O
basis	O
of	O
homology	O
templates	O
.	O

TITLE	O
:	O
[	O
Treatment	O
strategies	O
for	O
colorectal	B-PATH
cancer	I-PATH
patients	O
in	O
tumor	O
hospitals	O
under	O
the	O
background	O
of	O
corona	O
virus	O
disease	O
2019	O
].	O

TITLE	O
:	O
[	O
Several	O
suggestions	O
of	O
operation	O
for	O
colorectal	B-PATH
cancer	I-PATH
under	O
the	O
outbreak	O
of	O
corona	O
virus	O
disease	O
2019	O
in	O
China	O
].	O

(	O
3	O
)	O
The	O
colorectal	B-PATH
cancer	I-PATH
patients	O
with	O
suspected	O
or	O
confirmed	O
COVID	O
-	O
19	O
should	O
be	O
placed	O
in	O
the	O
isolated	O
room	O
with	O
separate	O
medical	O
devices	O
,	O
and	O
the	O
operative	O
room	O
with	O
negative	O
pressure	O
(	O
under	O
-	O
5	O
Pa	O
)	O
must	O
be	O
separated	O
.	O

The	O
transition	O
from	O
first	O
symptoms	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
highly	O
likely	O
to	O
be	O
due	O
to	O
uncontrolled	O
cytokine	O
release	B-PATH
.	O

STAT3	O
exhibits	O
a	O
proviral	O
function	O
in	O
several	O
viral	O
infections	O
,	O
including	O
those	O
of	O
HBV	O
,	O
HCV	O
,	O
HSV	O
-	O
1	O
,	O
varicella	O
zoster	O
virus	O
,	O
human	O
CMV	O
and	O
measles	B-PATH
virus	O
.	O

